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Summary 
 
In recent decades, the pharmaceutical drug discovery and development process has 
been hampered by identifying efficacious and safe drugs. Among absorption problems, 
interference with ion channels (hERG), extensive hepatic metabolism leading to 
inadequate metabolic profiles of discovery compounds, has been cited as one of the 
most common problems associated with failures in early drug discovery and 
development. 
Inadequate metabolic profiles of discovery compounds, namely low metabolic stability, 
an increased risk of CYP450 dependent inhibition and a number of clinically significant 
drug-drug interactions are largely due to oxidative degradation (phase-I metabolism). 
This degradation is usually enzymatically catalyzed by the most important members of 
the mono-oxygenases, the CYP450 superfamily. 
The most important and common member of the CYP450 superfamily, CYP3A4, is 
responsible for the metabolic degradation of over 60% of known drugs [1, 2]. 
Additionally, the relatively large active cavity site of CYP3A4, resulting in a large 
diversity of possible substrates, makes this isoform especially important in the 
evaluation of metabolic and safety profiles of drugs and metabolites. Furthermore, the 
large cavity site allows the optimal orientation of the drug molecule resulting in a 
successful attack of the chemically most liable positions of CYP3A4 substrates. 
Unlike for other CYP450 isoforms, structure-property relationships for CYP3A4 have so 
far not been feasible as various functions and mechanisms of components of the 
CYP3A4 active site are still not identified. 
Besides the electronic orientation of liable structural moieties within the cavity site is an 
additional factor influencing the CYP3A4 induced catalysis. Therefore improved 
knowledge of the ionization potentials could be an important factor in a better 
understanding of CYP450 catalysis. The ionization potential of a compound can be 
described as the compound’s redox potential. Guengerich and Lewis, for example, have 
proven the correlation between ionization  and redox potentials [1, 3, 4]. 
In the current study we could show that the redox potentials of discovery compounds 
are an important factor to be considered in the description of rat or human clearance 
and thus with the metabolic stability. 
Standard early metabolic stability determinations are biological based mainly focusing on 
the degradation of drug by microsomal or hepatic cell preparations. 
Usually these assays only deliver information on the rate of metabolism by the 
determination of the drug disappearance.  
Without doubt, there is a need for a better understanding of metabolic processes. A 
larger focus on structural aspects of drugs candidates could probably improve 
understanding of metabolic degradation processes and structure-effect relationships. 
Two novel approaches for early metabolic stability profiling of drug candidates have 
been developed and investigated in the current PhD-thesis. 
The first approach is based on redox chemistry. Ideally, the optimal redoxchemical 
indicator should exhibit reversible two-electron transfer behaviour to best simulate the 
two-electron transfer process occurring in the CYP450 catalytic cycle. 
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After intensive investigations, p-chloranil has been identified as a suitable component for 
a redoxchemical based assay which meets the required criteria off reversible two-
electron transfer behaviour. 
The second approach is electrochemical based. Several research groups have already 
worked on electrochemical approaches and tried to establish EC/LC/MS as 
screening/profiling tool for metabolic stability. Quite a few disadvantages, e.g. non-
physiological experimental conditions and low throughput have prevented EC/LC/MS 
from routine use so far. 
An external collaboration with Gatlik (Gatlik Ltd., Basel/CH) gave rise to the 
Electroactive Pharmaceutical Screening System (EPSS), a novel HT-cyclic voltammetric 
screening/profiling system which allows electrochemical determinations under more 
physiological conditions in the 96-well format. 
For the first time, a larger quantity of compounds can be measured per day. Obtained 
oxidation potentials well correlate with the microsomal rat clearance so that EPSS can 
be regarded as an attractive screening/profiling method compound ranking/selection 
based on the found relationship between redox potential and metabolic stability. 
The aim of the PhD-thesis was the development of fast and easy profiling systems, 
allowing improvement of the understanding of metabolic processes at the 
structural/compound level. Thus, compounds/compound classes with high probability to 
be metabolically instable with focus on phase-I metabolism processes can be identified. 
Based on the previously reported hypothesis and the obtained results of the PhD study, 
we therefore propose EPSS as a promising and attractive screening or profiling tool for 
early metabolic stability determinations in early drug discovery, as first information on 
the compound’s metabolic stability can be easily obtained without the use of biological 
materials. 
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Chapter 1: Introduction 
1.1 The Fate of a Drug Administered Orally in the Human Body [5] 
 
Drug action is the result of numerous and complex processes in the body. Typically, 
there is a chain of events which can be divided into three consecutive stages termed as: 
pharmaceutical, pharmacokinetic and pharmacodynamic phases. 
The fate of a drug in the human body and the most important processes occurring after 
oral application are depicted in Fig.1. 
 
 
 
Fig.1 Adapted from Mutschler, a schematic overview on the fate of a drug after oral application [5] 
 
 
Investigations at the pharmaceutical stage concern the application of a solid oral dose. 
The pharmacokinetic stage mainly deals with Absorption, Distribution, Metabolism and 
Elimination (ADME-processes), and thus with the determination of complex 
pharmacokinetic (PK) parameters. At the pharmacodynamic stage, drug-receptor 
interactions are described which should typically result in the desired effect at the in 
vivo level. 
Pharmacodynamic
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In particular, the pharmacokinetic stage can be regarded as the most complex of the 
previously described three stages.  
The uptake of an applied drug by the organism is evaluated via studies of its absorption 
behaviour. Detailed studies of tissue and distribution partitioning are essential in 
describing distribution behaviour which influence, in combination with protein binding, 
biotransformation and elimination processes. 
Elimination is defined as the process which decreases the concentration of a 
xenobiotic in the organism. Xenobiotics are chemical substances that are foreign to 
the biological system. They include naturally occurring compounds, drugs, 
environmental agents, carcinogens, insecticides and etc. [5] so the body’s natural 
objective is to rapidly remove xenobiotics. This fact provides the basis of the elucidation 
of biotransformation and metabolic pathways of discovery compounds. 
The optimisation and the decision-making processes are supported by numerous of in 
vitro and in vivo assays for the described complex phases. 
The results of the in vitro metabolic assays provide the basis for the establishment of 
further pharmacokinetic parameters of the drug at the pre-clinical stage e.g. the 
maximal concentration (Cmax), in vitro half life (t1/2) and area under the curve (AUC).  
 
1.2 Role of Early ADME Studies in Drug Discovery & Development 
 
In the past, especially in the 1980s & 90s of the last century, ADMET studies typically 
took place at the later stages of pre-clinical drug development [5-9]. This in turn led to 
an unacceptably high failure rate of discovery compounds due to PK/ADME problems. 
Numerous review articles were published about the major reasons for the failure of 
discovery compounds in 1991 as shown in Fig.2 [8, 9]. At that time, poor 
pharmacokinetic parameters combined with toxicity issues were the most common 
reasons for failures [5, 7, 9].  
 
 
 
Fig.2 Typical reasons for failures in 1991 [9] 
 
Numerous approaches for the early assessment or prediction of drug metabolism of 
discovery compounds have been proposed and introduced over the past few years by 
40%
30%
20%
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pharmaceutical companies with the goal of facilitating the development of new drug 
molecules with an overall suitable profile [4]. 
The importance of ADME in the fate of a drug (Fig.1) provides the rationale for 
studying ADME related parameters in the early phases of the discovery process. 
The drug discovery and development process currently involves several steps, from 
target identification and screening, lead generation and optimisation, pre-clinical and 
clinical studies to final registration of a drug and finally the market introduction 
(Fig.2)[8]. 
 
 
 
Fig.3 The drug discovery and drug development process [10] 
 
 
Early optimisation of ADME(T) (Absorption, Distribution, Metabolism, Elimination and 
lately Toxicology) related parameters are therefore an essential part of the pre-clinical 
lead optimisation (LO) phase. The implementation of ADMET profiling and optimisation 
at the early discovery and development phase has to be seen as an attempt to 
overcome major weaknesses of the drug development processes. The biggest 
advantage of ADMET profiling is its time- and cost effectiveness [9, 11]. 
The ultimate goal of early ADMET related optimisation processes is the selection of 
clinical candidates with favourable pharmacokinetic parameters and safety profiles.  
Following experiences in the early 90s with the unsuccessful development of new drug 
molecules, the pharmaceutical industry kept their main focus on the optimisation and 
metabolic profiles of discovery compounds [7, 9].  
These days, toxicology related problems and efficacy are the reasons for most drug 
failures whereas pharmacokinetic related attritions can be reduced [12, 13].  
Currently, ADMET studies especially studies on the metabolism of discovery compounds, 
are assessed in parallel with LO to avoid failure in late drug discovery. Not only 
metabolic stability determinations, but also CYP450 dependent inhibition and the 
investigations of significant drug-drug interactions are included in early metabolic 
profiling of discovery compounds. 
Metabolic stability studies are part of the early ADMET related optimisation processes 
performed in the pre-clinical discovery [9]. The importance of metabolic stability studies 
has been illustrated by a rapidly increasing number of research papers and review 
articles published over the last decade [6, 9, 12, 14, 15]. In the following chapters, 
more key concepts and definitions of metabolic stability are provided.
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1.3 Metabolic Stability: Definitions and Key Concepts 
1.3.1 Definitions 
 
Metabolic stability is a term widely used in the description of the rate and extent of 
metabolism of a compound [12]. A molecule which is rapidly and extensively 
metabolized is defined as a compound with a low degree of metabolic stability [11]. 
In vitro half life (t1/2) and the intrinsic clearance (CL_int) are the primary 
pharmacokinetic parameters used in the description of metabolic stability.  
Secondary pharmacokinetic parameters such as the hepatic clearance (CLH), 
bioavailability and in vivo half-life (t1/2) can be calculated on the basis of the 
primary pharmacokinetic values [12].  
Clearance is a pharmacokinetic term used for the description of drug elimination from 
the body without identification of the mechanism or the process. It is a key parameter in 
pharmacokinetics and therefore explained in more detail. 
The definition of clearance is the volume of fluid of a drug which is irreversibly cleared 
[CL = (ml/min/kg)] [16].  
The systemic clearance CLtotal is the main measure. For most drugs, the systemic 
clearance is a combination of hepatic clearance and renal clearance as shown in 
equation 1 [2, 14, 16]: 
 
 
renalhepatictotal ClClCL +=    (1) 
 
 
Alternatively, the total clearance (equation 2) may be defined as the rate of drug 
elimination divided by the plasma drug concentration [16]: 
 
 
ionconcentrat plasma
rate neliminatio
CL total =   (2) 
 
 
1.3.2 Intrinsic Clearance and Metabolic Stability  
 
Intrinsic clearance values are usually estimated by measuring the disappearance of the 
drug as a function of time. Therefore it is necessary to show the relationship of 
metabolic intrinsic clearance to metabolic stability described in the following paragraph. 
Since the mid 1970s, several practical attempts to relate in vivo pharmacokinetics to in 
vitro drug metabolism have been documented [6, 7, 11, 17]. Rane et al.[7] first 
developed the concept of intrinsic metabolic clearance (CLint). They demonstrated 
that in vitro metabolism rates correlate with hepatic extraction ratios determined from 
isolated perfused rat livers for a selected set of model compounds [7, 11]. More 
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recently, the issue of in vitro and in vivo correlations has been reviewed systematically 
[18, 19]. 
According to Houston et al.[19], intrinsic clearance is defined as the proportionality 
constant between drug concentration at the enzyme site and rate of metabolism as 
described by equation 3: 
 
 
eint C  CLmetabolism of Rate ∗=    (3) 
 
 
Rearrangement of (3) leads to equation 4 
 
 
 CL
C
metabolism of Rate
int
e
=    (4) 
 
 
As enzyme catalyzed reactions follow Michaelis-Menten kinetics, rates of metabolism can 
be related to the concentration at the catalytic site, maximum velocity of reaction 
(Vmax), and a constant, known as the Michaelis constant (Km). Km is defined as the 
substrate concentration at half maximal velocity of the reaction [11]: 
 
 
em
emax
C  K
C V
 v metabolism of Rate
+
×
== 0   (5) 
 
 
Assuming that Ce << Km, rearrangement of equation 5 leads to the following expression: 
 
 
   
 K
 V
  
C
metabolism of Rate
m
max
e
=         (6) 
 
 
Finally, equating 4 and 6 gives: 
 
 
 K
 V
  CL
m
max
int =       (7) 
 
 
According to equation 7 reasonable correlations between in vivo PK properties and 
parameters derived from in vitro metabolism studies are possible [11]. 
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1.3.3 Mathematical Concepts  
 
A number of mathematical models have been developed for the prediction of hepatic in 
vivo clearance (CL_in vivo) on the basis of in vitro clearance (CL_in vitro) data. Most 
commonly applied models are the “well-stirred” and “parallel-tube” model (Fig. 4). 
The "well-stirred" model is also known as the venous equilibrium model. It assumes that 
the drug concentration is constant throughout the hepatic compartment and equal to 
the outflow concentration [8]. 
The theory behind the “parallel-tube model” or sinusoidal model is based on an 
assumed greater uptake of the drug into the hepatocytes at the portal venous end of 
the tubes. The concentration declines exponentially along the tubes [8]. 
 “The average concentration within the organ is the logarithmic average of Cin and Cout ” 
[20]. Applying the theory for the “well-stirred“ model, the relationship between hepatic 
venous concentration Cout, incoming mixed arterial and venous blood concentration Cin, 
hepatic blood flow QH and intrinsic clearance Clint is expressed as follows in equation 8: 
 
 
intuH
H
inout
Cl  f Q
Q
  C C
⋅+
⋅=    (8) 
 
 
 
Remember that fu denotes the free fraction of drug in blood. The hepatic organ 
clearance ClH then becomes: 
 
 
intuH
intuH
 H
Cl  f  Q
Cl  f  Q
 Cl
⋅+
⋅⋅
=    (9) 
 
 
 
 
   
 
Fig.4 The “well-stirred” or venous equilibrium model (left) and the “parallel tube model” or sinusoidal model (right). The tanks are 
lined with rows of hepatocytes where the metabolism of the drug is supposed to occur. The small black arrows indicate the 
exchange [20]  
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1.4 Assessment of Drug Metabolism In Vitro and In Silico 
 
Based on theoretical knowledge of drug metabolism, various in vitro assays have been 
developed to study drug metabolism using recombinant enzymes, liver microsomes, 
fresh and cryopreserved hepatocytes and tissue slices [12]. All in vitro models are more 
or less routinely used for predicting drug clearance and the risk of drug-drug 
interactions (DDI) related to enzymatic inhibition [12]. 
 
• Assays based on recombinant enzyme systems provide the simplest in vitro 
model that contains some of the numerous catalyzing enzymes which are 
produced in the endoplasmatic reticulum (ER) of the eukaryotic host cells. The 
most commonly used recombinant expression systems are the bacoluvirus and 
human lymphoblastoid system. The major advantage of such assays is the 
simplicity. Other advantages are the possibility to study the activity of the specific 
enzymes separately, and these cell free assays are suitable for High-Throughput 
(HT)-screening.  
A major drawback in using recombinant enzymes is related to varying enzymatic 
activity in the preparations and these in vitro assays only provide information on 
phase-I metabolism. 
 
• The microsome-based assays are currently the standard in vitro model in industry 
for the estimation of CL_in vivo. Microsomes are prepared either from animal 
and/or human tissues and pooled microsomes are typically used to reflect 
average enzymatic activity found in humans or animals [12]. 
The major advantage of this model is the relative stability of enzyme activities 
during prolonged storage.  
A major disadvantage is the limited incubation time since enzymatic activities 
decrease after 2h of incubation. Above all, the supplementation of relevant 
cofactors and other reaction components is essential so the supplementation with 
selected cofactors only allows the analysis of the different contributing classes of 
metabolizing enzymes, such as CYP450s, FMO and UGT. 
 
• A third type of in vitro model uses either fresh or cryopreserved hepatocytes. The 
clearance of a compound can be estimated and predicted because all phase-I and 
phase-II enzymes and relevant cofactors are present [12]. Additionally, the 
potential for DDIs can be determined by this in vitro model. As a result, human 
hepatocyte experiments are considered to be very important.  
The limited availability of fresh human hepatocytes is a major drawback which 
has led to research in culturing and cryopreservation of hepatocytes to improve 
its availability when needed.  
 
• The most complex in vitro models are tissue models. These have the major 
advantage of very closely mimicking the in vivo situation. Consequently, tissues 
are a useful model for the study of the formation of metabolites, although they 
are not very well established in the prediction of metabolic clearance and DDIs. 
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Thus far, metabolic stability has always been estimated by one of the in vitro models 
described above. Generally, the time dependent disappearance of a compound is 
measured and used for the estimation of metabolic stability. However, fewer efforts 
have been directed towards the relationship between drug structure or properties and 
their metabolic stability. This is largely due to the limited information on the degraded 
products generated. 
Literature search revealed that hardly any structure-based metabolic stability 
assessment has been published so far and applied although there is an increasing need 
for structure based mechanistic understanding of metabolic processes [17].  
To overcome the hurdle of long and time consuming development steps in drug 
discovery and development, several in silico approaches towards predictive ADMET-
models have been described [17]. 
Predictive ADMET models exist out of three main components:  
 
1) A high quality of experimental data is essential for the training of the model. 
 
2) Descriptors of molecular structures that can be correlated with the experimental 
data. 
 
3) An appropriate modeling technology has to be available to produce the model 
[17].  
 
Good experimental ADMET data is not readily available, although amounts of data have 
been accumulated within the confidential files of big pharmaceutical companies [17]. 
Hence, published models tend to be built on small datasets which limits their robustness 
and prediction power [17].  
According to Dearden [17], in silico prediction of ADMET properties has progressed 
enormously over the past few years, so most physicochemical properties can be 
modelled today.  
Since the prediction and calculation of ADMET properties is cost- and time effective, it 
can be expected that the development of increasingly accurate predictive tools will be 
further advanced [17]. 
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1.5 Biotransformation and Drug Metabolism 
1.5.1 Liver and Drug Metabolism 
 
The liver is the major organ responsible for the metabolism and elimination of drugs and 
xenobiotics. From a physiological point of view, blood flow to this organ has important 
implications. It is supplied via the hepatic artery arising from the aorta (25%) and via 
the portal vein (75%) which is a conglomeration of venous returns from the intestines, 
spleen and mesenteries [21]. The liver is located in between portal and systemic 
circulation. Thus, the liver will usually receive drugs or xenobiotics entering via the 
portal system during oral absorption [21].  
Specific cells in the liver, hepatocytes, carry out all the chemical reactions which are 
associated with phase-I metabolism (oxidation reactions) [21] and most metabolising 
enzymes such as CYP450s are located in the endoplasmatic reticulum (ER).  
1.5.2 Lipophilicty and Metabolism 
 
Most drugs are rather lipophilic. For this reason, the definition of drug metabolism is the 
conversion of a lipophilic compound to a more hydrophilic compound which can be 
readily excreted by the kidneys [14, 16]. Lipophilic drug molecules usually undergo 
extensive metabolism in the liver, resulting in low bioavailability [14, 16].  
Compounds which are rapidly removed from the body are defined as compounds of low 
metabolic stability [12]. Biotransformation of a compound is normally linked with a 
reduction in lipophilicity and the formation of a metabolite which is usually less active 
than the parent compound [1, 2, 16]. For hydrophilic drugs (logD7.4<0), renal clearance 
is the predominant route of elimination. In contrast to renal clearance, the metabolic 
clearance increases with increasing logD and this becomes the major route for lipophilic 
compounds.  
The “rate of metabolism is a function of chemical liability and the ability to enter and 
leave the active site of the enzyme” [12]. Therefore, lipophilicity is an important 
physicochemical parameter to be considered in pre-clinical drug discovery. 
Lipophilicity is usually expressed as the partition coefficient of a compound between 
octanol and water [22, 23]. Measuring the distribution of a drug between two immiscible 
phases indicates the ability of a drug to partition between aqueous phases and lipid bio- 
phases depending on its relative concentration and affinity for each phase [24].  
Octanol was chosen as a solvent with good polarity and the ability to produce solubility 
in water to some extent [24]. The polarity of octanol best mimics the chemical 
constitution of biological membranes as they are rather complex anhydrous lipid phases 
[24]. Solvents other than octanol (e.g. isobutanol, hexan, cyclohexan) have also been 
tested [24]. Molecular size and hydrogen bonding capacity are two major molecular 
properties which contribute to the degree of lipophilicity [22]. 
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Lipophilic compounds are primarily subject to phase-I metabolism whereas hydrophilic 
compounds more readily undergo phase-II metabolism. Increasing lipophilicity inevitably 
leads to an increase of the intrinsic clearance so that affinity for metabolising enzymes is 
enhanced [22, 25] as shown in Fig.5 below:  
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Fig.5 Correlation lipophilicity (logD7.4) with unbound (free) hepatic intrinsic clearance (CLi (a), filled squares) and unbound (free) 
renal clearance (Cl(r) open triangles) adapted from van der Waterbeemd et al.[22] 
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1.5.3 Phase-I and Phase-II Metabolic Reactions 
 
Drug elimination in the body involves many complex rate processes. Although organ 
systems have specific functions, the tissues within the organs are not structurally 
homogenous, and elimination processes may vary in each organ. The volume of the 
distribution concept is simple and convenient, because all drugs are dissolved and 
distributed in body fluids. The advantage of the clearance approach is that it applies to 
all elimination rate processes, regardless of the mechanism for elimination. In addition, 
for first-order elimination processes, clearance in contrast to drug elimination rate is a 
constant [2]. 
Biotransformational processes are usually catalyzed by enzymes. There are very few 
exceptions where drugs are non-enzymatically metabolized. Although biotransformation 
enzymes exist in other tissues, e.g. kidney, lung, small intestine and skin also contain 
biotransformation enzymes, liver tissues remain the most important ones as the highest 
levels are found there [12, 14, 16]. 
Generally, drug metabolism can be divided into phase-I and II metabolism. Phase-I 
metabolism involves oxidation, reduction and hydrolysis reactions, catalyzed by a 
number of enzymes. The most important metabolizing enzymes are haem-containing 
(CYP450) and flavin containing mono-oxygenases (FMO) [12]. Phase-II metabolism 
enzymes, e.g. UDP-glucuronyltransferases (UGT) and sulfonyltransferases, catalyze 
conjugation reaction of lipophilic chemicals, for example products of phase-I metabolism 
processes. 
The most common drug biotransformation reactions are listed in Table 1. 
 
 
Table 1 Common drug biotransformation reactions [16] 
 
 
 
PHASE I REACTION PHASE II REACTION 
    
Oxidation Glucuronide conjugation 
 Aromatic hydroxylation  Ether glucuronide 
 Side chain hydroxylation  Ester glucuronide 
 N-,O- and S- dealkylation  Amide glucuronide 
 Desamination Peptide conjugation 
 Sulfoxidation, N-oxidation   
 N-hydroxylation Glycine conjugation (hippurate) 
Reduction   
 Azoreduction Methylation 
 Nitroreduction  N-methylation 
 Alcohol dehydrogenase  O-methylation 
Hydrolysis Acetylation 
 Ester hydrolysis Sulfate conjugation 
 Amide hydrolysis Mercapturic acid synthesis 
 
Chapter 1: General Introduction 
   
 23 
Most phase-I reactions are catalyzed by members of the CYP450 superfamily containing 
a haem moiety (Fig.6).  
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Fig.6 Haem moiety [1] 
 
CYP450 are ubiquitous in nature. To date more than 500 different isoforms of CYP450 
have been identified in humans, animals and plants [26]. However, only a few CYP450 
isoforms play a significant role in the drug metabolism process [26]. 
The CYP1A, 2A6, 2B6, 2C, 2D6, 2E1 and the 3A families are the most important 
isoforms.  
Therefore, CYP450 inhibition assays and DDI studies in pre-clinical discovery are 
performed with these isoforms [12]. 
The most versatile and abundant CYP450 isoform is 3A4 as it exhibits a large active site 
with low substrate specificity. It is involved in the metabolism of over 60% of the 
marketed drugs and also in a high number of significant DDIs [9, 11, 12, 14, 16, 27] so 
the assessment of metabolic profiles, especially that of CYP3A, plays an important role 
in pre-clinical drug discovery.  
 
 
Table 2 Summary of the structural characteristics of human CYP450 substrates [28] 
 
CYP450 Structural characteristics
1A2 Planar molecules, neutral or basic in character
2A6 Diverse relatively small neutral or basic molecules usually containing 1 aromatic ring
2B6 Angular medium-sized neutral or basic molecules with 1-2 hydrogen bond donor/acceptor atoms
2C9 Medium-sized acidic molecules with 1-2 hydrogen bond acceptors
2C19 Medium-sized molecules, mostly basic with 2-3 hydrogen bond acceptors
2D6 Medium-sized basic molecules with protonable nitrogen 5-7 A from site of metabolism
3A4 Relatively large, structurally diverse molecules
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Imipramine is an example for CYP450-mediated metabolism with a known, commercially 
available active metabolite and fully characterized metabolic pathway (Fig.7). 
Demethylations of imipramine are catalyzed by CYP3A4 and CYP1A2, whereas the 
hydroxylation is catalyzed by CYP2D6. 
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Fig.7  Metabolic pathway of imipramine with known phase-I metabolism and high in vivo clearance [29] 
 
 
For further understanding of CYP450 mediated phase-I metabolism, it is necessary to 
review the CYP450 catalyzed biotransformation reactions in more detail.  
Regardless of structural differences in individual CYP450s, the mechanism of the CYP450 
catalytic cycle is essentially the same across all isoforms [4].  
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The catalytic cycle of CYP450 (Fig.8) includes the following six steps [1, 4]: 
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Fig.8 Catalytic cycle of CYP450 as described by Lewis [1, 4]: 1) Substrate binding, 2) First reduction of Fe3+, 3) Oxygen binding  
4) Second reduction, 5) Product formation, 6) Product release 
 
 
1. Substrate Binding  
Binding of substrate to the enzyme lowers the redox potential of the CYP450 and 
induces a shift in the ferric iron spin-state equilibrium towards the high-spin form. 
Additionally, the desolvation of the active site results in a change in the entropy of the 
enzyme. “The substrate-bound complex is relatively stable, readily reduced to the Fe(2+) 
state because substrate binding lowers the CYP450 redox potential by about 0.1V.” [1, 4] 
 
2. First Reduction  
The transfer of the first electron from the reductase or redoxin is included in the fastest 
steps in the catalytic cycle. Substrate binding lowers the redox potential of CYP450. This 
suggests some co-operation between the binding interaction and the electronic pathway. 
 
3. Oxygen Binding  
This step includes the rapid binding of molecular dioxygen to the high-spin Fe(2+) 
CYP450-substrate complex. The oxyferrous complex is relatively stable, but the 
dioxygen is auto oxidizing to superoxide resulting in spectral changes. As a result of 
oxygen binding to CYP450 the ferrous iron returns to the low-spin configuration and the 
iron atom moves back into the plane of the porphyrin ring. Activated dioxygen (triplet 
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ground state) exhibits two unpaired electrons whereas high-spin ferrous CYP450 has 
only four electrons so significant pairing interactions are expected. 
According to Lewis, this is a possible explanation for the relevance of the shift from low- 
to high-spin which exhibits a high affinity for oxygen. Other electronic factors pertaining 
to both the ligand and the haem iron must also be important, for example the electron 
deficient nature of dioxygen and overall negative charge of the Fe (II) haem-cysteinyl 
complex.  
In addition, the haem iron is a good pi-donor which facilitates strong binding of pi-
acceptor ligands such as oxygen, carbon monoxide and nitrogen monoxide. 
 
4. Second Reduction  
This rate-determining step is the major pathway for the decomposition of the 
oxycytochrome CYP450 substrate complex. The addition of a second electron to the 
oxycytochrome CYP450 complex suggests the formation of a species formally expressed 
as either Fe2+O2
- or Fe3+O2
2-. With a bound substrate, the reduced oxycytochrome 
CYP450 complex undergoes rapid rearrangement to yield the oxygenated substrate and 
water. 
 
5. Product Formation  
An iron (V) oxene (Fe=O) intermediate is generated as the oxygenating species in 
CYP450 catalysis, weakening and facilitating cleavage of the dioxygen bond. The second 
oxygen forms a water molecule by acquiring two protons through rearrangement. 
 
6. Product Release 
A more hydrophilic metabolite is released. 
 
Lewis et al. [1] was among the first to consider the correlation between metabolic 
stability and redox potentials. As reported, the haem moiety seems to play an important 
role in the set-up for this theory. He also stated that substrate binding lowers the redox 
potential of CYP450. In addition, the rate of reaction between the haemoprotein and 
hydrated electrons may be dependent upon a number of different parameters such as 
MW, number of aromatic residues and the net surface charge. These parameters 
become important again in Chapter 4, pp.68 [1]. 
The source of electrons is either NADH or NADPH depending on the isoform involved [1]. 
In Fig.9 possible routes of electron transfer for different CYP450 systems are illustrated. 
It is suggested, however, that electrons may be transferred through a potential gradient 
from reductant to oxidant species, between the interacting species and terminating in 
various oxygen redox couples [1]. 
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1.6 Structure of CYP3A4 
 
Crystal structures of CYP450s possess a largely conserved tertiary structural core of 
amino acid residues, representing the key structural, and functional elements 
characteristic of CYP450 isoenzymes including several β-sheet elements and many α-
helices [1, 25]. An additional helix was observed located at the extreme N-terminus of 
CYP3A4, but the significance of that helix is yet unknown.  
First crystal structures for human CYP3A4, which is the most abundant isoform and 
metabolizing over 60% of endogenous and exogenous compounds, were reported by 
Williams et al.[30] and Yano et al.[31] in 2005.  
One of the most interesting features of the active site cavity of CYP3A4 is its volume 
[32]. The active site is defined as “the area within the cytochrome P450 protein that can 
bind a substrate, giving it access to the active oxygen”[32]. Owing to its relatively large 
size it has the capacity to oxidize a variety of both, large and small molecules. 
Moreover, when a small molecule binds to CYP3A4, a significant portion of the cavity 
remains unfilled by the substrate and therefore contacts between the substrate and 
enzyme are not as extensive [33]. Additionally, the unfilled portion of the cavity is often 
sufficiently large to bind another substrate or effector molecule, as suggested by kinetic 
and fluorescence studies on the binding behaviour of CYP450 [33].  
Substrates of CYP3A4 or more generally CYP3A have more freedom to find their 
“catalytically competent” orientations in the active site [34] so CYP3A4 can additionally 
attack the most favourable chemical position. In the catalysis of other CYP450, 
substrates spend a significant amount of time in non-productive positions as their active 
sites are much smaller than that of CYP3A4 [34]. 
Major routes of catalysis for CYP3A4 are either aliphatic oxidation or N-dealkylation [34]. 
The major sites of oxidation are allylic positions in the compound [34]. Moreover, 
catalysis can proceed either by abstracting hydrogen atoms, as is the case in aliphatic 
carbon hydroxylation, or electrons where circumstances are more favourable [34]. For 
instance, N-dealkylation of aliphatic tertiary amines by an initial one-electron oxidation is 
regarded as chemically facile due to low E1/2 of those functions[34].  
Hence, substrates of CYP3A4 have diverse structures, which significantly complicate the 
rational prediction of their metabolism and identification of potential DDI [32]. Active 
sites of other CYP450s, such as 2D6 or 2C9 for instance, are smaller in size in 
comparison to CYP3A4 [33]. Consequently, substrate specificity is increased and 
therefore, unlike the case of CYP3A4, structure-activity relationships (SAR) for these 
substrates are feasible. 
Binding of CYP450 to substrates triggers an interaction with the CYP450 redox partners 
by inducing a conformational change [1, 32]. Several spin states are accessed when the 
first electron is transferred to form the high-spin ferrous state of the CYP450. Molecular 
oxygen can bind fairly rapidly and easily so that the ferrous state becomes low-spin [1]. 
Additionally, it was suggested that the CYP450 converts the dioxygen into the 
superoxide anion by electron transfer from ferrous iron as illustrated in equation 14. [1].  
This electron transfer induces the formation of ferric iron from ferrous iron, illustrated in 
equation 14.  
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 O Fe O Fe -2
3
2
2 +↔+ ++   (14) 
 
 
Importantly for the activation of the oxygen, the porphyrin ring which encapsulates the 
iron is a good σ-donor and pi-acceptor tetradentate ligand [1, 4]. Lewis and 
Guengerich’s catalytic cycle for CYP450 [1, 4] suggests that the iron peroxide, an 
intermediate of the haem group during the catalytic cycle, could act as a nucleophilic 
reagent for the oxygen. Electrophilic oxygenation is more likely carried out by an iron 
oxene, iron hydroperoxide or an iron hydroxide which potentially exhibits the 
characteristics of a hydroxyl radical [1, 4]. From the electronic viewpoint, an iron–oxene 
radical could potentially very well represent the optimum electronic configuration for an 
electrophilic attack of certain types of substrates such as aromatic compounds  and 
tertiary amines [1, 4]. 
Substrate binding lowers the CYP450 redox potential [1, 35] and the fact that proton 
transfer as well as electron transfer is facilitated suggests the participation of several 
amino residues in the active site cavity of CYP450 being ionizable. Therefore,       
ionization constants are regarded as one of the most important physicochemical 
properties besides lipophilicity [4]. The presence of an ionizable group seems to be 
important for the binding to the active site and the determination of the regioselectivity 
of the metabolic reaction [1, 4, 32]. 
Lipophilicity is of great importance in the metabolism of substrates CYP3A4 [4]. 
Furthermore, CYP3A4 is predominantly hydrophobic [34] so its substrates are rather 
lipophilic with values ranging from logD7.4 0.4 to 8 [4].  
It should be noted that besides the two physicochemical parameters lipophilicity and 
ionization potentials, other structural parameters such as redoxchemical behaviour play 
also an important role in CYP450 mediated conversion processes. 
A general overview of electron transfer pathways is provided in Fig.8. 
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1.7 Aim of the PhD-Thesis 
 
Increased failure rates of drug discovery compounds in the last decades established 
fundamental research activities in the field of ADMET. 
With the introduction of systematic metabolic studies in early drug discovery, attrition 
rates of discovery compounds could be reduced. To date, the estimation and prediction 
of the discovery compound’s metabolic stability is still regarded as a key issue in the 
drug discovery and development process.  
As has been described, early metabolic stability determinations have been primarily 
focused on assays (microsomal stability, hepatic stability), which usually only delivers 
information on the rate of metabolism by the determination of the drug disappearance. 
Currently, these assays are standard in the pharmaceutical industry but they can hardly 
deliver sufficient information on drug structural aspects influencing the metabolic liability 
of discovery compounds beside lipophilicity and ionization. 
Without doubt, there is a need for a better understanding of the metabolic processes in 
lead selection and optimisation. A larger focus on structural aspects of drug candidates 
could probably improve the understanding of metabolic degradation processes and 
structural-effect relationships. 
Most drug candidates and drugs undergo phase-I metabolism processes which are 
mainly enzymatically catalyzed by the CYP450 superfamily. CYP3A4 is the most 
important and abundant isoform of this superfamily and is involved in the metabolism of 
over 60% of known drugs [1, 2]. In comparison to other metabolic active enzymatic 
systems, the active cavity site of CYP3A4 is relatively large in size and therefore allows 
the oxidation of various compound classes.  
Hence, substrates of CYP3A4 are structurally diverse. Especially in the case of CYP3A4, 
it is most likely that besides enzymatic activity other factors such as catalytic activity, 
drug structural and property related parameters additionally play an important role in 
the prediction of the suitability of drug candidates. 
CYP3A4 substrates are more likely to obtain their best electronic orientation in the active 
cavity site of CYP3A4. Consequently the chemically most liable position of the substrates 
can be attacked more easily. Simply the ionization potential of a compound is the same 
energy at its highest occupied electronic energy level E(HOMO). The knowledge of this 
energy was stated as a first indicator of potential reactivity in the CYP450 system [1, 3]. 
The substrate’s redox potential are an important factor for the PhD-thesis [1, 4]. 
With the introduction of novel analytical techniques [36-42], new approaches for fast 
redox behaviour profiling of drug candidates became feasible.  
Cyclic voltammetry was the analytical method of choice. It is a fast and reliable 
electrochemical method for the determination of redoxchemical characteristics of 
compounds. Standard cyclic voltammetry used to be performed in a single mode, and 
large compound consumption. 
An external collaboration with Gatlik Ltd. (Basel) gave rise to a novel HT-screening 
system: the EPSS, an electroactive pharmaceutical screening system. Redoxactive 
behaviour of discovery compounds can be screened fast and reliable by that novel HT-
cyclic voltammetry system. Measurements under physiological-like conditions as well as 
low compound consumption of substances are some of its advantages. 
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Another approach involved the simulation of the two-electron transfer which occurs 
during the catalytic cycle of CYP450 by redoxreactions. Several redoxactive compounds 
exhibiting reversible two-electron transfers were identified as redoxindicators (RDI) with 
the help of cyclic voltammetry. 
A redoxchemical based assay for the prediction of metabolic stability was developed 
with p-chloranil as RDI.  
Therefore, the aim of the PhD-thesis was the development of fast and easy profiling 
systems, allowing improvement of the understanding of metabolic processes at the 
structural level and the identification of compounds/compound classes with a high 
probability of metabolical instability with focus on phase-I metabolic processes. 
 
The PhD-thesis is structured in a theoretical and an experimental part with the 
experimental part subdivided into three publishable chapters: 
 
Chapter 2 (pp. 30) contains a detailed description and comparison between classical 
and HT-cyclic voltammetry. 
Chapter 3 (pp. 44) deals with the identification of redoxindicators for the development 
of a redoxchemical based p-chloranil assay. 
Chapter 4 (pp. 68) includes the data analysis of results retrieved by cyclic voltammetry 
and p-chloranil assay. It also reports results of the multivariate data analysis (PLS) 
which was performed for the creation of a suitable model for the prediction of metabolic 
stability. 
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Chapter 2: Description and Comparison of Classical Cyclic 
Voltammetry with High-Throughput Cyclic Voltammetry for the 
Determination of Redox Potentials  
 
2.1 Introduction  
 
Cyclic voltammetry was used as an analytical method for the determination of 
reduction/oxidation potentials (redox potentials). Firstly, cyclic voltammetric 
measurements were performed in a classical manner. Subsequently, a HT-cyclic 
voltammetric set-up developed by Gatlik Ltd (Basel) was adapted and applied in the 
analysis of redoxchemical related metabolic stability determinations. 
In the following chapter, a description and comparison of classical cyclic voltammetry 
and HT-cyclic voltammetry is given. Interpretation of the data will be provided in 
Chapter 4 (pp. 68).  
 
2.1.1 Background on Electrochemistry 
 
Electrochemistry is comprised of several aspects of molecular sciences. Besides the 
movement of charges in an electrical field, electron-transfer induced processes are an 
important issue in chemistry and life sciences [43-48].  
Numerous electroanalytical methods have been developed in recent decades such as  
linear sweep voltammetry, differential pulse voltammetry, paleography, chrono-
potentiometry and cyclic voltammetry (CV) [43].In the current study, we have only 
focused on cyclic voltammetry. 
“Cyclic voltammetry is an electrochemical method for studying variable potentials at an 
electrode involving application of a triangular potential sweep, allowing one to sweep 
back through the potential region just covered ” [44]. In particular, cyclic voltammetry 
has gained considerable popularity because of its large scope [43]. In addition to 
thermodynamic data, (i.e. redox potentials), cyclic voltammetry can be utilized to obtain 
kinetic parameters of electron-transfer induced reactions and provide information on the 
stability and follow-up transformations of primarily formed intermediates [43, 46]. 
 
2.1.2 Experimental Aspects of Cyclic Voltammetry 
 
In Fig.1, a typical sketch of an experimental set-up for CV is illustrated. Normally, an 
electrochemical cell contains a three-electrode system; a working electrode, an auxiliary 
electrode and a reference electrode [44]. These electrodes are in contact with an 
electrolyte, an ionic conductor [44, 47, 49]. The potentiostat sets the control parameters 
of the experiment and it induces a cyclic linear potential sweep on the working electrode 
resulting in the characteristic current-potential curve. The potential is measured as a 
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function of time [43-45, 47]. The electric current at the working electrode is defined as 
faradaic current due to the electron transfer. 
 
 
 
 
Fig.1 Schematic sketch for a general set-up of an electrochemical cell 
 
 
The auxiliary electrode is driven by the potentiostat circuit and balances the faradaic 
process at the working electrode with an electron transfer in the opposite direction [47]. 
Reference electrodes are used as external references for the experiment and their 
potentials are calibrated with internal standards such as ferrocene (FOC) or ferricyanide 
(FeCN). 
The following materials for electrodes are very common: Pt or Au as a working electrode, 
Pt or Au as an auxiliary electrode and Ag/AgCl or SCE as a reference electrode [44]. 
Ag/AgCl and SCE reference electrodes are commonly used in experimental aqueous 
conditions [47]. 
In CV, the potential applied to the working electrode is scanned in a linear manner 
between two potential values, Emin and Emax. The electron transfer of the redoxreaction 
occurs on the surface of the working electrode within the predefined potential range. 
The potential provides qualitative information about the analyte of interest. The surface 
of the working electrode is more reductant or oxidant depending on the potential 
applied to it. Therefore, the more negative the potential becomes, the more improved 
and effective the electrode becomes as a reducing agent and vice versa [48]. 
Supporting electrolytes, such as TBAP or KCl, enhance conductivity in the 
electrochemical system [43-45, 47, 48].  
The most important parameter in CV is the scan rate, v: 
 
 
t
E
 v 
∆
∆
=    (1) 
 
 
∆E: difference between the upper and lower potential limit 
∆t:  time 
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The potential is applied in a saw-tooth manner to the working electrode and the current 
is monitored as illustrated by Fig.2 [44, 45]:  
 
 
 
Fig.2 Variation of applied potential  with time in cyclic voltammetry, showing the initial potential, Ei, the final potential Ef, maximum 
Emax, and minimum Emin potential, The sweep rate dE/dt=v. For linear sweep voltammetry consider only one segment. The fact that 
the initial sweep is positive is purely illustrative. 
 
A common cyclic voltammetric cycle starts at Ei (initial potential); the potential is 
increased to its upper limit Emax at a constant scan rate, and then reversed at t1 running 
back to Emin. At Emin and t2, the scan direction of the potential is changed once more 
and again it is increased to reach Emax. The number of cycles is varied depending on the 
focus of the experiment. 
For illustration purposes, a typical cyclic voltammogram for reversible charge transfer is 
shown in Fig.3.  
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Fig.3 Cyclic voltammogram for a reversible charge transfer, Epc: cathodic peak potential, Epa: anodic potential, Eλ: switching 
potential, E1/2: half-wave potential, ipc: cathodic peak current, ipa: anodic peak current, i 0 : current at E, ipa: anodic peak current 
at baseline. 
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Reversible reactions are kinetically rapid oxidation-reduction reactions at an electrode 
surface under mass-transfer-limited conditions [48]. For diffusion-controlled reactions 
stirring should be suppressed during the measurement [43-45, 47, 48]. The parameters 
of greatest interest for a reversible voltammogram are the peak cathodic potential (Epc), 
the peak anodic potential (Epa), the peak cathodic current (ips), and the peak anodic 
current (ipa). The formal redox potential of the voltammetric response provides 
qualitative information about the redox couple [45].  
Quantitative information regarding the concentration of the analyte is obtained from 
peak heights according to the Randles- Ševčik, equation 2 [43-45, 47, 48]: 
 
 
1/2*
0
1/2
1/21/2
3/23/2
p vCAD
T R
 F n
 0.443  i =  (2) 
 
 
ip: peak current in amperes 
A: electrode area in cm2 
D: diffusion coefficient in cm2s-1 
C: concentration in mol cm-3 
V: sweep rate in V/s-1 
 
 
Not only does equation 2 illustrate the proportionality of the peak current to the 
concentration, but more importantly it also predicts that the peak current of a reversible 
redox process, plotted against the square root of the sweep rate, must vary in a linear 
fashion. Therefore, the sweep rate or scan rate is an important parameter, as scan rates 
cannot be increased relative to the redox behaviour.  
Consequently, if the anodic peak potential and the cathodic peak potential are of great 
interest, the normal potential (E°) can be expressed as an average of the anodic peak 
potential (Epa) and cathodic peak potential Epc, so equation 2 is valid: 
 
 
2
)E(E
  E
pcpa +
=°   (3) 
 
 
In a reversibly cyclic voltammogram, where Epa - Epc ~ 59 mV, the peak separation is 
inversely proportional to the number of electrons transferred, n: 
 
 
n
0.0592
 )E-(E  E pcpa ==∆  (4) 
 
 
Initially, the shape of the curve resembles that of a linear sweep voltammogram, but 
after reversal of the sweep there is a rapid change in current on account of the high 
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concentration of oxidizable species close to the electrode generated on the reductive 
sweep [44, 45]. When the potential is close to the value which is required to oxidize the 
reduced species, there is a substantial anodic current until all the oxidation is complete, 
and the current returns to zero [44, 45].  
Fig.4, in contrast, shows an example of an irreversible cyclic voltammogram: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 Cyclic voltammogram for an irreversible charge transfer carried out at HT-cyclic voltammetry in aqueous media 
 
 
Till date cyclic voltammetric measurements have been performed in the classical single 
mode. 
Electro active pharmaceutical screening system (EPSS) is a novel way of performing 
cyclic voltammetry which utilises the classical experimental set-up and three-electrode 
system. The sensor plate, used with EPSS, contains 96 small electrochemical cells, set in 
serial. Each of the 96 wells contains a planar three-electrode system.  
The system capacity allows the measurement of up to 96 compounds. For the first time, 
cyclic voltammetry can now be used as a profiling or screening tool. New applications 
become favourable, for example profiling or screening of drug-like molecules in the early 
drug development stage. 
Therefore, the focus of the current study was the development of a new application 
based upon the EPSS system with a subsequent technical modification to measure 
molecules under physiological-like conditions, and a comparison of the classical method 
and HT-methods.  
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2.2 Experimental Section 
2.2.1 Drugs and Chemicals 
 
p-Chloranil, chloranilic acid, o-chloranil, menadione, DDQ, juglone, tetra butyl 
ammonium perchlorat (TBAP), ferrocene, used in this study were purchased from Fluka 
(Buchs, Switzerland) and used without further purification. 1, 2-naphthoquinone was 
obtained from Sigma-Aldrich (Buchs, Switzerland).  
Spectroscopic grade dimethylsulfoxide (DMSO) was purchased from Acros and 
electrochemical grade ACN from Fluka (Buchs, Switzerland). The pH of the solutions, 
used in the assay, was adjusted with sodium dihydrogen phosphate buffer (NaH2PO4) 
from Fluka (Buchs, Switzerland) at pH 7.4. KCl (analytical grade) was purchased from 
Merck (Switzerland). 
 
2.2.1.2 Preparation of Sodium Dihydrogen Phosphate Buffer (PB) [50] 
 
3.0 g of NaH2PO4 was weighed into a 500 ml volumetric flask and dissolved in 250 ml 
ultra pure distilled (Invitrogen®) water. Next, the exact pH was adjusted to 7.4 with 
approximately 4.0 ml of 2 M NaOH using a Metrohm® 827 pH lab pH-meter and the 
solution was further diluted with water to 500 ml total volume. In the final step, 
filtration with Millipore Steritop ExpressTM Plus 0.22 µm filter systems was performed to 
increase stability of the buffer. 
 
2.2.2 Cyclic Voltammetry 
 
Classical Approach. First, cyclic voltammetric measurements were performed with 
macro electrodes in non-aqueous solvents on a Metrohm Polarecord E 506 and VA 
scanner E 612 with a VA stand 663 (Metrohm AG, Herisau, Switzerland). The set-up 
of the electrochemical chamber used in this experiment can be seen in Fig.1. 
Measurements were carried out in acetonitrile (ACN) and in DMSO at room temperature. 
Supporting electrolyte, 0.01M TBAP was added to enhance conductivity and minimize 
double-layer effects.  
A platinum disk was used as a working electrode and the platinum wire as auxiliary 
electrode. A standard calomel electrode (SCE) was used for reference. Scan rates 
ranged from 0.15-0.8 V/s depending on the molecule. Ferrocene (FOC/FOC+) was used 
as an internal reference (E0’:0.398 V vs. SCE). Sample concentrations varied from 10-3 M 
to 10-5 M and the total reaction volume was constant at 25.0 ml. A hepes buffer system 
at pH 7.4 with Cbuffer: 50.0 mM was used. For the measurement of water-insoluble 
compounds, a mix of DMSO 100%: water (50:50) was tolerated. The total run time for 
the measurement of one single compound was 20 min and the system was connected to 
a computer to enable data analysis by the software CycloVoltammetrie CycVolt.6.EXE, 
Version 3.2.2. [51]. 
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Fig.5 Schematic drawing for an electrochemical cell used in the classical experimental set-up [45] 
 
High-Throughput Approach. Electroactive pharmaceutical screening system (EPSS, 
Gatlik Ltd., Basel) is a HT-screening system. EPSS was adapted to cyclic voltammetric 
measurements via the novel integration of potentiostat, multiplexing system and 
measurement unit into one compartment. Measurements are no longer carried out in 
electrochemical chambers but on sensor plates instead. These 96-well sensor plates, 
invented by Gatlik Inc. (Basel, www.gatlik.com) contain three macro-electrodes in each 
well. Gold is used as both, a working and auxiliary electrode. The reference electrode is 
a secondary electrode, made of Ag/AgCl. All measurements were carried out at 20°C at 
pH 7.4 in 0.5 mM PB and 0.0001 mM KCl supporting electrolyte. For the enhancement of 
solubility of low water-soluble compounds, 10% DMSO was added. 
The average scan rate was 0.640 V/s. Ferrocyanide (FeCN/FeCN+) and ferrocene 
(FOC/FOC+) were used as internal references (E0’ (FOC): 0.252 V vs. Ag/AgCl). Sample 
concentrations varied from 0.001 mM to 0.0001 mM. Total reaction volume per well can 
vary from 35.0-55.0 µl depending on the sensor plate type. EPSS was connected to a 
computer and data was imported into Excel and analyzed by a macro provided by Gatlik 
Ltd. 
After the measurement, the sensor plate was cleaned with distilled water and ethanol 
using a cotton stick. The estimated average lifetime expectancy of a sensor plate is 8 
uses before discarding. The total scan time of the whole sensor plate is 45 min, if 96 
wells are scanned 5 times with an average scan rate of 0.5 V/s. 
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Fig.6 Picture of EPSS sensor plate placed on   Fig.7 Example of a sensor plate V4 (Gatlik, Basel) with a total well the 
measurement unit      volume of 55 µll  
 
2.2.3 Data Analysis  
 
All results, acquired in Excel, were transferred to Origin 7.0 (OriginLab Cooperation, 
Northampton, USA) for the graphical presentation, whereas all statistical calculations 
were carried out using Statistica 7.1 (StatSoft, Tulsa, USA). 
 
2.3 Results 
 
The focuses of the study were first the development of a method using the new EPSS 
system and second the determination of redoxchemical behaviour of commercially 
available compounds by cyclic voltammetry. In addition, the results from both, the 
classical and EPSS methods were compared as depicted in Fig.8. 
The initial application of EPSS was for the determination of viscosity so our aim was to 
modify EPSS for our specific purposes, such as the determination of redoxactive 
behaviour of discovery compounds. Secondly, feasibility was shown by repetition of 
experiments already conducted using the classical method. 
Method development was initiated by following the subsequent experimental strategy: 
Measurements using the same compounds were repeated with EPSS. The EPSS system 
used the same experimental conditions as with the classical set-up but important 
parameters, such as the electrolyte concentration and the sample concentrations, had to 
be adjusted to conform to reaction requirements of EPSS. Furthermore, these initial 
experiments were the basis for the development of a method simulating physiological-
like conditions with EPSS and the subsequent modification of some technical aspects.  
Validation and comparison of the EPSS with the classical system was carried out at pH 
7.4 in PB at a concentration of 0.5 mM.  
Table 1 shows the results, obtained by the classical method and EPSS, including the 
experimental error. 
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Table 1 Electrochemical Potentials for commercially available electron acceptors measured by the classical and HT-cyclic 
voltammetry (number of repetition per compound: 4), values are FOC-corrected. Used buffer system was hepes buffer. 
 
 
Compound Reduction potential
Classical cyclic voltammetry HT- cyclic voltammetry
Ered [V], DMSO,Graz Ered [V], buffer,pH:7.4,EPSS
ferrocene (ISTD)  0.368 ± 0.031    0.151 ± 0.012
2,3 dichloro-5,6 dicyano-benzoquinone  0.575 ± 0.006    0.522 ± 0.010
o-chloranil  0.155 ± 0.017    0.010 ± 0.014
p-chloranil  0.078 ± 0.092   -0.131 ± 0.004
chloranilic acid * -0.220   -0.151 ± 0.003
juglone  -0.433 ± 0.095   -0.454 ± 0.023
1,2-naphtoquinone  -0.505 ± 0.036   -0.463 ± 0.03
menadione  -0.615 ± 0.009   -0.612 ± 0.037
chalkon  -1.394 ± 0.004   -1.360 ± 0.051
* Only 1 datapoint could be obtained for chloranilic acid
 
 
Therefore, both methods deliver similar results under the described conditions. Fig.8 
correlated the values of classical versus HT-methods. The correlation yielded a R2: 0.979 
with an estimated standard error of 0.0907. 
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Fig.8 Correlation of data recorded at classical method and EPSS (HT-method), the correlation yielded a R2: 0.9799, n=9. 
Statistical values are as follows:  F-value: 342.93, STD error of estimate: 0.0907 intercept: 0.068. Number of cases: n=9  
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2.4 Discussion 
 
The major goals of the current study were the development of a new application of the 
EPSS system with a subsequent technical modification to measure molecules under 
physiological-like conditions and the comparison of the classical method with the HT- 
method. 
However, the two methods seemed to be comparable as shown in Fig.8. Looking at this 
graph, low experimental errors were detectable for both methods. The only explanation 
for the larger standard deviation with EPSS was the fact that these experiments were 
performed with an open system. Although all solutions were strongly de-gassed, re-
oxygenation was not preventable. 
 
2.4.1 Classical Cyclic Voltammetry 
 
One of the most notable weaknesses of the classical method was the large amounts of 
solvents required as well as long time-consuming cleaning steps. 
25.0 ml of solvent per experiment were needed for the measurement of one single 
compound. Measurements, classically performed, are not suitable for profiling/screening 
purposes, as up to two compounds can be measured simultaneously, if a second 
electrochemical chamber unit is available applied in serial. It is more suitable for 
deducing specific properties of selected compounds. Solubility was another issue as the 
threshold concentration was easily infringed. Measurements in aqueous systems, such 
as hepes buffer, failed because of solubility problems. For most compounds, the 
solubility threshold concentration was reached. Therefore, no suitable cyclic 
voltammetric results were obtained when using the PB as solvent. 
In the classical experimental set-up (Fig.5), the electrochemical chamber was always 
covered by a lid. Solutions had been degassed 10 min before starting the experiment. 
Usage of organic solvents (ACN, DMSO) is clearly advantageous for the classical system 
and ACN of electrochemical grade is usually the solvent of choice for the record of 
precise and sharp voltammograms, unless the compound is not soluble in ACN.  
 
2.4.2 HT-Cyclic Voltammetry: EPSS 
 
The EPSS method was developed from the assay conditions implemented for the 
classical one, with the ultimate goal of developing a method for EPSS which can be 
applied under physiological-like conditions. 
After that, EPSS was validated and compared with the classical system by using 9 (8 + 1 
internal standard) selected commercially available redoxactive compounds. Major 
modifications and studies were necessary as volatility and shape of electrode meant it 
was not possible to apply the classical conditions directly to the EPSS method. For 
example for EPSS, TBAP had to be replaced by KCl as it seemed to be more 
advantageous for the enhancement of conductivity in this case. This was particularly 
beneficial for the Ag/AgCl secondary electrodes which require Cl-ions for conductivity 
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reasons [52]. With EPSS, disposable sensor plates were used. These were normal 
conductivity plates with 96 three-electrodes in each well. The total reaction volume 
amount was 35.0 to 55.0 µl, depending on the sensor plate type. 
Covering the sensor plate with plastic or aluminium, failed because of the risk of 
capillary effect. Moreover, most commercially available foils contain glue on the reverse 
side so it was most likely the case that the solvent came into contact with the glue. 
Leaving the system open had the disadvantage that the Ar-degassed reaction solutions 
were quickly re-oxygenated. Neither ACN, DMSO nor other volatile solvents were 
expedient.  
A clear advantage of EPSS was the possibility of measuring up to 96 compounds 
simultaneously. Total run time for one sensor plate measuring 96 wells and 5 scans 
each took 45 min at a scan rate of 0.64 V/s. What is more, even slightly insoluble 
compounds were measurable in PB as long as the threshold concentration was not 
reached.  
The sensitivity of electrochemical experiments is influenced by the shape of electrodes. 
At the moment, the electrode shape in our sensor plates is the inter-digitated electrode 
type, so impurities were easily traced.  
 
2.4.3 Solvent-Related Issues 
 
Normally, electrochemical experiments are first conducted in pure ACN because it 
produces a curve shape resolution which facilitates easy evaluation of curve shapes and 
its peak. Secondly, DMSO or any other solvents are used to obtain the same results. 
Typically, curve resolution and shape is less sharp in DMSO or aqueous solvents. 
Initially, hepes buffer was used as reaction solvent for EPSS measurements. However, 
based on the appearance of unsolicited signals in the blank run indicating hepes buffer 
as a potential reaction partner, the buffer system was changed to phosphate buffer with 
all other conditions (concentration, ionic strength and pH value) kept the same.  
The reaction solvent of a single compartment system was ACN, DMSO and PB. 
Interestingly, the results in DMSO obtained from the classical method and results in PB 
from EPSS correlated well as illustrated in Fig. 8. 
 
2.4.4 Internal Standards 
 
Common internal references were used such as the FeCN-complex for aqueous solutions 
and FOC for organic solvents [52]. Gagné et al. [52] have described the suitability of 
internal references such as FOC. Measurements of a reduction potential is facilitated by 
the use of reliable and universally accepted reference electrodes such as normal 
hydrogen electrode (NHE), saturated calomel electrode (SCE) and Ag/AgCl electrode.  
Unfortunately, they have not been able to find any good reference electrodes that work 
for any aqueous phases as measurements in aqueous media have not been extensively 
researched so far. 
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For this reason, the usage of an internal standard like FOC as well as FeCN-complex is 
clearly advantageous [52].  
The cyclic voltammetric experiment is performed without FOC or FeCN first. FOC/ FeCN 
is added to the reaction solution and the experiment is then repeated [52]. Both the 
FOC and FeCN-complexes have a characteristical curve shape, showing reproducible 
reversible electrochemical behaviour. The redox potential of FOC is the absolute zero of 
the experiment so all formal cyclic voltammetric redox potentials are usually referred 
against internal standards e.g. FOC or FeCN.  
Solubility of FOC is an issue in the physiological-like conditions as FOC is completely 
insoluble in aqueous media. The addition of 10% DMSO decreases the risk of 
precipitation. Experiments with 5% FOC resulted in no signals. In the case of aqueous 
conditions, FeCN should be preferably used. 
 
 
Ferrocene_ACN 100%
-1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8
E/V/AgAgCl
-0.000016
-0.000014
-0.000012
-0.000010
-0.000008
-0.000006
-0.000004
-0.000002
0.000000
0.000002
0.000004
0.000006
0.000008
0.000010
0.000012
I/
A
0.552
0.367
 
Ferrocene in buffer_EPSS
-0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
E/V/AgAgcl
-0.000006
-0.000005
-0.000004
-0.000003
-0.000002
-0.000001
0.000000
0.000001
0.000002
0.000003
0.000004
I/A
0.251
0.171
 
Fig.9 Cyclic voltammogram ferrocene in acetonitrile,              Fig.10 Cyclic voltammogram ferrocene in phosphate buffer,   
scanning from 0.6 to 1.0 V with a scan rate of 0.8 V/s,                       scanning from -0.3 to 0.8V with a scan rate of 0.64 V/s,     
signals retrieved by classical cyclic voltammetry                signals retrieved by EPSS, HT-cyclic voltammetry                                                                              
 
 
Solvent induced differences in the curve shape can also be investigated in Fig.9 and 
Fig.10. The cyclic voltammogram of FOC (Fig.9) conducted in ACN showed much 
sharper resolution than the cyclic voltammogram of FOC in PB (Fig.10). 
Interestingly, cyclic voltammetry at slow scan rates results in reversible behaviour, while 
faster scan rates reveal quasi-reversible behaviour [43, 47, 52]. 
 
2.4.5 Further Approaches in Electrochemistry 
 
Not many comparisons between classical and HT-cyclic voltammetry measurement are 
reported in literature. Shi et al. [53] described an electrochemical method to carry out 
experiments on microelectrodes based on microchips.  
Recently, a literature search to obtain references with descriptions of similar systems 
such as EPSS has not revealed any results.  
Another approach to applying electrochemistry for profiling or screening purposes is an 
electrochemical flow-cell coupled to LC/MS (EC/LC/MS) [40, 54]. Karst et al. [40] 
FeFe
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investigated the suitability of this method for the fast detection of electrochemical 
behaviour when performing a LC/MS experiment. This electrochemical flow-cell is 
commercialized by ESA.INC (Chelmsford, USA).  
Again, unknown concentrations and time are two main disadvantages to this method. 
The flow-cell is coupled with LC/MS so it is a part of one single run, which does not give 
much time for the compound to react electrochemically [36, 40, 55]. Furthermore, this 
system does not work under physiological-like conditions due to the required use of 
polar eluents in most LC/MS experiments and, thin-layer or wall-jet cells have a 
reputation for being contaminated very easily by reaction side products [36, 40].  
The use of phosphate buffer is not possible, since it induces the risk of precipitation 
inside the instrument. In comparison with EPSS, this method does not provide any 
further information on the redoxreaction type.  Gun et al. [55] showed that EC/LC/MS 
could be used as a powerful tool for the investigation of complex electrochemical 
transformations.  
In principal, EC/LC/MS is a useful tool for a quick answer of unspecific electrochemical 
questions related to mass changes detectable in mass spectra. However, for the 
retrieval of comprehensive information on the redox behaviour, the strongest 
recommendation is to use EPSS. 
 
2.5 Conclusions and Perspectives 
 
For the first time, a HT-tool for the electrochemical profiling or screening of redoxactive 
molecules is available. Up to 96 samples can be measured in parallel to enable rapid 
determination of electrochemical characteristics. Tedious cleaning steps can be avoided, 
as the sensor plates are disposable. If problems related to measurements in volatile 
solvents can be resolved, the EPSS would be a good profiling or screening system for 
early drug discovery. Moreover, for the specific studies of the redoxchemical behaviour 
of compounds, EPSS is suitable as both the number and rate of scans can be optimized 
with relation to the experimental focus. 
Although EC/LC/MS seemed to be more advantageous being coupled to LC/MS, it does 
not really permit experiments under physiological-like conditions and quantitative 
analysis of concentrations is not possible. Although numerous publications about 
EC/LC/MS are available, results have never been reported for an extended dataset. 
EC/LC/MS is more suitable for the rapid determination of unspecific redox behaviour 
resulting in mass changes whereas EPSS provides the information on the redox kinetics 
and the time-dependent change of the compound [36, 40].  
The shape of the electrodes is the major determinant for specificity and concentration 
related issues. Currently the inter-digitated electrodes are used, allowing low 
concentration for the experimental set-up. One potential application of this technique is 
the measuring of a compound’s electrochemical stability in physiological systems. 
However, the range of potential explicit applications of EPSS still needs to be 
investigated.  
Literature search revealed that electrochemistry has become recognized as a suitable 
tool for research in early drug discovery phase or bioelectrochemistry [36, 40, 56]. 
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Smith et al. [56, 57] have described an interesting approach in their review article to 
determine the redoxchemistry of the amyloid-β-peptide (a precursor for Alzheimer’s 
disease) by EC/LC/MS. The growing significance of electrochemistry is illustrated by a 
number of publications which use electrochemistry to model phase-I metabolism [36, 40, 
55]. 
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Chapter 3: Redoxchemical Approach for the Prediction of 
Metabolic Stability 
 
3.1 Introduction 
 
In Chapter 2 (pp. 33) the development of the method for HT-cyclic voltammetry has 
been already discussed. This method could be useful in supporting the electrochemical 
approach for compound profiling based on the relationship between redox potentials 
and metabolic stability. 
In the following chapter, focus is mainly on the development of an assay based on a 
redoxchemical process by using a simple to handle redoxindicator (RDI), and the 
application of the results in the quantification and prediction of metabolic stability. This 
chapter deals with the development of a redo chemical process based on p-chlorine and 
describes analytical and compound related challenges that were encountered.  
The most commonly occurring quinines are benzoquinones, naphthoquinones and 
anthraquinones. They are predominant in nature and are important components of 
several functional biological systems such as electron transport chains and protein 
carboxylation. Some quinones, such as ubiquinones, coenzyme Q and vitamin K, are 
metabolically significant [58]. The name “quinone” refers to compounds containing 
benzoquinone isomers as part of their structure [58]. Their carbonyl groups are more 
ketene-like, and although their structure is derived from aromatic compounds, they are 
not aromatic [58]. Halogenated quinones such as p-chloranil (2, 3, 5, 6 tetrachloro-1, 
4-dibenzoquinone) or DDQ (dichlor-diquino-dimethane) are often used as strong 
oxidizing agents in organic chemistry.  
Quinone chemistry is similar to that of α−β-unsaturated ketones. Their redox features 
are broadly based on the electrophilic reactivity determined by the carbonyl groups and 
the reaction of polarized double bonds with nucleophiles [58]. Quinones are involved in 
two different types of redox transitions, namely reactions involving only electron 
transfer and reactions nucleophilic addition, implying either oxidation or reduction of the 
quinoid ring. Quinones, in our case p-chloranil, are one or two electron acceptors. These 
one or two-electron transfer mechanisms can be observed in reversible two-peak cyclic 
voltammograms. Estimated reduction potentials of p-chloranil and juglone were Ered: -
0.131 V vs. FOC (EPSS) and Ered: -0.454 V vs. FOC (EPSS) respectively. 
An extensive literature search of molecules with well-documented electrochemical 
properties was conducted. Subsequently, nine compounds with a reduction potential 
close to that of CYP450 and a radical intermediate were selected for CV-measurements.  
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p-Chloranil (Fig.1) satisfied these criteria: 
 
O
O
Cl
ClCl
Cl
 
 
Fig.1 2,3,5,6-tetrachloro-1,4-dibenzoquinone (p-chloranil) 
 
 
The goal of the current study was the development of a HT-screening assay based on 
redoxchemical interactions. The assay should provide data simulating redox behaviour 
as observed in biological systems with focus on metabolic stability. Therefore, a strong 
electron acceptor such as p-chloranil was chosen as suitable component. 
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Fig.2 General reaction pathway of p-chloranil with a sample S 
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3.2 Experimental Section 
3.2.1 Drugs and Chemicals 
 
p-Chloranil, chloranilic acid, o-chloranil, menadione, DDQ and juglone used in this study 
were purchased from Fluka (Buchs, Switzerland) and used without purification. 1, 2- 
naphthoquinone, imipramine, ciprofloxacin, venlafaxin, verapamil, paroxetine and 
loratadine were obtained from Sigma-Aldrich (Buchs, Switzerland). All other compounds, 
namely sertraline, prochlorperazine, desipramine, nitrendipine, 5-methoxy psoralen and 
8-methoxy coumarin were obtained from an internal compound depository. 
Internal compounds with CL_high_mic were obtained as 100% DMSO stock solutions 
from an internal compound depository. Dopamine, pyrocatechine and spectroscopic 
grade DMSO were purchased from Acros (Belgium). The pH of the reaction solutions 
was adjusted with phosphate buffer (PB) (Merck) at pH 7.4. 
 
3.2.1.1 Preparation of Sodium Dihydrogen Phosphate Buffer  
 
A detailed description of the buffer preparation is provided in Subchapter 2.2.1.2 (p.35). 
 
3.2.1.2 Preparation of p-Chloranil Solution  
 
A 10.0 mM (2.45 mg/ml) p-chloranil stock solution was prepared by dissolving 2.45 mg 
p-chloranil in 1 ml DMSO 100%. The stock solution was further diluted with 980 µl 
DMSO 100% to a 0.2 mM working solution. 
 
3.2.2 Methods 
 
3.2.2.1 Cyclic Voltammetry 
 
In Chapter 2, Subchapter 2.2, p.38, Materials and Methods for cyclic voltammetry have 
already been described more detail. Thus, there is no repetition in Chapter 3. 
 
3.2.2.2 UV-Spectroscopy  
 
Primary UV-spectroscopic measurements were conducted using a SPECTRAmax Plus 384 
v1.18 Feb01 2005 (serial number: MN 03536) for 96 or 384 UV-well plates and 
SoftMax® Pro 4.8 (Molecular Devices Cooperation) for data analysis (both Molecular 
Devices Cooperation). 
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3.2.2.3 LC/MS Equipment: Agilent 1100 Series and 6140  
 
The LC/MS system Agilent 1100 Series (Agilent Technologies, Waldbronn, Germany) 
comprised of a DE 23930947 column oven, DE 23902690 auto sampler, two DE 
43619228 and DE 23913504 binary pumps and used an Agilent Extend C18, 1.8 µm, 
4.6x50 mm analytical column maintained at a temperature of 60 °C, a DE 54200390 80 
Hz Full spectral Ultra Fast LC diode array UV detector and a G1946D MSD SL single quad 
MS with API-ESI as ionization source. 
For separations with basic eluents, a Waters Xbridge® C18 2.5 µm, 4.6 x 75 mm 
analytical column was used because its detection range covered a pH range from 1-12. 
Data was acquired using an interface and the chromatograms analysed using Agilent 
Chemstation® Rev.B.03.01 (317). 
The LC/MS system Agilent 1200 Series with 6140 MSD (Agilent Technologies, 
Waldbronn, Germany) comprised of a TCC SL column oven, DE 23902690 auto sampler, 
two binary pumps SL, Agilent Eclipse Plus® C18 1.8 µm, 2.1x50 mm analytical column 
maintained at a temperature of 60 °C and a DAD SL 80 Hz Full spectral Ultra Fast LC 
diode array UV detector with a 10 mm measurement unit and a G1946D MSD single 
quad MS with API-ESI as ionization source.  
Agilent Eclipse Plus® C18 1.8 µm, 2.1x50 mm was identified as suitable for rapid 
resolution. Data was acquired using an interface and the chromatograms were analysed 
using the software as described above. 
3.2.2.4 LC/MS Method: Agilent 1100 Series and 6140  
 
For Agilent 1100 Series, a linear mobile phase gradient (1.0 ml/min) consisting of 
water (A): ACN (B): formic acid (65:35:0.1) was run. After 0.4 Min to 1.0 Min the 
gradient reached its maximum of water (A): ACN (B): formic acid (5:95:0.1) before 
returning to starting conditions. The column was equilibrated with 65% A during 0.5 
min prior to next injection. Total runtime was 2.5 min. Detection of the analytes was by 
in-line UV-detection at 254, 280, 292, 310, 320 nm. 
For Agilent 1200 Series with 6140 MSD the gradient, run for this assay consisted of 
solvent A 95% water +0.1% formic acid and solvent B 5% ACN + 0.1% formic acid. 
The gradient profile was 5- 95%B for 0.6 min at 1.0 ml/min and the column was 
equilibrated with 95% A for 0.2 min prior to each injection. Total runtime was 2.5 min. 
Detection of the analytes was by inline UV-detection at 254, 292, 310 and 320 nm. 
3.2.2.5 MS-Parameters for Agilent 1100 and 6140 Series  
 
Mass spectrometric parameters for the instruments of 1100 Series and 6140 Series 
were similar except for the peak width and step size. With 6140 the step-size was set 
at 0.15 min and peak width was at 0.05 min. The capillary voltage was 3500 V (positive 
and negative electrode). Standard conditions were used for the spray chamber (13 
L/min, flow of drying gas at 300°C and 60 psig for nebuliser pressure). Mass detection 
was set up for a range of molecular weights between 150 and 600 g/mol using a 
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fragmentor voltage of 150 V and a peak width of 0.1 Min. All mobile phases were freshly 
prepared before each run due to stability issues. Peak height ratios between pure 
sample and sample+p-chloranil were used for quantitative analysis. 
3.2.3 Final conditions for the sample preparation 
 
p-Chloranil solution was prepared as described detailed in Subchapter 3.2.1.2 
(p.49).Total reaction volume was 100.0 µl containing 5.0 µl 0.01 mM p-chloranil, a 5.0 
µl 0.01 mM sample and a 90.0 µl 50 mM PB. Samples, obtained in the 5 mM 8.0 µl 
format were prepared and diluted with 100% DMSO to the working solution 
concentration (0.2 mM). All liquids were degassed with Ar gas for 20 min to remove 
oxygen from the solution. Further steps in sample preparation were automated and 
performed with a Tecan Gemini® robotic system. UV-half area plates were covered with 
an aluminium foil which was pre-pierced to allow the robotic system to fill the wells. In 
the final step, p-chloranil was pipetted to each well to start the incubation. The system 
was incubated for 30 min and 30.0 µl 0.1 M HCl was added to adjust the final pH to 6.5. 
Subsequently, aliquots of the reaction volume were transferred into a NUNC 96 Agilent 
HPLC plate and covered with a pierceable foil. Finally, the LC/MS experiment was begun.  
In Fig.3, the sample procedure is illustrated graphically: 
 
 
 
 
Fig.3 The principal steps of the sample preparation for p-chloranil assay 
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3.2.4 Assay Optimisation 
 
The method was optimized by analysis of the time dependency, substrate and RDI 
dependency.  
Time dependent product formation was investigated by selecting seven different time 
points (5, 20, 75, 90, 140, 170 and 210 min). Results are presented in Fig.11 (page 59). 
Time dependency of substrate and RDI concentrations were investigated using similar 
procedures (Fig.11) by varying substrate and RDI concentration at constant time. Eight 
different substrate and RDI concentrations (0.1, 0.075, 0.05, 0.025, 0.01, 0.005, 0.0025 
and 0.001 mM) were chosen. All other parameters remained unchanged. Measurements 
were performed in triplicate. 
3.2.5 Data Analysis 
 
All results, acquired in Excel, were transferred to Origin 7.0 (OriginLab Cooperation, 
Northampton, USA), whereas all statistical calculation were made with Statistica 7.1 
(StatSoft, Tulsa, USA). The peak heights of the sample before and after 30 min 
incubation with p-chloranil were compared. The difference between the two peak 
heights was expressed as percentage decrease of compound (%CPDdis). 
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3.3 Results and Discussions 
 
The major goal of the current study was the development of a fast and reliable 
redoxchemical assay to measure discovery compounds under physiological-like 
conditions using p-chloranil as the RDI and LC/MS as an analytical technique. This assay 
should simulate redox behaviour of compounds in biological systems. Consequently, the 
strong electron acceptor p-chloranil was chosen to interact with compounds from early 
drug discovery.  
Initially, the assay was designed for UV-spectroscopy using a 96-well plate reader but 
soon transferred to LC/MS due to interferences of absorptions maxima (λmax) of sample 
and RDI. 
Mass spectrometry (MS) was only used for structure determination or crosschecking. 
Almost all the experiments were conducted with a chromatographic system of the 
Agilent 1100 series. With the introduction of Agilent 6140 RRLC with fast MSD, a 
modern and further developed version of Agilent 1100 Series, experiments were 
repeated and compared. The major difference between the two LC/MS systems was 
sensitivity and scanning speed for peak detection.  
 
3.3.1 Selection of p-Chloranil 
 
Preliminary experiments before beginning of this study were conducted with p-chloranil. 
Polar and non-polar solvents such as acetonitrile (ACN), ethanol (EtOH) and 
dimethylsulfoxide (DMSO) and different analytical or experimental conditions were 
tested. However, aqueous conditions had not been tested previously in the preliminary 
experiments. Furthermore, p-chloranil exhibited certain oxidation ability in terms of 
reactions with sample solutions.  
Chemically, p-chloranil is a pi-acceptor, showing high electron affinity due to its 
tetrachlorosubstitution [59]. Cl has a strong negative inductive effect on the quinoid ring. 
For that reason, p-chloranil was taken as a key structure for a literature data search 
conducted with Beilstein (MDL CrossFire Commander Version 7.9 SP2 (Build 46)) [60].  
Selection criteria were either compounds including quinoid structures or small 
compounds with well-documented electrochemical properties.  
This data is collected and a selection of 9 compounds is depicted in Table 1. Only 8 
compounds are shown in Table 1, as the ninth compound is the internal standard FOC. 
Potentials are illustrated either in half-wave potentials or peak potentials. The entire 
information is given in the appendix. 
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Table 1 Literature data of selected compounds with documented electrochemical data 
 
 
Compound MW Structure  E-Pot 
[61] 
Solvent Method Lit.Ref 
       
p-chloranil  245.88  -0.33 ACN CV [62-72] 
   0.35 ACN   
   -0.88 DMF CV   
   0.78 MeOH Pot.Tit   
   0.24 CH2Cl2 CV   
   0.312 C6H6    
chlorac 208.99  0.42 H2O CV [65, 73-78]  
        
       
       
ochlor 254.88  0.833 C6H6  [65, 79, 80] 
   0.794 H20    
       
mena 172.18  -0.225  P [58, 81-84] 
   -0.277  CV  
       
        
jug 174.16  0.22 DMSO CV  [65, 81, 85] 
   0.45     
       
12naphQ 158.16  0.579 EtOH  [65] 
       
       
chalk 208.26  -0.62 H2O P  
   -1.0061   [86, 87] 
   -1.19 Buffer P  
DDQ 227.01      
       
       
       
       
 
 
Data in Table 1 was identified as fairly inconsistent. Comprehensive information 
regarding experimental conditions or technical details was rarely provided. Consequently, 
the above eight compounds were measured using cyclic voltammetry, covering a range 
from -1.0 V to ~1.0 V, and ferrocene (FOC) as internal standard.  
Initial cyclic voltammetric experiments were only possible in ACN and DMSO due to the 
classical CV method. However, with the introduction of HT-cyclic voltammetry, 
measurements under physiological-like conditions were possible.  
The goal of the electrochemical study was the identification of a set of compounds 
covering a broad range of reduction potentials and ideally exhibiting a value close to the 
CYP450’s (Ered: -0.25 V) and reversible electrochemical behaviour [88].  
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The entire results of the CV-measurements have already been presented in Table 1 of 
Chapter 2, p.41. 
Juglone and p-chloranil (Fig.4 and Fig.5 respectively) were identified as examples for 
the CV-measurements reported previously. Hence, their reduction potentials were in a 
range which was expedient for successful sample oxidations. Naturally, there were 
differences regarding the experimental and literature values which were due to different 
electrode materials and experimental conditions. 
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Fig.4 Cyclic voltammogram of 0.01 mM juglone 
measured in 100% DMSO at a scan rate of 150 mV/s 
in a range from 600 mV to -1000 mV using classical 
CV 
 
 
Fig.5 Cyclic voltammogram of 0.01 mM p-chloranil 
measured in 100% DMSO at a scan rate of 150mV/s 
in a range from 600 mV to -1000 mV using classical 
CV 
 
 
 
Initial assay development and validation was carried out with juglone (5-hydroxy-1, 4-
napthoquinone) as it showed reversible two-electron accepting behaviour. Its λmax was 
determined as 424 nm in PB.  
Continuing experiments of juglone with commercially available compounds indicated 
juglone’s oxidizing properties were not strong enough for a significant change of UV-
spectra. The lack of substituents with strong negative inductive effects is one of the 
reasons why it is a weaker oxidant. For this reason, juglone was exchanged for p-
chloranil.  
Further optimisations of concentration and reaction volumes enabled the re-introduction 
of p-chloranil as a strong oxidant. What is more, the initial solubility problem of p-
chloranil was solved by the determination of its threshold concentration by reducing 
concentrations. Its λmax was determined at 292 nm in PB and the λmax of its 
hydroquinone (HQ) at 310 nm.  
With the extension of the dataset from commercially available compounds to discovery 
compounds, the low λmax of 292 nm soon appeared to be an obstacle as most discovery 
compounds have a λmax in a similar range. Thus, interferences of UV spectra were to be 
expected. To facilitate differentiation and strengthen the significance of this assay, the 
analytical technique was transferred from UV-spectroscopy to LC/MS. For data analysis, 
the peak height of the sample alone was compared with peak height of the sample after 
incubation with p-chloranil. Quantification via peak area was not appropriate due to
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occasionally appearing broad peaks. MS measurements, performed in the full scan mode, 
were required for additional structural information. 
3.3.2 Stability of p-Chloranil 
3.3.2.1 Light Influence 
 
Factors affecting the stability of p-chloranil were studied. The influence of light was 
tested by an experiment using an aluminium cover for UV plates. The analytical method 
of choice was UV-spectroscopy.  
The experimental set-up involved preparation of two sample plates at the final sample 
preparation conditions, one of which was provided with an additional light-protecting 
cover. 
Protecting p-chloranil from light achieved more stability. After 40 min, 25.43% of p-
chloranil was degraded in the absence of a light protecting cover whereas light 
protection increased the stability of p-chloranil by at least to 10%, as illustrated in Fig.6. 
Time in min (x-axis) was plotted against the natural logarithmic quotient of the 
absorption at the specific time point divided by absorption at time point t=0 (y-axis). 
Following this experiment, all tubes containing p-chloranil were protected from light with 
aluminium foil.  
In addition, p-chloranil was always added last, to ensure the same starting point for the 
incubation.  
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Fig.6 Influence of light on the degradation of p-chloranil using an aluminium (Al) cover. A kinetic measurement during 40 min was 
performed using three different wavelengths (292 nm, 310 nm and 650 nm). Measurements at 650 nm were necessary to 
crosscheck solubility of compounds. The measurement interval was 1 min and ODmin was set 0, ODmax at 1. The p-chloranil sample 
without Al-cover showed at higher degree of degradation (25.43%) than the sample with Al-cover (15.43 %). 
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3.3.2.2 pH-Related Influences 
 
Kinetic experiments of p-chloranil in aqueous media with neutral to slightly alkaline pH 
values indicated pH related degradation. Consequently, for the evaluation of potential 
pH-related influences on the absorbance spectra of p-chloranil, an experiment was 
launched at two different pH values (6.5 and 7.4) with similar experimental conditions to 
that of Sarr et al. [89, 90] . All reaction solutions were purged heavily with Ar to avoid 
oxygen influence. By decreasing the pH value, decomposition was either slowed down 
or even stopped as illustrated in Fig.7. 
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Fig.7 Influence of pH value on the degradation of p-chloranil using aluminium cover. Measurement was done with UV-Vis-
spectroscopy performing a kinetic measurement over 40 min using three different wavelengths at 292 nm, 310 nm and 650 nm. 650 
nm was necessary to crosscheck solubility of compounds. The measurement interval was 1 min with ODmin was set at 0, ODmax at 1.
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According to Hancock and Bishop [91, 92] hydrolysis of p-chloranil produces chloranilic 
acid. Sarr et al. [89] intensively studied the behaviour of p-chloranil in aqueous media in 
the pH range from 6.5 up to 9 with observed change in absorbance spectra. Raymond 
et al. [93] also reported the fast degradation of p-chloranil in aqueous media. In Fig.8 
the degradation of p-chloranil to chloranilic acid as described in the publication of 
Veltsitas [94] is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.8: Degradation of p-chloranill to chloranilic acid according to Veltsitas [94] 
 
 
Furthermore, a new step was introduced into the sample preparation procedure. After 
t=30 min, the incubation of p-chloranil/ sample was terminated by adding 30.0 µl 0.1 M 
HCl to reach the final pH of 6.5 and make an LC/MS experiment feasible, as degradation 
was no longer proceeding. 
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3.3.2.3 Physical Stability of p-Chloranil  
 
In addition, the ageing of solid p-chloranil should be taken into account. The p-chloranil 
powder is hygroscopic and undergoes rapid decomposition to its hydroquinone (HQ). In 
practice, any given container of a p-chloranil sample should not be used for longer than 
2-3 months after opening.  
A constant Ar atmosphere covering the powder in the container was found to slow down 
degradation. The difference between freshly opened powder and older powder are 
illustrated in Fig.9.  
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Fig.9: Degradation kinetics of p-chloranil measured with Agilent 6140 under the conditions mentioned in Material and Methods, 
pp.46 
 
Two p-chloranil solutions were prepared containing either fresh p-chloranil in 100% 
DMSO or old p-chloranil in 100% DMSO solutions at a concentration of 0.01 mM and 
subsequently measured chromatographically.  
Measurements were conducted by multiple injections. The curve with green points 
represents the old p-chloranil after multiple injections, whereas the curve with red dots 
represents the freshly opened powder. 
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3.3.3 Compound Selection Procedure 
 
A set of 12 commercially available compounds (Table 2) with reportedly high in vivo 
clearance (CL_in vivo) were chosen for the reaction with p-chloranil. These compounds 
covered a broad range of CL_in vivo [16] from 0.1 to 50 ml/min/kg and were incubated 
under the assay conditions described previously. Besides structural diversity, one of the 
major selection criteria was a high microsomal instability. 
 
 
Table 2 Structures of commercially available compounds with their CL_mic [16] 
 
NAME STRUCTURES CL_mic_rat
[µl/min/mg protein]
desipramine 777.67 prochlorperazine 973
verapamil 650 ciprofloxacine 4.8
loratadine 434.91 venlafaxine 643.67
8-Me-Coumarin 225.54 nitrendipine 66.13
5-Me -Psoralen 1033.67 sertraline 97.75
paroxetine 2.15 imipramine 2180
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Five of these commercially available compounds with particularly high CL_in vivo were 
used for incubations with p-chloranil and measured kinetically by UV-spectroscopy. The 
obtained results are presented in Fig.10.  
Following first-order kinetics, the ratio of the term lnAt/A0t (A stands for absorption) is 
plotted versus time (min). 
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Fig. 10 Degradation kinetics of five commercially available compounds [loratadine (lora), imipramine (imi), loratadine derivative 
(lora+derivative), paroxetine (paro) and sertraline (sertra)] after their incubation with p-chloranil at equimolar concentrations of 
0.01 mM. 
 
3.3.4 Assay Set-Up  
 
Several experiments modulating RDI, sample concentration, incubation time and assay 
conditions were performed to optimise reaction conditions. 
Fig.11 illustrates an example of the evaluation of concentration dependency on rate for 
pure p-chloranil and loratadine (lora), imipramine (imi) and sertraline (sertra) incubated 
with p-chloranil respectively. These commercial compounds were chosen as examples 
due to the good availability of their major metabolites. 
Equimolar conditions of 0.01 mM substrate and p-chloranil were appropriate as a linear 
plot of k vs. time was observed. Initially, assay development was carried out with 
juglone, another quinone showing reversible redoxchemical behaviour, but soon 
replaced by p-chloranil because juglone did not exhibit the expected oxidation capability.  
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Fig. 11:  Concentration dependency of three different commercially available compounds loratadine (lora), imipramine (imi), 
sertraline (sertra) and RDI p-chloranil at equimolar concentration of 0.01 mM. The reaction followed first order kinetics. The λmax 
was chosen for p-chloranil at 320 nm. The number of cases was n=4. The incubation length was set to 30 min.  
 
 
Concentration (substrate and p-chloranil) dependent behaviour was similar to that of 
juglone so when the concentration dependency experiment was repeated, only single 
measurements per concentration were performed. Thus, no error bars are presented in 
Fig.11. 
Finally, the assay set-up was as follows: sample concentration at 0.01 mM, RDI 
concentration at 0.01 mM, 10% DMSO, PB and an incubation time of t=30 min. The 
reaction was stopped by adding 30.0 µl 0.1 M HCl to the reaction solution decreasing 
the pH to its final value of 6.5 and inhibiting the formation of hydroquinone (HQ) or 
trichlorhydroquinone (TCHQ). 
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3.3.5 Assay Validation: Reproducibility, Robustness 
 
Reproducibility and robustness are two important criteria for a stable assay set-up. For 
that reason inter-day as well as intra-day variability of p-chloranil was evaluated. 
First of all, consistency in retention times was checked. The retention times (RT) of p-
chloranil were 1.105 min for Agilent 6140 Series and 0.552 min for Agilent 1100 Series 
respectively.  
Table 3 illustrates the RSD % for 13 injections of p-chloranil on various days and 
months. 
 
 
Table 3: Relative standard deviation of p-chloranil for its retention times for Agilent 1100 Series  
 
Retention times average SD RSD %
(RT: 0.552 min)
p -chloranil 0.551 0.006 1.086
(n=13)  
 
 
Fig.12 is a representative example with p-chloranil of the chromatograms recorded with 
the Agilent 1200 Series with 6140 MSD.  
 
 
 
 
 
Fig.12: Representative chromatogram of p-chloranil measured with Agilent 1200 series and 6140 MSD. The gradient run for this 
assay consisted of 95% A (water +0.1% formic acid) and solvent 5% B (ACN + 0.1% formic acid). The gradient schedule is 5- 95% 
B for 0.6 min at 1.0 ml/min. The column is re-equilibrated with 95% A during 0.2 min prior to next injection. Total run time was 2.5 
min. Detection of the analytes was by inline UV-detection at 254,292, 310, and 320. 
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The assay was validated on different days with various batches of freshly prepared p-
chloranil. The results of this validation are presented in Table 4. For the calculation of 
the RSD of the intra-day variation, the average of a triple experiment was taken, 
whereas for the calculation of inter-day variation, the averages of two days were taken. 
These experiments were performed chromatographically and measured in triplicate. 
 
Table 4 Intra-day, inter-day assay variability for p-chloranil (RDI) alone 
 
Analyte Concentration Intra-day variation Inter-day variation
(mM) (RSD,%) * (RSD,%)
p -chloranil 0.01 5.38 3.19
(n=3)
0.01 3.19 2.57
0.01 1.15 3.41
0.01 3.19 3.41
* Inter-day variations are the mean of triple experiments of two days  
 
Fig.13 illustrates a representative chromatogram of an internal sample (K5_2nd). It 
proves the effect of p-chloranil on the sample, as after 30 min only 70% of the initial 
concentration of K5_2nd remained. 
 
 
 
Fig.13 Example of a chromatogram measuring K5_2nd after the incubation t=30 min with p-chloranil. Measured with Agilent 1100 
series and MSD. The gradient run for this assay consisted of A (water +0.1% formic acid) and B (ACN + 0.1% formic acid). The 
gradient schedule is 5-95% B for 0.6 min at 1.0 ml/min. The column is re-equilibrated with A 95% for 0.2 min prior to next injection. 
Total runtime was 2.5 min. Detection of the analytes was by inline UV-detection at 254,292, 310, and 320 nm. 
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3.3.6 Reaction Products of p-Chloranil and MS 
 
As previously described in Materials and Methods (Subchapter 3.2, pp 49) the ionization 
source used was API-ESI. Assay development also increased experience in the handling 
of p-chloranil and an understanding of its reaction pathway.  
MS-measurements for p-chloranil were challenging, because for successful detection of 
signals in the negative scan mode, p-chloranil had to convert into its 
tetrachlorosubstituted hydroquinone first. Characteristic isotopic patterns for Cl allowed 
easier interpretation.  
In Fig.14 a calculated isotopic pattern for tetrachlorohydroquinone TClHQ (MW: 
247.89) is provided. 
 
 
 
 
 
Fig.14 Calculated isotopic pattern for tetrachlorohydroquinone (TClHQ) using a web calculating tool [95] 
 
 
Chloranilic acid has been identified as one of the reaction products of p-chloranil in 
aqueous media. The absorption maximum of chloranilic acid occurs at λmax: 320 nm in 
PB which is close to that of p-chloranil (λmax at 292 nm) as mentioned previously. By 
UV-spectroscopy, differentiation of those peaks was unfeasible, but chromatographic 
separation enabled their visualization. This observation was confirmed by direct injection 
of chloranilic acid. 
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In Fig. 14 and 15, the calculated isotopic patterns of tetrachlorohydroquinone (TClHQ) 
and chloranilic acid are shown as a basis for the comparison with the experimental 
results retrieved. 
 
 
Fig.15 Calculated of isotopic pattern for chloranilic acid (chlorac) using a web tool [95]  
 
In Fig.16 two isotopic patterns are depicted, the ones of both TClHQ and chloranilic acid. 
The typical isotopic pattern for both tri- and tetrachlorosubstitution are visible for TClHQ, 
but masses at 208.9 suggested the formation of chloranilic acid (208.9 g/mol). Closer 
inspection of the isotopic pattern of chloranilic acid retrieved experimentally suggested a 
trichlorosubstitution but the expected mass for trichlorosubstitution does not correlate 
with the MW as shown in Fig.16. No satisfactory explanation was available for this effect. 
TClHQ was injected to better understand the mixed isotopic pattern with p-chloranil as 
shown in Fig.19. 
 
 
 
Fig.16 Isotopic pattern of TClHQ and chlorac measured with Agilent 6140 Series. The gradient run for this assay consisted of A 
(95% water +0.1% formic acid) and solvent B 5% (ACN + 0.1% formic acid). The gradient schedule was 5- 95% B for 0.6 min at 
1.0 ml/min. The column was re-equilibrated with 95% A for 0.2 min prior to next injection. Total runtime was 2.5 min. Detection of 
the analytes was by inline UV-detection at 254,292, 310, 320 nm. Standard conditions for MS were used. 
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Following this, more isotopic patterns of p-chloranil are shown. Fig.17 illustrates the 
calculated values whereas Fig.18 and 19 provide an overview of isotopic patterns 
retrieved from our experiments: 
  
 
 
Fig.17 Calculated isotopic pattern of p-chloranil using a web tool [95] 
 
 
Freshly prepared p-chloranil was analyzed via LC/MS and the result is shown in Fig.18. 
It exhibited the characteristic tetrachlorosubstitution pattern. 
 
 
 
 
Fig.18 Isotopic pattern of fresh p-chloranil analysed with Agilent 6140 Series. The gradient run for this assay consisted of A 
(95% water +0.1% formic acid) and solvent B 5% (ACN + 0.1% formic acid). The gradient schedule was 5- 95% B for 0.6 min at 
1.0 ml/min. The column was re-equilibrated with 95% A for 0.2 min prior to next injection. Total runtime was 2.5 min. Detection of 
the analytes was by inline UV-detection at 254,292, 310, 320 nm. Standard conditions for MS were used. 
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In Fig.19 there is obviously a difference in the isotopic pattern as the characteristics for 
tetrachlorosubstitution are no longer visible. 
 
 
 
 
Fig.19 Isotopic pattern of mixture of p-chloranil and TClHQ analyzed with Agilent 6140 Series. The gradient run for this assay 
consisted of A (95% water +0.1% formic acid) and solvent B 5% (ACN + 0.1% formic acid). The gradient schedule was 5- 95% B 
for 0.6 min at 1.0 ml/min. The column was re-equilibrated with 95% A for 0.2 min prior to next injection. Total runtime was 2.5 min. 
Detection of the analytes was by inline UV-detection at 254,292, 310, 320 nm. Standard conditions for MS were used. 
 
 
In order to confirm these observations, the study with p-chloranil and its reaction 
behaviour was repeated in another internal lab at F. Hoffmann-La Roche with more 
sophisticated equipment (Appendix, Results from p-Chloranil Studies pp. 115, [96, 97]) 
Colleagues from the department Applied Analytical Methods, section Molecular Structure 
Research at F. Hoffmann-La Roche agreed to analyze the reaction products of p-
chloranil and determine its reaction behaviour under our assay conditions. 
The results are attached in the appendix [96, 97]. One of their major results was the 
identification of tetrachlorohydroquinone which was probably formed by oxidation of p-
chloranil in the ionization source of LC/MS/MS. They also discovered that direct flow 
injection of p-chloranil into MS did not enhance the formation of hydroquinone.  
They repeated direct flow injection of p-chloranil dissolved in ACN/MeOH and the 
isotopic pattern was in accordance with a tetrachloride-substitution. Moreover, direct 
flow injection of p-chloranil, dissolved in PB, also revealed an isotopic pattern 
characteristic of tetrachloride substitution. Both ACN and PB, which were used for the 
chromatographic experiment, did not contain of any modifiers. Subsequent experiments 
with standard experimental LC/MS conditions revealed a mixture of isotopic patterns of 
HQ and p-chloranil. Formic acid in the mobile phase (added to increase the ionization of 
the compounds), probably contributes to the decomposition of p-chloranil in the 
ionization source. The results of their experiments were similar to those already 
retrieved by our lab. A major finding was the immediate formation of HQ once the 
LC/MS experiment was launched. However, there also seemed to be a time dependent 
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formation of HQ and TCHQ documented with chromatograms found in the appendix. In 
summary, our results were confirmed by those of our colleagues. 
One of their recommendations was to avoid API-ESI or formic acid as a modifier. API-
ESI was described in the literature as difficult to handle with regard to other issues [89].  
Sarr et al. [89] reported that most likely a basic environment is created due to the 
enrichment of hydroxide ions during electro spray ionization. Moreover, he stated that 
the environment in the electro-spray chamber seemed to be sufficient for alkaline 
hydrolysis [89]. Finally, an example for complete decomposition of p-chloranil is shown 
in Fig.20. A similar one was published by Sarr et al.[89]. 
 
 
 
 
 
Fig.20 Example for decomposition of p-chloranil after short incubation in aqueous medium at pH 7.4 with Agilent 6140 Series. 
The gradient run for this assay consisted of A (95% water +0.1% formic acid) and solvent B 5% (ACN + 0.1% formic acid). The 
gradient schedule was 5- 95% B for 0.6 min at 1.0 ml/min. The column was re-equilibrated with 95% A for 0.2 min prior to next 
injection. Total runtime was 2.5 min. Detection of the analytes was by inline UV-detection at 254,292, 310, 320 nm. Standard 
conditions for MS were used. 
 
 
3.4 Conclusions and Perspectives 
 
p-Chloranil is a compound with complex reaction behaviour due to its tetrachloride-
substitution. Assay development was therefore accompanied with numerous challenges 
and working with p-chloranil required some precautions.  
Solutions of p-chloranil should always be prepared freshly before each experiment and 
stored in the dark. In addition all reaction solutions should be degassed with Ar before 
use.  
As p-chloranil is inexpensive, it is advantageous to exchange the bottle of powder 
regularly if used intensively, or at least ensure that the powder is always stored under 
Ar atmosphere. 
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Intensive investigations revealed that quantification by peak height comparison of 
sample and sample after p-chloranil incubation offered reasonable results. Quantification 
via peak area was not possible as occasionally broad peaks occurred. 
The assay per se works, if quantification is based on the disappearance of the sample. 
Its experimental results will be further discussed in Chapter 4 (p.71). 
Clearly advantageous for the p-chloranil assay are the low amounts of compound 
required for the assay. Including a final DMSO concentration of 10% in the final assay 
conditions enabled concentrations of 0.01 mM for both p-chloranil and most internal 
samples. 
The assay showed reasonable reproducibility and robustness, expressed in a small SD. If 
the assay set-up is taken for further research, a replacement of p-chloranil with a 
compound with similar oxidant properties but less complex reaction behaviour in 
aqueous media could be advantageous. o-Chloranil is a potential compound for the 
replacement of p-chloranil as o-chloranil exhibits a more positive reduction potential as 
p-chloranil (Ered (ochlor) vs. FOC: 0.010 V), but literature has not reported any complex 
reaction behaviour in aqueous media. 
For the routine application of the assay, only LC is necessary as MS is only used for the 
answering of structure specific questions. Additionally, in case of the lack of 
chromophoric structures, MS-analysis can be used to detect metabolite formation. If MS 
is used routinely for quantification, a replacement of modifier should be considered 
because of a tendency for formic acid (FA) adducts formation in API-ESI/MS. 
Hence, this assay may be suitable for applications in early drug discovery and 
complement microsomal clearance information if the currently existing problems are 
solved. Results which were obtained in the current chapter will be further discussed in 
Chapter 4 (p.68). 
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Chapter 4: Prediction of Metabolic Stability by Redoxchemical and 
Electrochemical Approaches 
 
Results obtained from the electrochemical (Chapter 2, pp.33) and redoxchemical 
approach (Chapter 3, pp.47) for the early metabolic stability profiling of discovery 
compounds are further discussed in the following chapter. 
 
4.1 Introduction 
 
Due to extensive biotransformation, insufficient metabolic stability of discovery 
compounds is still a major bottleneck in the drug discovery process [13]. Numerous in 
vitro approaches have been introduced in the past few years for the early determination 
of metabolic profiles.  
The primary aim of metabolic studies is the detection of a compound’s most likely site of 
metabolism, enabling compound modification in the early stages of the drug discovery 
process. 
Metabolic stability is a term widely used in the description of the rate and extent of 
metabolism of a compound [12]. For example, a compound with a low degree of 
metabolic stability is rapidly and extensively metabolized [11]. 
Usually, metabolic stability studies involve the determination of two pharmacokinetic 
parameters: in vitro half-life (t1/2) and intrinsic clearance (Clint) which are used for 
the description of metabolic stability.  
The intrinsic clearance is based on three basic parameters: the blood flow through the 
organ (Q), the intrinsic capability of the organ to clear the drug (Clint) and the limitation 
on drug uptake into the clearing organ [12, 98]. 
Applying the theory of the “well-stirred” model, the relationship between hepatic venous 
concentration Cout, incoming mixed arterial and venous blood concentration Cin, hepatic 
blood flow QH and intrinsic clearance Clint is expressed as follows: 
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intuH
 H
Cl  f  Q
Cl  f  Q
 Cl
⋅+
⋅⋅
=
  (1)
 
 
 
Clearance and its relationship to metabolic stability have already been discussed 
extensively in Chapter I, pp. 12, of this thesis and will not be further mentioned 
hereafter. 
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4.1.1 Biotransformation and CYP450 
 
Most drugs with a low degree of metabolic stability are usually associated with extensive 
biotransformation reactions. 
Biotransformation is defined as the conversion of a lipophilic to a more hydrophilic 
compound which can be readily excreted by the kidneys [12, 22, 23].  
Generally, biotransformation is divided into phase-I and phase-II metabolism. Phase-I 
metabolism involves oxidation, reduction and hydrolysis reactions and is catalyzed by a 
number of enzymes. Phase-II metabolism involves conjugation reactions, so 
biotransformation is normally linked with a reduction in lipophilicity and the formation of 
a metabolite that is less active than the parent compound [99]. Most phase-I reactions 
are catalyzed by cytochromes P450 (CYP450). 
CYP450s are enzymes of a superfamily with a haem-containing moiety [39]. Some of 
these isoforms exhibit high substrate specificity, based on the structural diversity in the 
active site of the enzyme, which perform essential biosynthetic functions such as steroid 
synthesis [35, 39, 100]. 
Only a few CYP450 isoforms play a significant role in the drug metabolism process 
[26].These are the isoforms of the CYP1A, 2A6, 2B6, 2C, 2D6, 2E1 and 3A families. 
The most versatile and most abundant isoform is CYP3A4 whose most interesting 
feature is an active site cavity of large volume resulting in a low substrate specificity [32]  
and a high capacity to oxidize a variety of both small and relatively large compounds 
[32]. If small molecules are bound to CYP3A4, a significant portion of the cavity remains 
unfilled by the substrate. Hence, the contact between the substrate and enzyme is not 
extensive and the unfilled portion of the cavity is sufficiently large to bind another 
substrate [33]. In such cases, orientation of the substrate to the active site of CYP3A4 is 
also important. 
 
4.1.2 CYP450 Catalysis 
 
The CYP450 catalysis itself is redoxchemical driven. Electrons obtained from an electron 
transport chain are needed for the formation of a high-energy oxidizing species [39, 101, 
102]. The high-energy oxidizing species is needed for efficient hydroxylation of an 
inactive C-H bond by the relatively inert oxygen molecule which is in its triplet ground 
state [39, 100].  
Several parameters contribute to the activation of CYP450. Coordination environment 
and the dielectric setting of the haem are both important as they significantly contribute 
to the high amount of electron energy required for the activation of the enzyme [1, 35, 
39].  
For the redoxchemical process of CYP450 catalysis, the haem moiety (Fig.1) (iron-
protoporphyrin) is very important as it is the electroactive component of CYP450 [39]. 
 
Chapter 4: Prediction of Metabolic Stability 
 
 
 73 
N
R1
N
R2
N
N
Fe2+
X
Y  
     
 Fig.1 Haem moiety [1] 
 
In the substrate-free form of CYP450, six coordination sites around the iron atom are 
offered by the haem moiety. The nitrogen atoms of the tetrapyrrole macrocycle occupy 
the four lateral sites whereas the proximal site is occupied by a sulfur atom of the 
thiolate (cysteine) group and the distal site by a weakly bound water molecule [39]. 
Substrate binding lowers the redox potential of CYP450 [1, 35]. Above all, the fact that 
electron transfer is facilitated suggests the participance of several ionizable amino 
residues in the active site [1].  
Lewis et al. [1, 35] suggested a correlation between the ionization energy and 
redoxchemical potential. 
The ionization potential is the energy which is needed to abstract an electron. Ionization 
potential of a compound are equal to the energy of the compound’s highest occupied 
electronic level [1, 35]. This energy can indicate the potential reactivity in the CYP450 
system so this knowledge is useful for further structure modifications. 
 
4.1.3 Aim of the Study 
 
Substrates of CYP3A4 are rather diverse in their structures and rather lipophilic in nature 
with values ranging from logD7.4 0.4 to 8. Therefore CYP3A4 is involved in the 
metabolism of over 60% of marketed drugs today and also in a high number of 
significant drug-drug interactions (DDI) [9, 11, 12, 14, 16, 27].  
Prediction of CYP3A4 metabolism is complicated. In general, metabolic stability 
determinations are based on the rate of disappearance of the parent drug in the 
presence of human liver microsomes or hepatocytes and its subsequent classification 
into high, medium or low metabolic stability [12, 21, 23, 39]. 
But the identification of certain structural fragments for CYP3A4-catalyzed metabolism 
usually is not possible by these experiments. 
Additionally, unlike other CYP450 isoforms e.g. CYP2D6, structure-activity relationships 
(SAR) of CYP3A4 substrates have not been feasible so far.  
Currently, very little is known about CYP3A4 crystal structures [31]. Although there are 
some publications available about crystal structures of substrate-free CYP3A4, the 
purpose of the amino acid residues in the whole enzyme is yet unknown [30, 31].  
De Graaf et al. [25] have also published an integrative approach to model CYP450 in 
silico although to date nobody has provided suitable tools for the prediction of CYP3A4 
catalyzed metabolism. 
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Hence, our approach was the estimation of the electronic nature of CYP3A4 by 
measuring the Eox and correlating CL_mic_rat vs. Eox-potential. The analytical method of 
choice was HT-cyclic voltammetry. A detailed description of method development and 
modification of EPSS has already been provided in Chapter 2 (pp. 33). 
A second approach was a redoxchemical one as it involved mimicking the two-electron 
transfer which occurs by redoxreactions during the catalytic cycle of CYP450.  
Several redoxactive compounds with reversible two-electron transfer behaviour were 
identified as potential redoxindicators by cyclic voltammetric measurements (RDI) and a 
redoxchemical based assay was developed. In our case the development was carried 
out with p-chloranil, a quinoid redoxindicator. 
Therefore, the aim of the PhD-thesis was the development of fast and easy profiling 
systems, allowing to improve on a long term perspective the understanding of metabolic 
processes at the structural level and the identification of compounds/compound classes 
with high probability to be metabolically instable with focus on phase-I metabolic 
processes. 
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4.2 Experimental Section 
 
Information regarding the chemicals used, buffer composition and preparation and 
preparation of p-chloranil solution has already been described previously in Chapter 3, 
Subchapters 3.2, pp.45. 
 
4.2.1 Selection Procedure of Datasets 
 
Two datasets were collected. The first dataset consisted of 35 drug-like commercially 
available compounds as only these 35 compounds were found to have high in vivo 
clearance in human. Known phase-I metabolism was the main selection criterion for this 
dataset to exclude other ways of elimination or metabolism. Although human in vivo 
clearance was published for these marketed drugs, no information on microsomal rat 
clearance (CL_mic_rat) was available [16]. Therefore, these compounds were measured 
internally in the department of DMPK, F. Hoffmann-La Roche for consistent CL_mic_rat 
data.  
The second dataset consisted of 65 drug-like molecules which were extracted from the 
internal data repository. In this instance, selection criteria were availability and 
CL_mic_rat data. These compounds showed CL_mic_rat ranging from 200 up to 3000 
µl/min/mg protein. 
Sometimes, the oxidation potentials of the compound have not been measurable 
because their Eox laid outwith the experimental range. 
Additionally, several commercial compounds and internal discovery compounds had to 
be omitted due to chemical instability. Therefore the final dataset consisted of 53 
compounds (12 commercial compounds and 41 in-house compounds). 
Structures of commercially available compounds have been already presented in Table 
2 (Chapter 3, Subchapter 3.3.3 p.60). 
 
4.2.2 Collection of Structural, Metabolic and Electrochemical Information 
from Literature 
 
The aim of the literature search was the identification of recurring structures which are 
responsible for phase-I metabolism. These structures were the basis for a SAR, shown 
in Table A in the appendix. 
Availability of data regarding electrochemical potential of commercially available drugs 
was checked by an extensive literature search. The Human Drug Database (HDDB), 
an internal database, contained entries derived from Dollery [29], PDR [29] and 
Goodman and Gilman’s [103].  
All drug molecules in HDDB have been collected and fragmented by in silico methods. 
With the aid of daylight software (Daylight, Aliso Viejo, California, USA) the results were 
clustered into groups of structurally obtained information (Cl), cluster number (Cl_num) 
and number of fragments (No_frag) and a new database called HDDB_fragments was 
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created. This database included 809 fragments retrieved by the fragmentation 
performed previously.  
Furthermore, in Beilstein database (MDL CrossFire Commander Version 7.9 SP2 (Build 
46)) a general search for entries of molecules was launched with the criteria: MW ≤ 500 
and electrochemical characteristics (POT). 
This electrochemical information was stored in a new database called Beilstein_frag. 
Subsequently, the HDDB and Beilstein_frag databases were cross-referenced, 
resulting in the assignment of the electrochemical properties of 138 drug-like molecules 
in the Beilstein_frag_database. 
In addition, a substructure search of the fragments against the Beilstein_frag 
database was performed.  
All in silico operations were performed on Linux systems. The results have been 
collected in several tables. All collected information is attached in the appendix of this 
thesis (Tables B, C, D, and E in the Appendix).  
Additionally, information on phase-I metabolism has been collected for the 138 
molecules. Again, these tables are attached in the appendix. The fragment-based table 
contains of several co-generic series which have been selected to observe the structure 
activity relationship (SAR) using an in-house tool called RoSARa.  
The whole literature search process is shown schematically in Fig.2. 
 
1)   2)    
 
 
Fig.2 Data retrieval using MDL CrossFinder Commander and Human Drug Database (HDDB). In 1) the initial literature 
search was conducted using Beilstein. In 2) the retrieved data of 1) was further clustered and analyzed. 
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4.2.2.1 Descriptors for In Silico Prediction 
 
25 Property based descriptors were assumed to influence both the microsomal clearance 
(CL_mic_rat) and the electrochemical potentials (Eox). With the exception of CL_mic_rat 
and the Eox, all 23 other descriptors were calculated. 
These were used to express the molecular size, polarity, flexibility (number of rotatable 
bonds), rigidity, electronic properties, formation of hydrogen bonds (number of donor 
and accepting atoms), hydrophilicity (hphil surf, hphil volume) and lipophilicity (PSA, 
clogP) (MOLOC Software systems, Switzerland) of the molecules.  
Quantum mechanical descriptors have been calculated with the program ParaSurf’07 
(CEPOS InSilico Ltd., Bedford, UK). 
 
4.2.3 Methods 
 
Detailed information on the equipment of LC/MS determination, method and parameters 
has already been provided in Chapter 3, Subchapter 3.2.2.2, pp.49. 
Additionally, information on the experimental set-up of EPSS and its conditions has 
already been provided in Chapter 2, Subchapter 2.2.2, and pp. 38. 
Sample preparation procedure and incubation conditions were previously described in 
Chapter 3, pp. 49 and therefore are not further discussed here. 
 
4.2.4 Data Analysis 
 
PLS was used as computational approach to analyze complex datasets using SIMCA+11 
(Version 11.0.0.0, Jun 12,2005, Umetrics AB, Sweden) [104]. According to Wold et al. 
[105], “PLS is an abbreviation for partial least square modeling in latent variables or 
projection to latent structures”.  
PLS can be seen as a particular regression technique for modeling the association 
between X and Y. It is a useful technique for dealing with both complicated and 
approximate relationships within datasets [105]. For the current study, the evaluation of 
the dependency between two parameters such as the CL_mic_rat and the Eox was of 
major importance. 
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4.3 Results and Discussions 
 
The aim of this study was the invention of methods which are fast and reliable for the 
determination and prediction of metabolic stability. These methods were based on 
redoxchemistry and electrochemistry. Method invention descriptions have been provided 
in Chapters 2 (pp. 33) and Chapters 3 (pp. 47). 
The identification of recurrent structures in relationship to high CL_mic_rat and low 
oxidation potential, preferably in the range of the CYP450’s oxidation potential was of 
great importance. 
 
4.3.1 Literature Search Results 
 
An extensive literature search was conducted regarding the collection of marketed drugs 
with known electrochemical activity. Hence, diverse datasets were collected as they 
contained information from the whole century. For more facile interpretation of this data, 
additional information on the solvent or type of reference electrodes used in the 
experiment is required but was not provided. Due to the lack of this information, none 
of these tables were shown in this paper. 
Chosen compounds were measured electrochemically in our lab environment. 
 
4.3.2 Redoxchemical Results 
 
An assay was developed for the prediction of metabolic stability which is based on 
redoxchemical processes. 
The redoxchemical reversible catalytic CYP450 process is the basis for the selection of p-
chloranil as redoxindicator (RDI). The selection process of the p-chloranil and assay 
development has already been described in more detail in Chapter 3 (pp. 47).  
Quantitative analysis was done by LC/MS via comparison of peak heights. The results of 
the 53 compounds analysed are shown in Fig.3. CL_mic_rat is plotted vs. the 
percentage decrease in compound concentration after the incubation (t= 30 min) with 
p-chloranil but it does not correlate well. However there is a general trend visible of 
increasing loss of compound with increased CL_mic_rat. 
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Fig.3 Comparison of p-chloranil assay and microsomal rat clearance. Percentage of compound disappeared (%CPDdis) was plotted vs. 
microsomal rat clearance (CL_mic_rat). Dots represent commercial compounds and triangles stand for internal compounds. 
 
 
Among these 53 compounds, 41 compounds were internal discovery compounds and 12 
were commercially available compounds, all with known high CL_mic_rat. 
For interpretation, the graph was subdivided into four subdivisions. 
The reaction behaviour of p-chloranil was rather complex as has been discussed 
previously in Chapter 3 (pp. 47)  
Regarding the quantification with p-chloranil, Slifkin’s [90] and Veltistas [94] proposal to 
quantify p-chloranil in aqueous media via its hydrolytic conversion to the chloranilic acid 
in neutral to basic solution was attempted. However, further experiments in aqueous 
media proved the impracticality of this proposal. 
Several additional possibilities for the suitable quantification of the p-chloranil assay 
were investigated. Firstly, the theoretical CL_mic_rat was calculated using the “well-
stirred” model conditions.  
Usually, the weight of the liver and concentration of the protein are essential for the 
calculation of the theoretical CL_mic_rat. We have therefore proposed replacing the 
weight of liver and concentration of protein with the concentration and MW of p-
chloranil. Some initial results were promising but using this approach for data analysis 
did not appear to be reproducible. This was largely due to the problems caused by 
quantification via p-chloranil and therefore further investigations were conducted. 
The second quantification approach involved monitoring the amount of chloranilic acid 
generated during the sample incubation process with p-chloranil.  
1 2 
3 4 
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The observed hydrolytic conversion of p-chloranil at pH 7.4 by Slifkin [90], Veltsistas [94] 
and our lab was the basis for the second quantification approach although a reasonable 
correlation was also not possible by this method. 
The third and simplest quantification approach was the comparison between the peak 
height of pure sample and sample after incubation with p-chloranil. Taking peak heights 
seemed to be more appropriate than quantification via peak area since this was not 
always good because of occasionally occurring broad peaks. This is probably due to the 
complex reaction behaviour of p-chloranil. 
In the following paragraphs several possibilities for the lack of correlation between 
CL_mic_rat and %CPD disappeared are discussed.  
The first discussion concerns compounds appearing in subdivision 2. All compounds in 
this subdivision contain an indol ring system as scaffold. 
Taking a closer look at the compounds in the 2nd subdivision of Fig.3, the highest 
located one (E5_2nd) contains a thiophene fragment with a CL_mic_rat of 1878 
(µl/min/mg), whereas compounds 2 (G5_2nd) and 3 (M5_2nd) following subsequently, 
have the same 1-(methylamino)-3-phenylbutane substituent at a different in position on 
the indol ring (Fig.4).  
 
 
N
1
2
345
6
7  
 
Fig.4 Scaffold indol 
 
Interestingly, performing a 1-(methylamino)-3-phenylbutane substitution at position 4 
instead of 3 leads to a higher %CPDdis and hence, CL_mic_rat is also increased. It is 
likely that position 3 is more liable to oxidative metabolism. Consider the two former 
compounds, G11_2nd and K9_2nd; in all 4 compounds position 3 is blocked.  
Like compounds 2 and 3 just discussed, G11_2nd also has an indol-ring as scaffold, with 
a methanesulfonyl-benzen substituent at position 3 and piperazin at position 7. K9_2nd 
too has an indol-ring but a (2, 6-dichlor-phenyl)-methyl-sulfide substituent on position 3 
and piperazine at position 5. 
Hence, all compounds differed in respect to their CL_mic_rat. It was assumed that the 
sulfonyl moiety lead to a lower clearance of CL_mic_rat of only 90 µl/min/mg.  
K9_2nd with a CL_mic_rat of 701 µl/min/mg is represented by the grey dot in subdivision 
4, but an explanation for its small percentage of compound decrease after incubation 
with p-chloranil is not readily available. However, it is not an outlier in Fig.3. On one 
hand, the sulfide provides two lone pairs which could contribute to a reaction, but on 
the other hand, the piperazine at position 5 makes the molecule metabolically more 
stable.  
Compounds in subdivision 3 were considered to be relevant in the prediction of 
metabolic stability. 
Seven compounds in subdivision 4 are coloured individually, as these appear as outliers 
in Fig.3 but not for EPSS in Fig.9 (p.80). 
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In Fig.5, two structures of the coloured compounds are shown: 
 
 
     
 
 
 
a)       b) 
 
 
 
 
 
 
Fig.5 Outliers: a) paroxetin (yellow)      b) ciprofloxacin (red) 
 
 
Structures and physicochemical properties of these compounds in Fig.9 were closely 
examined within the group of outliers and explanations have been sought.  
One possibility is the assumption of a classical acid-base reaction taking place. At 
neutral pH conditions, p-chloranil was assumed to convert to chloranilic hydroquinone as 
observed experimentally in our labs and described in Chapter 3 (pp. 47).  
 
 
    
 
 
         
 
 
1)                2) 
Fig.6 Conversion of p-chloranil to its hydroquinone at pH: 7.4. Each hydroxyl group exhibits a pka value: 1) pka1: 5.25 2) pka2: 6.56  
 
 
Considering the pKa values of hydroquinone (HQ), the first pKa of the hydroxyl group 
is at 5.25 and the second at 6.56, suggesting an acid-base reaction. The pKa values 
have been taken from an internal database of experimental data. Moreover, at pH: 7.4, 
the HQ was negatively charged and thus could either react with the basic part of 
zwitterions or the bases themselves. 
This offers one possible explanation for the coloured outliers since only two of seven 
coloured compounds were either acidic or zwitterionic, while the remaining compounds 
were bases.  
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Fig.7 Reaction pathway of p-chloranil via radical intermediate in aqueous media at pH 7.4 
 
 
The example of paroxetine shows the complexity of the reaction behaviour of p-chloranil. 
Probably, p-chloranil is activated by a hydroxyl ion forming the radical intermediate of p-
chloranil as shown in Fig.7. Furthermore, it is likely that the hydroxyl radical is affecting 
the lone pair of the piperidine nitrogen, creating a double bond in the piperidine ring 
system which then can be readily oxidized by p-chloranil. However, the oxidation can 
also take place in the α-position of the nitrogen in the piperidine ring. 
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Fig.8 Possible explanation of increased compound instability of paroxetine. Paroxetine was only indicated as fragment 
 
 
Analysis of the metabolic pathway of paroxetine indicates that the only site of 
metabolism is at the 1, 3-dioxolane moiety. Other sites besides the secondary nitrogen 
of the piperidine ring which are liable to oxidation are not available. Chemical reactions 
usually differ from enzymatic reactions and it is probable that in enzymatic reactions 
only the dioxolane moiety is affected, whereas chemical oxidations with p-chloranil give 
no conclusive results.  
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4.3.3 Electrochemical Results 
 
A second assay for the prediction of metabolic stability was performed electrochemically 
using the same dataset of 53 compounds as for the p-chloranil assay. Results by cyclic 
voltammetry (CV) were additionally used for the prediction of metabolic stability. In 
Fig.9, a correlation can be seen between CL_mic_rat vs. Eox. The coloured dots are 
those compounds which have been identified as outliers in Fig.3.  
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Fig.9 Correlation of Eox-potential referred versus ferrocene (FOC) against microsomal rat clearance. Dots represent commercially 
available compounds, triangles internal compounds. Apart from the pink and brown dot, the other coloured dots represent com-
pounds which have been identified as outliers in the plot of the p-chloranil assay [101]. 
 
 
Dividing Fig.9 into four subdivisions enabled an easier interpretation, with -0.1 V set as 
a limit for metabolically unstable compounds. Hence, the more negative the 
electrochemical potential, the more CL_mic_rat and metabolic instability were increased. 
Therefore it was suggested to define that range (subdivisions 1 and 3) as an alert range, 
where compounds should be re-examined and modifications made if necessary. LC/MS 
was used only in context of structural determinations and verifications.  
There were two examples in subdivision 1 and 3, prochlorperazine (pink dot) (Fig.10) 
and desipramine (brown dot) (Fig.11) which are both commercially available 
compounds. It is known for both drugs that they are metabolized via cytochrome P450.  
They act against psychiatric disorders. Prochlorperazine belongs to the class of 
antipsychotic agents and is a highly potent neuroleptic. Desipramine is a tricyclic 
antidepressant. 
According to Toledo et al. [106], imipramine and desipramine, its active metabolite, 
exhibited an irreversible voltammogram as visible in Fig.11.   
1 
4 3 
2 
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Fig.10 First example for compounds in Fig.9: prochlorperazine Fig.11 Second example for compounds in Fig.9. desipramine 
measured with EPSS at a scan rate of 0.640 V/s in a scan range measured with EPSS at a scan rate of 0.640 V/s in a scan 
from -0.5 to 1.0 V, No. of scans n= 5 in 5 mM HB, pH: 7.4         range from 0 to 1.5V, No. of scans n=5 in 5 mM HB, pH: 7.4  
 
4.3.4 Mass Spectrometric Confirmation of Successful Electrochemical 
Conversion 
 
In Fig.13 and 14 the chromatographic separation and MS results of an internal 
compound are shown as an example for successful electrochemical conversion. The 
isoxazole ring is required for a compound’s successful redoxreaction. In Fig.12, a 
potential pathway is suggested for the observed demethylation after cyclic voltammetry. 
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Fig.12 Demethylation reaction of an in-house compound 
 
 
 
 
 
 
The blue peak represents the sample without electrochemical treatment, whereas the 
red peak is the sample after cyclic voltammetry at a different retention time indicating 
generation of a new, demethylated product. 
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Fig.13 Example of an internal compound for the appearance of a demethylated compound after electrochemical oxidation; LC-result, 
Agilent 1100 series MSD SL at conditions described in Materials and Methods, Chapter 4. 
 
 
 
 
Fig.14 Example of an internal compound for the appearance of a demethylated compound after electrochemical oxidation; MS-
result using Agilent 1100 series MSD SL at conditions described in Materials and Methods, Chapter 4. 
 
Very often, cyclic voltammetric measurements were subsequently analyzed by LC/MS. 
Frequently only low amounts of demethylated or hydroxylated metabolites were found 
which made quantification difficult sometimes. Most of the time no clear baseline 
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separation between metabolite S’ and sample S occurred so newly generated masses 
were only detectable by extracted ion chromatograms.  
 
4.3.5 Statistical Determinations using PLS-Analysis 
 
The intention of PLS-analysis was the facilitation of the interpretation of complex 
datasets. Due to the promising correlation in Fig.9, the electrochemical data was further 
analyzed. Furthermore, PLS analysis should disclose dependencies between the 
Cl_mic_rat and physicochemical properties if any physicochemical parameter could 
sufficiently describe the CL_mic_rat. 
Based on the results of the p-chloranil assay shown in Fig.3, several PLS models have 
been created. Subsequently, a model with CL_mic_rat as an independent y-variable and 
PSA, hydrophilicity parameters and  %CPDdis as the x-variable was created with a 
R2:0.128 and Q2: 0.097. As expected, results showed a lack of correlation and no further 
results or graphs were shown in this context.  
Furthermore for EPSS, several PLS-models have been calculated for the entire dataset of 
53 compounds using CL_mic_rat as an independent parameter.  
In Table 1, an overview of these PLS models are provided for EPSS: 
 
 
Table 1 Overview of PLS models (CL_mic_rat) with CL_mic_rat as independent variable was used as independent variable) using Eox 
as input result 
 
Model r2 Y q2 P Comment
M1 0.496 0.481 1 all 53 compounds
M2 0.443 0.426 1 only bases extracted of 53 compounds
 
 
 
In model 1 (M1), all 53 compounds were included. CL_mic_rat was the independent 
variable (y-variable) and all the other parameters such as PSA, charge and hydrophilicity 
were set as x-variables. Eox was identified as the most predominant parameter 
significantly influencing the CL_mic_rat. The model was validated with 20 permutations 
and no better model was subsequently obtained as illustrated in Fig.15.  
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Fig.15 Permutation plot 20 permutations 1 component, CL_mic_rat (ml/min/mg protein): R2: (0.0, -0.0363), Q2: (0.0, -0.0834) 
 
 
To verify that none of the 23 physicochemical parameters could describe the CL_mic_rat 
too, a loading plot was created. This plot (Fig.16) shows that Eox is the predominant 
parameter but charge also has a significant influence. For understanding and 
interpretation, the 53 compounds have been subdivided based on their ionization 
constants (pKa). 
 
 
 
 
Fig.16 Loading scatter plot with R2[61]: 0.1479437, R2 [61] : 0.185738 
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Only the group of bases was large enough for the calculation of a second model 2 (M2) 
created following the same procedure as for M1. Eox was again identified as 
predominant parameter. 
Finally a model (M1) was created showing a one-to-one correlation of CL_mic_rat and 
Eox. 
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Fig.17 M1 a computational model, created by RoSARa. The R2 was 0.496, the Q2: 0.481 and 1 variable. 
    Equation for M1: CL_mic_rat= -Eox + c 
 
All relevant physicochemical properties including charges were calculated for 53 
compounds. In the PLS-analysis each property was set as the x variable in turn with Eon 
as the independent variables and several models were created. The best model was M1, 
illustrated by an observed vs. predicted values plot in Fig.17 (Table E in the 
Appendix shows all the relevant values) with Eox acting as predominant parameter for 
the description of Cl_mic_rat. Its coefficient exhibited a negative value; the more 
negative the oxidation potential, the higher the CL_mic_rat.  
Several other models with lower R2 and Q2 values were created too. The best model 
after M1 was the correlation between Eox and acc.  
If a model was created without Eox as independent variable, a model with very low R
2 
was retrieved. 
A logarithmic fit has also been investigated for possible quantification of Eon and CL_mic 
(Fig.9) 
EPSS has proved to be a useful tool for the estimation of metabolic stability in early pre-
clinical development. M1 could be used as appropriate model to predict the correlation 
between CL_mic_rat and Eox. 
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Of course, a dataset of 53 compounds is not sufficient and future focus in this study 
should be the enlargement of the current dataset. 
4.3.6 Comparison of Classical and Novel Determination/Prediction of 
Metabolic Stability 
 
The introduction of EPSS, a HT-tool, made electrochemical screening of redoxactive 
molecules feasible for the first time. Up to 96 samples could be potentially measured in 
parallel allowing a fast determination of electrochemical characteristics. Promising 
results in Fig.9 suggest its application in pre-clinical development, such as the ranking or 
grouping of compounds related to their redox characteristics, which have been proven 
to be related to their metabolic stability. 
Several approaches for the determination and mimicking of phase-I metabolism with 
electrochemistry were recently performed and described [37, 42, 54, 107, 108]. Karst 
[40, 41], Jurva [37, 42] and Johannson [38] gained lots of knowledge in the field of 
EC/LC/MS, an electrochemical flow chamber coupled to LC/MS.  
Although EC/LC/MS seemed to be more advantageous at first glance, it did not really 
work well under physiological-like conditions because chromatographic methods still 
required large amounts of nonpolar solvents and quantitative questions in terms of 
concentrations could not be sufficiently answered. EC/LC/MS seemed to be more 
suitable for the rapid determination of unspecific redox behaviour resulting in mass 
changes whereas EPSS provided the information concerning the redox kinetics and the 
time-dependent change of the compound concentration [36, 40].  
Jurva et al. [37, 40] reported several issues in terms of the EC-flow through cell which 
have prevented routine use so far. This included insufficient quality of instrumentation 
and the requirement of tight control of the vaporizer temperature due to thermo spray 
mass spectrometry [37]. As a result, temperature regulation was a major source of error 
due to difficulties associated with compound stability and the handling of the systems.  
Johansson [38], a member of Jurva’s staff, published another method to mimic phase-I 
metabolism using EC/LC/MS [37] and suggested several methods for oxidation reactions 
using EC/LC/MS [37]. Moreover, they reported that results obtained electrochemically 
were concordant with results from microsomal incubations [37]. However, their 
electrochemical approach showed some limitations [109-111]. Some CYP450-mediated 
reactions were not imitable by electrochemistry, specifically those compounds containing 
aliphatic components [37]. EC/LC/MS exhibited another problem: the dilemma of the 
electrolyte concentration. On one hand, electrolytes were needed to provide better 
electrochemical conversion, but on the other hand high concentrations of electrolytes 
resulted in increased background and decreased sample signals if EC was combined with 
LC/MS [37].  
Our aims differed to that of Jurva, Karst and Johannson, as we intended to obtain a 
valuable model for the prediction of metabolic stability whereas Jurva, Karst and 
Johansson [37, 38, 40-42, 54, 112] were more focused on mimicking phase-I 
metabolism. Of course, phase-I metabolism was the major criterion for the selection of 
our drug candidates too but as has already been stated, the major focus was on the 
correlation of Eox vs. CL_mic_rat shown in Fig.9.  
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For selectivity and significance, separation of electrochemical and chromatographic 
determinations was more advantageous for EPSS. With EPSS, cyclic voltammetric 
measurements were performed and/or samples were further analyzed in LC/MS by 
transfer of samples. Moreover, EPSS allowed working under physiological-like conditions 
and the study of the rate of reaction between nucleophiles and electrophiles [37]. 
However, EPSS did not give any information on regioselectivity, but subsequent LC/MS-
analysis showed clearly if demethylations had taken place after CV [37]. Obviously, 
aliphatic structures were not affected easily by electrochemical oxidation [37] most likely 
due to the high energy barrier which needed to be overcome for aliphatic hydroxylation 
[37]. High energy barriers would have resulted in a high electrochemical potential which 
could not be obtained in our experiments [37].  
Although the number of lead series was increased due to the introduction of 
combinatorial chemistry, the number of new chemical entities has decreased. 
Moreover, metabolism studies used to be performed in very late phases of pre-clinical 
development, when the number of compounds had already been reduced [12, 37]. With 
the introduction of the parallel approach to drug discovery, metabolism studies were 
performed earlier requiring simple, fast and reliable screening tools [12, 37]. Metabolic 
stability and toxicological issues are still the bottleneck for most discovery compounds. 
It is therefore essential to develop a tool to reduce the number of inappropriate 
metabolically instable compounds [37]. Our approach in comparison to the current 
standard involving the liver microsome and hepatocyte incubations is faster in 
performing the assay and less susceptible to variations in experimental conditions. 
One major disadvantage of our electrochemical approach is the fact that oxygen is a 
disturbing factor. Therefore, all reaction solutions were degassed by Ar intensively 
before use. The major advantage of EPSS is data retrieval within a short period of time 
without the need for biological materials. Sample preparation for EPSS was less 
complicated than for liver microsomes incubations as liver microsomes (LM) have to be 
created in an elaborate procedure. Moreover LM incubations required supplementation 
of relevant cofactors for the initiation of the reactions. Limited time of storage and 
incubations were accounted as major disadvantage of LM incubations, but this 
technique is advantageous since it provides a first glimpse of specificity. Above all, 
metabolic stability determination via EPSS could be easily performed in very early stages 
of pre-clinical development. 
4.4 Conclusions and Perspectives  
 
Both approaches for the investigation of early metabolic stability profiling are novel. 
Neither the redoxchemical nor the electrochemical one have been published so far, even 
though several experimental attempts in electrochemistry were conducted to determine 
phase-I metabolism of compounds. One analytical approach was the electrochemical 
flow-cell coupled to LC/MS. 
Cyclic Voltammetry, particularly HT-cyclic voltammetry (EPSS) allowed physiological-like 
conditions. For the first time, a relationship between the electrochemical oxidation 
potential and microsomal rat clearance could be demonstrated. PLS-analysis was used 
to analyse complex datasets and revealed Eox as a predominant parameter if CL_mic_rat 
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was set as independent variable. As a result EPSS can be applied in early drug discovery 
phases for early compound profiling of discovery compounds.  
For further validation of this approach, the dataset should be increased up to hundreds 
of compounds to improve predictability.  
This new technique enables a fast, non-biological measurement of the electrochemical 
behaviour of a compound as a first indicator for reactivity in CYP450 mediated 
metabolism. 
The redoxchemical approach was less successful. The p-chloranil assay set-up was well 
defined but reproducible results were hindered by the fact that p-chloranil itself showed 
a complex reaction behaviour in aqueous media.  
The example of paroxetine (Chapter 4, Fig.8, p.82) demonstrated that the redoxreaction 
with p-chloranil did not suggest a potential pathway of metabolism. Although the 
microsomal rat clearance of paroxetine was low, the compound loss after the incubation 
with p-chloranil was high. Till date, a suitable explanation for that finding was not 
available. 
Moreover, a correlation between CL_mic_rat and %CPDdis could not be seen. We would 
rather speak of a trend which is certainly visible in Fig.3 (Chapter 4, p.71).  
Therefore, an interesting modification of the p-chloranil assay could be a replacement of 
p-chloranil. As previously mentioned o-chloranil is a potential compound as it exhibits a 
positive reduction potential but is similar to p-chloranil structural wise. 
Further studies on p-chloranil in aqueous media are required to gain a better 
understanding of its reaction products. The experimental set-up of this assay can be 
easily used as basis for further improvements.  
Both approaches are novel and promising for early metabolic stability compound 
profiling and are worth for continuing studies. 
To conclude the investigations of the PhD-thesis, the goals of this thesis have been met. 
A fast reliable and non-biological method for the ranking of compounds according to 
their electrochemical characteristics establishing a link to metabolic stability could be 
developed. 
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Chapter 5: Final Considerations and Perspectives 
 
The drug discovery and development process is still accompanied by several challenges 
although highly sophisticated in vitro models and in silico prediction models are applied 
early.  
Drug metabolism, for example, does account for one of the problems in drug discovery 
and drug development. 
A large fraction of discovery compounds are lipophilic which make them liable to 
oxidative metabolism most likely enzymatically catalyzed by CYP450. 
After a paradigm shift at the end of 90s, metabolism profiling was loaded in front of 
other drug optimisation activities. 
With comprehensive compound profiling in early phases of drug discovery, metabolically 
instable structures can be identified and subsequently optimized. 
So far, metabolic stability determinations have been conducted on a biological basis. 
Usually in these assays subcellular hepatic fractions (microsomes) or hepatocytes are 
used. Above all, conducting these assays is time consuming and gained results typically 
only deliver information on the rate of metabolism but little information on the resulting 
products at the structural level. 
Both experimental approaches for early metabolic stability profiling of discovery 
compounds are novel and described by the PhD-thesis. Till date none of the HT-
approaches, neither the redoxchemical nor the electrochemical using cyclic voltammetry 
have been published. 
The redoxchemical approach was challenging. The evaluation and optimisation of a 
suitable experimental set-up, which results can be used for the theoretical CL_mic 
calculations, were hindered by the fact that p-chloranil showed a complex reaction 
behaviour in aqueous media. 
Some compounds showed an increased loss of compound but did not correlate in 
respect to their microsomal clearance. It was described on the example of paroxetine in 
Chapter 4 (pp.68). 
Further investigations on the degradation of p-chloranil in aqueous media or 
replacement of p-chloranil vs. o-chloranil are recommendable. 
Some publications about the EC/LC/MS method to simulate phase-I metabolism are 
known. 
These research groups have never focused on cyclic voltammetry as analytical 
alternative to EC/LC/MS. This was probably due to the unavailability of suitable technical 
modifications of the classical experimental set-up. 
With the introduction of EPSS, new methods and experimental approaches became 
feasible. Cyclic Voltammetry, particularly HT-cyclic voltammetry (EPSS) allows aqueous 
conditions for the determination of redox potentials.  
By the application of EPSS, a relationship between the electrochemical oxidation 
potential and microsomal rat clearance can be demonstrated. A statistical method for 
data analysis, PLS, was used to analyse complex datasets and revealed Eox as a 
predominant parameter. 
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Obtained results support the application of EPSS in early drug discovery for compound 
profiling with focus on metabolic stability.  
This new technique enables a fast, non-biological measurement of the electrochemical 
behaviour of a compound as a first indicator for reactivity in CYP450 mediated 
metabolism. 
For further validation of this approach, the dataset should be increased up to hundreds 
of compounds to improve predictability. Currently, only 53 compounds have been used. 
Advantage of this approach is time and low amounts of compounds necessary. 
Moreover, obtained results call EPSS for toxicological problems. The electrochemical 
measurements of GSH-adduct formations could be another topic as numerous 
compounds are also failing due to GSH- adduct formations. 
Both assays are fast and easy to perform. If the number of compounds in the dataset is 
increased and p-chloranil is replaced by another redoxactive compound, it will be an 
attractive tool to implement in early ADME of pre-clinical drug discovery.  
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7. Abbreviations 
 
ACN:   acetonitrile 
DMSO:  dimethylsulfoxide 
DDQ:   dichlorodicyanoquinomethan 
p-chlor:  p-chloranil  
chlor ac:  chloranilic acid 
jug:   juglone 
HT:   high-throughput 
RDI:   redoxindicator  
CPD:  compound 
Cl:  chlorine 
FOC:  ferrocene 
CV:  cyclic voltammetry 
PB:  phosphate buffer 
HB:  hepes buffer 
CL_mic_rat: rat microsomal clearance 
CL_mic: microsomal clearance 
ER:   endoplasmatic reticulum 
in vivo CL: in vivo clearance 
Eox:  electrochemical oxidation potential 
HLM:  human liver microsomes 
HP:  hepatocytes 
LC/MS: Liquid Chromatography- Mass Spectrometry 
EC/LC/MS: Electrochemistry- Liquid Chromatography- Mass Spectrometry 
EC:  Electrochemistry 
CV:  cyclic voltammetry 
ADME:  acronym for absorption, distribution, metabolism and elimination. 
Vmax:  velocity of reaction 
DDI:  drug-drug interaction 
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Km   Michaelis constant 
CYP450: Cytochrome P450  
FMO:  flavin-monooxygenases 
UGT:  UDP-glucuronyltransferases 
DDI:  drug-drug interaction 
MW:  molecular weight 
PK:  pharmacokinetic properties 
EPSS:  electro active pharmaceutical profiling/screening system 
SCE:   standard calomel electrode 
Ag/AgCl:  silver/silver chloride electrode 
FeCN:  ferrocyanide 
o-chlor:  o-chloranil 
1,2-naphQ:  1,2-naphthoquinone 
mena:  menadione 
chalk:  chalkon 
Au:  gold 
Ag:  silver 
KCl:   potassium chloride 
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8. Glossary 
 
ADMET: absorption, distribution, metabolism, elimination and 
toxicology 
 
Clint: intrinsic clearance. This describes the enzyme catalysed 
removal of a drug by the system and therefore is not 
influenced by other physiological determinants of clearance, 
such as hepatic blood flow. 
 
CYP450: cytochrome P450. These enzymes are involved in the 
oxidative metabolism of a high proportion of marketed drugs 
 
Km: the Michaelis-Menten constant describing the affinity of a 
substrate for an enzyme. The Km is equal to the substrate 
concentration at which the reaction rate is half maximal. 
 
Discovery compounds: term for compounds in pre-clinical development, belonging 
to the lead series identified 
 
Signal transduction: “A basic process in molecular cell biology involving the 
conversion of a signal from outside the cell to a functional 
change within the cell” [113]. 
 
Pharmacokinetics: “This is the science which describes quantitatively the uptake 
of drugs by the body, their biotransformation, their 
distribution, metabolism, and elimination from the body. Both 
total amounts and tissue and organ concentrations are 
considered” [114]. 
 
Pharmacodynamics: This is a scientific discipline, which is a part of pharmacology 
and deals with the effect of drugs on tissues and organs [5]. 
 
 
Xenobiotic: A xenobiotic is a chemical which is found in an organism but 
which is not normally produced or expected to be present in 
it [115]. 
 
Bioavailability: The percentage of drug that is detected in the systemic 
circulation after its administration [116]. 
 
Half life (t1/2): The time required to convert one half of a reactant to 
product [117]. 
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Cyclic voltammetry: Electrochemical technique for studying variable potential at 
an electrode involving of a triangular potential sweep 
 
Working electrode: An electrode that serves as a transducer responding to the 
excitation and the concentration of the substance of interest 
in the solution investigated, and that permits the flow of 
current sufficiently large appreciable changes of bulk 
composition within the ordinary duration of a measurement. 
  
Reference electrode: A nonpolarizable electrode that generates highly reproducible 
potentials; examples are the calomel electrode, silver-silver 
chloride electrode, and mercury pool [44].  
Auxiliary electrode: Auxiliary electrodes are used for the transfer of electric 
current to the working electrode [44] 
Potentiostat:   An electronic instrument that controls the voltage difference   
    between a working electrode and a reference electrode both  
contained in an electrochemical cell. The control is 
implemented by injecting current into the cell through an 
auxiliary electrode. The potentiostat measures the current 
flow between the working and auxiliary electrodes [118]. 
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Fig.4 The “well-stirred” or venous equilibrium model (left) and the “parallel tube model” or sinusoidal  
model (right). The tanks are lined with rows of hepatocytes where the metabolism of the drug is 
supposed to occur. The small black arrows indicate the exchange, Page 17 
 
Fig.5 Correlation Lipophilicity (logD7.4) with unbound (free) hepatic intrinsic clearance (CLi (a), filled 
squares) and unbound (free) renal clearance (Cl(r) open triangles) adapted from van der Waterbeemd et 
al., Page 21 
 
Fig.6 Haem moiety, Page 23 
 
Fig.7 Metabolic pathway of imipramine with known phase-I metabolism and high in vivo clearance, Page 
24 
 
Fig.8 Catalytic cycle of CYP450 after Lewis: 1) Substrate binding, 2) First reduction of Fe3+ 3) Oxygen 
binding 4) Second reduction 5) Product formation 6) Product release, Page 25 
 
Fig.9 Electronic transfer pathways in various CYP450 systems, Page 29 
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Fig.1 Schematic sketch for a general set-up of an electrochemical cell, Page 34 
 
Fig.2 Variation of applied potential  with time in cyclic voltammetry, showing the initial potential, Ei, the 
final potential Ef, maximum Emax, and minimum Emin potential, The sweep rate dE/dt=v. For linear sweep 
voltammetry consider only one segment. The fact that the initial sweep is positive is purely illustrative. 
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Fig.3 Cyclic voltammogram for a reversible charge transfer, Epc: cathodic peak potential, Epa: anodic 
potential, E: switching potential, E1/2: half-wave potential, ipc: cathodic peak current, ipa: anodic peak 
current, i 0 : current at E, ipa: anodic peak current at Baseline. Page 35 
 
Fig.4 Cyclic voltammogram for an irreversible charge transfer carried out at HT-cyclic voltammetry in 
aqueous media, Page 37 
 
Fig.5 Schematic drawing for an electrochemical cell used in the classical experimental set-up, Page 39 
 
Fig.6 Picture of EPSS with a sensor plate placed on the measurement unit, Page 40   
   
Fig.7 Example of a sensor plate V4 (Gatlik, Basel) total well volume of 55 µl Page 40 
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Fig.8 Correlation of data recorded at classical method and EPSS (HT-method), the correlation yielded 
a R2: 0.9799. Statistical values are as follows:  F-value: 342.93, STD error of estimate: 0.0907 intercept: 
0.068. Number of cases: n=9, Page 41 
 
Fig.9 Cyclic voltammogram ferrocene in acetonitrile, scanning from 0.6 to 1.0 V with a scan rate of 0.8 
V/s, signals retrieved by classical cyclic voltammetry, Page 44 
 
Fig.10 Cyclic voltammogram ferrocene in phosphate buffer scanning from -0.3 to 0.8V with a scan 
rate of 0.64 V/s, signals retrieved by EPSS, HT-cyclic voltammetry, Page 44                                                                      
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Fig.1 2,3,5,6-tetrachloro-1,4-dibenzoquinone (p-chloranil), Page 48 
 
Fig.2 General reaction pathway of p-chloranil with a sample S, Page 48 
 
Fig.3 The principal steps of the sample preparation for p-chloranil assay, Page 51 
 
Fig.4 Cyclic voltammogram of 0.01 mM juglone measured in 100% DMSO at a scan rate of 150 mV/s 
in a range from 600 mV to -1000 mV using classical CV, Page 55 
 
Fig.5 Cyclic voltammogram of 0.01 mM p-chloranil measured in 100% DMSO at a scan rate of 150mV/s  
in a range from 600 mV to -1000 mV using classical CV, Page 55  
 
Fig.6 Influence of light on the degradation of p-chloranil using an aluminium cover. A kinetic 
measurement during 40 min was performed using three different wavelengths (292nm, 310nm and 650 
nm). Measurements at 650 nm were necessary to crosscheck solubility of compounds. The measurement 
interval was 1 min and ODmin was set 0, ODmax at 1. The chloranil sample without Al-cover showed at 
higher degree of degradation (25.43%) than the sample with Al-cover (15.43 %), Page 56 
 
Fig.7 Influence of pH value on the degradation of p-chloranil using aluminium cover. Measurement 
was done with UV-Vis-spectroscopy performing a kinetic measurement during 40 min using three different 
wavelengths at 292nm, 310nm and 650 nm. 650 nm was necessary to crosscheck solubility of compounds. 
The measurement interval was 1 min and ODmin was set 0, ODmax at 1. Page 57 
 
Fig.8 Degradation of p-chlorine to chloranilic acid according to Sarr, Page 58 
 
Fig.9 Degradation Kinetics of p-chloranil measured with Agilent 6140 under the conditions mentioned in 
Material and Methods, Page 59 
 
Fig.10 Degradation kinetics of five commercially available compounds [loratadine (lora), imipramine (imi), 
loratadine derivative (lora+derivative), paroxetine (paro) and sertraline (sertra)] after their incubation 
with p-chloranil at equimolar concentrations of 0.01 mM, Page 61 
 
Fig.11 Concentration dependency of three different commercially available compounds as loratadine 
(lora), imipramine (imi), sertraline (sertra) and as RDI p-chloranil at equimolar concentration of 0.01 mM. 
The reaction followed first order kinetics. The λmax was chosen for p-chloranil at 320 nm. The number of 
cases was n=4. The incubation length was set to 30 min., Page 62 
 
Fig.12 Representative chromatogram of p-chloranil measured with Agilent 1200 series and 6140 MSD. 
The gradient run for this assay consisted of A 95% water +0.1% formic acid and solvent B 5 % ACN + 
0.1% formic acid. The gradient schedule is 5- 95% B for 0.6 min at 1.0 ml/min. The column is re-
Figure Index 
 
 
 112 
equilibrated with 95% A during 0.2 min prior to next injection. Total run time was 2.5 min. Detection of 
the analytes was by inline UV-detection at 254,292, 310, and 320, Page 62 
 
Fig.13 Example of a chromatogram measuring K5_2nd after the incubation t=30 min with p-chloranil. 
Measured with Agilent 1100 series and MSD. The gradient run for this assay consisted of A (water +0.1% 
formic acid) and solvent B (ACN + 0.1% formic acid). The gradient schedule is 5- 95% B for 0.6 min at 
1.0 ml/min. The column is re-equilibrated with 95% A for 0.2 min prior to next injection. Total runtime 
was 2.5 min. Detection of the analytes was by inline UV-detection at 254,292, 310, and 320 nm, Page 64 
 
Fig.14 Calculated isotopic pattern for tetrachlorohydroquinone (TClHQ) using a web calculating tool, 
Page 65 
 
Fig.15 Calculated of isotopic pattern for chloranilic acid (chlorac) using a web tool, Page 66 
 
Fig.16 Isotopic pattern of TClHQ and chlorac measured with Agilent 6140 Series. The gradient, run 
for this assay consisted of A 95% water +0.1% formic acid and solvent B 5% ACN + 0.1% formic acid. 
The gradient schedule is 5- 95% B for 0.6 min at 1.0 ml/min. The column is re-equilibrated with 95% A 
during 0.2 min prior to next injection. Total runtime was 2.5 min. Detection of the analytes was by inline 
UV-detection at 254,292, 310, 320 nm. Standard conditions for MS were used, Page 66 
 
Fig.17 Calculated isotopic pattern of p-chloranil using a web tool, Page 67 
 
Fig.18 Isotopic pattern of fresh p-chloranil immediately analyzed after preparation with Agilent 6140 
Series. The gradient, run for this assay consisted of 95% A (water +0.1% formic acid) and solvent 5% B 
(ACN + 0.1% formic acid). The gradient schedule is 5- 95% B for 0.6 min at 1.0 ml/min. The column is 
re-equilibrated with 95% A during 0.2 min prior to next injection. Total runtime was 2.5 min. Detection of 
the analytes was by inline UV-detection at 254,292, 310, 320 nm. Standard conditions for MS were used. 
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Fig.19 Isotopic pattern of mixture of p-chloranil and TClHQ with Agilent 6140 Series. The gradient, 
run for this assay consisted of A 95% water +0.1% formic acid and solvent B 5% ACN + 0.1% formic 
acid. The gradient schedule is 5- 95% B for 0.6 min at 1.0 ml/min. The column is re-equilibrated with 
95% A during 0.2 min prior to next injection. Total runtime was 2.5 min. Detection of the analytes was by 
inline UV-detection at 254,292, 310, 320 nm. Standard conditions for MS were used. Page 68 
 
Fig.20 Example for decomposition of p-chloranil after short incubation in aqueous medium at pH 7.4 
with Agilent 6140 Series. The gradient, run for this assay consisted of 95% A (water +0.1% formic acid) 
and solvent 5% B (ACN + 0.1% formic acid). The gradient schedule is 5- 95% B for 0.6 min at 1.0 
ml/min. The column is re-equilibrated with 95% A for 0.2 min prior to next injection. Total runtime was 
2.5 min. Detection of the analytes was by inline UV-detection at 254,292, 310, 320 nm. Standard 
conditions for MS were used, Page 69 
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Fig.2 Data retrieval using MDL CrossFinder Commander and Human Drug Database, Page 76 
 
Fig.3 Comparison of p-chloranil assay and microsomal rat clearance. Percentage of compound 
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Fig.4 Scaffold indol, Page 80 
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Fig.6 Conversion of p-chloranil to its hydroquinone at pH: 7.4. Each hydroxyl group exhibits a pka value: 
1) pka1: 5.25 2) pka2: 6.56, Page 81 
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Fig.11 Second example for a compound in Fig.9. desipramine measured with EPSS at a scan rate of 
0.640 V/s in a scan range from 0 to 1.5V, No. of scans n=5 in 5 mM HB, pH: 7.4 Page 84 
 
Fig.12 Demethylation reaction of an in-house compound Page 84 
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Fig.16 Loading Scatter plot with R2 [61]: 0.1479437, R2 [61]: 0.185738 Page 87 
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Results from p-Chloranil studies [96] [97]  
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Table A: Structure-Activity Relationships of literature data related to their Eox  
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Table B: Fragment-Table [69, 84, 119-192] 
 
 
Chemical Name MW MF Structure E [V] conditions
index
» P: polarography
» V: voltammetry
» CV: cyclic voltammetry
» RE: reference electrode
» WE: working electrode
» AE: auxiliary electrode
DIBENZO-AZEPINE-DERIVATIVES
dibenzoylcycloheptene 206.2 C15H10O solvent: DMF » P
E1/2 (1): -1.52 » WE:  not described
E1/2 (2): -1.96 » AE: not described
» RE: SCE
5-methylene-5H- 204.3 C16H12 solvent: ACN » CV
dibenzo[a,d]cycloheptene E1/2: -2.26 » WE:  Pt-wire
solvent: DMF » AE: Pt- wire
E1/2: -2.24 » RE: NHE
iminodibenzyl 195.3 C14H13N Eox:-1.057 » method not very well
 described
iminostilbene 193.3 C14H11N solvent: DMSO » CV
5H-dibenzo[b,f]azepine ISTD: Ferrocene
E1/2: 0.27 » WE:  Pt-wire
» AE: Pt- wire
» RE: Ag/AgCl
carbamazepin 236.3 C15H12N2O solvent: ACN » CV
» WE:  glassy carbon
Tegretol Ep:-2.27 » RE: Ag/AgCl wire
» AE: Pt-wire
iminodibenzyl-5-carbonyl 257.7 C15H12ClNO solvent: ACN » direct current P/ CV
chloride E1/2(1): -1.91 » WE:   dropping Hg
Intermidiate of Carbamazepin E1/2(2): -2.23 » AE: Pt- wire
» RE: GKE (?)
solvent: - » CV
Ep : -1.955 
-2.275
CYCLOPROPAN - DERIVATIVES
cyclopropane 42.1 C3H6 solvent: ACN » CV
E1/2: 3.41 » WE:  Pt-wire
» AE: Pt- wire
» RE: Ag/AgCl
cyrazepam 339.8 C19H18ClN3O solvent: BR-Buffer » coulometry
benzodiazepincyclopropyl » WE:  stirred Mercury 
methylamine » AE: Graphit in sat KCl
» RE: Ag/AgCl
methylcyclopropene 54.1 C4H6 solvent: DMF !! Not very much information 
Eox: 2.41 on the electrochemic method !!
O
N
N
Cl O
N
O N
N
N
N
Cl
N
O
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dicyclopropylmethanone 110.2 C7H10O solvent: DMF » CV
Ered: -3.188 » WE:  GCE
» AE: Pt-wire coil
» RE: Ag/AgCl
1-cyclopropyl-ethanone 84.12 C5H8O solvent: DMF » CV
Ered: -3.215 » WE:  GCE
» AE: Pt-wire coil
» RE: Ag/AgCl
1,1-dimethyl-cyclopropane 70.13 C5H10 solvent: ACN » preparative electrolysis
Eox: 2.5 the electrode material has 
not been described
4-cycloprpylanisole 148.2 C10H12O solvent: ACN » CV
Eox: 1.42 » WE:  Au
» AE: Pt-wire 
NOTE! Irreversible Cyclic Voltamograms » RE: SCE
1-(4-cyclopropyl-phenyl)- 160.22 C11H12O solvent: ACN » CV
ethanone E° : -2.48 » WE:  Au
» AE: Pt-wire 
» RE: Ag/AgCl
NAPHTHALENE -DERIVATIVES
2-benzyl-6-methoxy - 248.32 C18H16O solvent: ACN » CV
 naphthalene Ep/SCE: 1.42 » WE:  Pt-blead
» AE: Pt-wire coil
» RE: Ag/AgCl
6-acetyl-2-dimethylamino 213.28 C14H15NO solvent: ACN » CV
naphthalene Eox: ~ 0.7  ISTD: Ferrocene
PRODAN » WE:  Pt-disk
» AE: Pt-wire
» RE: aq.SCE
1,4-dimethxy-5,6- 216.28 C14H16O2 solvent: CH2Cl2 » CV
dimethylnaphthalene Eox: 0.4 ISTD: Ferrocene
» WE:  glassy carbon
» AE: Pt-plate
» RE: Ag/AgCl
5,6,7,8- 216.13 C10H4F4O solvent: ACN » CV
tetrafluonaphth-2-ol Eox: 1.84 » WE:  no info
» AE:  no info
» RE: Ag/AgCl
2-methoxy-1-(2-methyl- 212.29 C15H16O solvent: ACN » Photoanimation
1-propenyl)naphthalene Eox1/2 : 0.9 
naphthalene-1-carboxylic 284.35 C18H20O3 solvent: ACN » CV
acid 4-hydroxy-methyl- Eox1/2 : -1.91 ISTD: Ferrocene
cyclohexyl ester » WE:  glassy carbon
S.55 Report Fragments_I » AE: Pt-plate
» RE: Ag/AgCl
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1,2,3,4- 184.28 C14H16 solvent: DMSO » CV
tetramethyl-naphthalene Eox : 1.55 » WE:  Pt-wire
» AE: Pt-gauze
» RE: SCE
methoxynaphthalene 158.2 C11H10O solvent: ACN » CV
Eox : 1.41 » WE:   Pt-wire
» AE: Pt-gauze
» RE: Ag/AgCl
1,2,3,4,6,7- 212.33 C16H20 Article is in Russian
hexamethyl-napthalene
2-methoxy-6- 172.23 C12H12O solvent: ACN » CV
methyl-napthtalene Ep/SCE: 1.41 » WE:  Pt-blead
» AE: Pt-wire coil
» RE: Ag/AgCl
1.6-dimethoxynaphthalene 188.2 C12H12O2 solvent: ACN » P
E1/2 (ox): 1.28 » WE:  dropping Hg (red.)
E1/2 (red): -2.68 » WE:  rotating Pt  (oxd.)
» RE: SCE
2,7-dimethoxy- 188.2 C12H12O2 solvent: ACN » P
naphthalene E1/2 (ox): 1.47 » WE:  dropping Hg 
E1/2 (red): -2.68 » WE:  rotating Pt  (oxd.)
» RE: SCE
ANTHRACENE-DERIVATIVES *
9-ethyl-anthracene 206.29 C16H14 solvent: ACN » CV
E°0x: 1.14 ISTD: Ferrocene
» WE:  Pt-disk
» AE: Pt-wire
» RE: aq.Ag/AgCl
anthracene-9-carbaldehyde 206.2 C15H10O solvent: ACN » CV
E°0 -1.462 ISTD: Ferrocene
» WE:  Pt-disk
» AE: Pt-wire
» RE: aq.Ag/AgCl
9,10-dimethyl-anthracene 206.29 C16H14 solvent: CHCl3 » CV
E°0x: 1.16 ISTD: Ferrocene
» WE:  Pt-disk
» AE: Pt-wire
» RE: aq.Ag/AgCl
9-methoxymethyl- 222.29 C16H14O solvent: DMSO » CV
anthracene Eox(A
-): -1.635 ISTD: Ferrocene
Ered(HA): -2.295 » WE:   no information
» AE: no information
» RE: no information
9-chloro- 226.7 C15H11Cl solvent: DMSO » CV
10-methyl-anthracene Eox(A
-): -1.35 ISTD: Ferrocene
Ered(HA): -2.207 » WE:   no information
» AE: no information
» RE: no information
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BENZOPYRANON-DERIVATIVES
6-methyl coumarines 160.2 C10H8O2 solvent:  MeOH » P
no further information 
E1/2: 1.63 on the electrode material
5-methoxypsoralen 216.2 C12H8O4 solvent:  H2O » CV
Eox: 1.63 
no further information 
irreversible oxidation on the electrode material
7-methyl-coumarin 160.2 C10H8O2 solvent:  H2O » CV
Eox: 2.17 no further information 
irreversible oxidation on the electrode material
psoralen 186.2 C11H6O3 solvent:  H2O » CV
Eox: 1.89 no further information 
on the electrode material
7,8-dihydroxy- 178.1 C9H6O4 E1/2: -1.8 » P
coumarin pH-dependency no further information 
on the electrode material
4-methyl-coumarin 160.2 C10H8O2 E1/2: -1.64 » P
no further information 
Note! No information concerning solvents or electrode material on the electrode material
3-methyl-coumarin 160.2 C10H8O2 E1/2: -1.68 » P
no further information 
on the electrode material
7-hydroxycoumarin 162.1 C9H6O3 E1/2: -1.67 » P
(Umbelliferone) no further information 
on the electrode material
6-hydroxycoumarin 162.1 C9H6O3 E1/2: -1.56 » P
no further information 
on the electrode material
3,4-dimethylcoumarin 174.2 C11H10O2 E1/2: -1.73 » P
no further information 
on the electrode material
3,4,7-trimethyl- 188.2 C12H12O2 E1/2: -1.81 » P
coumarin no further information 
on the electrode material
7-hydroxy-4-methyl- 176.2 C10H8O3 E1/2: -1.82 » P
coumarin no further information 
on the electrode material
8-methoxy coumarin 176.2 C10H8O3 E1/2: -1.56 » P
no further information 
on the electrode material
coumarin 146.2 C9H6O2 E1/2: -1.53 » P
no further information 
on the electrode material
7-aminocoumarin 161.2 C9H7NO2 solvent: ethanolic » P
buffer solution » WE:  dropping Hg
E1/2: -1.052 » AE:  mercury
» RE:  SCE
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QUINOLINONE
4-quinolinol 145.16 C9H7NO
9-acridone 195.22 C13H9NO solvent: DMF » P
Ep
red : -2.25  » WE:  dropping Hg
» AE: Pt  
» RE: SCE
10-vinyl-10H - 221.26 C15H11NO solvent: DMF » P
acridin-9-one Ep
red : -2.2   » WE:  dropping Hg 
» AE: Pt  
» RE: SCE
3-chloro-10H - 229.67 C13H8ClNO solvent: DMF » P
acridin-9-one Ep
red : -1.9 » WE:  dropping Hg 
» AE:   Pt  
» RE: SCE
10-methyl-10H - 209.25 C14H11NO solvent: ACN » CV
acridino-9-one Ep
ox : 1.47 » WE:  Pt
» AE:   Pt  
» RE: SCE
6-chloro-2-methoxy-10H- 259.69 C14H10ClNO2 solvent: DMF » P
acridin-9-one Ep
red : -1.7 » WE:  dropping Hg 
» AE:   Pt  
» RE: SCE
QUINOLINE
quinoline 129.2 C9H7N solvent: DMF » P
E1/2
red: - 2.18 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
2,6-dimethyl-quinoline 157.21 C11H11N solvent: DMF » P
E1/2
red: - 2.31 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
2-methyl-quinoline 143.19 C10H9N solvent: DMF » P
E1/2
red: - 2.2 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
6-methyl-quinoline 143.19 C10H9N solvent: DMF » P
E1/2
red: - 2.19 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
4-methyl-quinoline 143.19 C10H9N solvent: DMF » P
E1/2
red: - 2.25 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
8-methyl-quinoline 143.19 C10H9N solvent: DMF » P
E1/2
red: - 2.22 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
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2,4-dimethyl-quinoline 157.21 C11H11N solvent: DMF » P
E1/2
red: - 2.82 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
2-chloro-quinoline 163.61 C9H6ClN » CV
» WE:  dropping Hg 
» AE: -
NOTE! Irreversible reaction » RE: SCE
8-aminoquinoline 144.18 C9H8N2 solvent: BR » P
E1/2
red: 1.38 » WE:  dropping Hg 
» AE:   Pt  
» RE: SCE
8-hydroxyquinoline 145.16 C9H7NO solvent: BR » P
E1/2
red: 1.28 » WE:  dropping Hg 
» AE:   Pt  
» RE: SCE
2-phenyl-quinoline 205.3 C15H11N solvent: ACN » CV
E1/2
red:  - » WE:  Pt-disk
» AE: Pt-wire
» RE: Ag-wire
quinoline-4-carboxylic 173.2 C10H7NO2 solvent: buffer » P
 acid E1/2
red: 0.795 » WE:  dropping Hg 
» AE:   Pt  
» RE: SCE
isoquinoline 161.3 C11H15N solvent: ACN » CV
E1/2: 1.21 » WE:  Pt
» RE: Ag/AgCl
» AE: Pt
ISOBENZOFURAN
isobenzofuran-1,3-dione 148.12 C8H4O3 solvent: ACN » P
E1/2: -2.05 » WE:  dropping Hg 
» AE:   -
» RE:SCE
CYCLOPENTAN
1-fluoren-9-yl-piperidine 249.4 C18H19N solvent: Me2SO
E1/2: -0.518 
indan-1-one 132.2 C9H8O solvent: DMF » CV
Eox1/2: 1.97 » WE:   Pt
» RE: SCE
» AE: Pt
cyclopentan 70.1 C5H10 solvent: fluoro » P
sulphonic acid » WE:   Pt
E1/2: 2.0 » RE: SCE
» AE: Pt
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QUINONES/QUINONE-DERIVATIVES
1H-indazole-4,7-dione 148.1 C7H4N2O2 solvent: acetic » Redox Titration
acid
E1/2: 0.48  
2,5-bis-aziridin-1-yl-[1,4]bezoquinone190.2 C10H10N2O2 solvent: MeOH » P
E1/2: -0.115  » WE:  dropping Hg
» RE: Ag/AgCl
» AE: Pt-wire
anthraquinone 208.2 C14H8O2 solvent: ACN » CV
Eox1/2: 0.9 » WE:   Au
» RE: Ag/AgCl
» AE: Pt
1-amino-anthraquinone 223.2 C14H9NO2 solvent: MeOH » direct current P
Eox1/2: -0.24 V » WE:   -
» RE -
» AE: Pt-wire
1,5-dichloro-anthraquinone 277.1 C14H6Cl2O2 solvent: CH2Cl2 » CV
Eox1/2: -0.84 » WE:   Pt
» RE: SCE
» AE: Pt
p -chloranil 245.9 C6Cl4O2 solvent: ACN » not described
 E1/2:  - 0.33     
solvent: CH2Cl2 » CV
E1/2: 0.24   
p -bromanil 426.7 C6Br4O2 solvent: CH2Cl2 » CV
Eox1/2: 0.03  » WE:   Pt
» RE: SCE
» AE: Pt
2-methyl-1,4-benzoquinone 184.2 C12H8O2 solvent: DMF » CV
Eox1/2: 0.44 V » WE:   Pt
» RE: SCE
» AE: Pt
1-methyl-1H- 182.2 C8H6N2O2 article only available in Russian
benzimidazole-4,5-dione
1,4-benzoquinone 108.1 C6H4O2 solvent: ACN » CV
∆E:  0.91 
solvent: DMF » P
E1/2:   - 0.39 
1,4-naphthoquinone 158.16 C10H6O2 solvent: ACN » not described
E' 0:  0.459
solvent: ACN » P
E1/2: -0.685 
2,3-dichloro-[1,4]naphthoquinone227.1 C10H4Cl2O2 solvent: DMF » CV
Eox1/2: 0.53 » WE:   Pt
» RE: SCE
» AE: Pt
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menadione 172.18 C11H8O2 solvent: - » P
2-methyl-1,4-naphthoquinone E1/2:  - 0.225 
solvent: - » CV
E'pc1:  -0.277 
2,3,5,6-tetramethyl- 164.2 C10H12O2 solvent: benzo » CV
[1,4]benzoquinone nitrile » WE:   glassy carbon
Eox1/2: -0.9 » RE: Ag/AgCl
» AE: Pt-wire
2,3-dihydro-1H-indane 118.2 C9H10 solvent: ACN » P
E1/2: 1.59 » WE:   Pt
» RE: Ag/AgCl
» AE: Pt
2,5-diamino-3,6-dichlro- 207.0 C6H4Cl2N2O2 solvent: ACN » CV
[1,4]benzoquinone Eox1/2: -0.72 » WE:   Pt
» RE: SCE
» AE: Pt-wire
CYCLOHEXAN
5,5-dimethyl- 140.18 C8H12O2 solvent: DMSO » P
cyclohexane-1,3-dione Eox: -0.23 » WE:   Pt
» RE: Ag/AgCl
» AE: Pt
CYCLOHEXENE
192.3 C13H20O solvent: ACN » CV
E1/2
red: -1.89 » WE:  Pt-wire
» AE: Pt-wire
» RE: Ag-wire
PYRIDINE-DERIVATIVES
4-methyl-pyridine 93.1 C6H7N solvent: DMF » P
E1/2
red: - 2.76 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
2,5-dimethyl-pyridine 107.2 C7H9N solvent: DMF » P
E1/2
red: - 2.82 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
2-methyl pyridine 93.1 C6H7N solvent: DMF » P
E1/2
red: - 2.80 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
2,5-dimethyl-pyridine 107.2 C7H9N solvent: DMF » P
E1/2
red: - 2.85 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
2,4,6-trimethyl-pyridine 121.2 C8H11N solvent: DMF » P
E1/2
red: - 2.91 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
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[1,5] naphthyridine 130.2 C8H6N2 solvent: DMF » P
E1/2
red: - 1.86 » WE:  dropping Hg 
» AE:   Pt  
» RE: Ag/AgCl
TETRAHYDROPYRAN
chromeno[2,3-b]pyridin-5-one 197.2 C12H7NO2 solvent: DMF » CV
E0red: - 1.48 » WE:  glassy carbon
» AE:   Pt
» RE: Ag/AgCl
2,4,6-trimethyl-tetrahydropyran 128.2 C8H16O solvent: ACN » P
Eox1/2: - 1.48 » WE:  Pt
» AE:   Pt
» RE: Ag/AgCl or SCE
xanthene 182.2 C13H10O solvent: DMSO » CV
E0red: - 1.36V » WE:  Pt-disk
E0ox:  - 1.76V » AE:   Pt-wire
» RE: Ag/AgCl
5H-benzpyrano- 184.2 C11H8N2O solvent:  MeOH » P
[1][4,3-d]pyrimidine E1/2: -1.15 » WE:  dropping Hg 
» AE:   Pt  
pH: 1.39 » RE: Ag/AgCl
PYRROLIDINE
1-ethyl-pyrrolidine 99.2 C6H13N solvent:  ACN » CV
Eox1/2: 1.08 » WE:  glassy carbon 
» RE: SCE
» AE:  Pt-coil
2-pyrrolidine 85.1 C4H7NO solvent:  DMSO » CV
Eox1/2: 0.03 » WE:  Pt
» RE: Ag/AgCl
» AE:  Pt
PYRAN
5-iodo-phtalic acid 274.0 C8H3IO3 solvent:  buffer » P
anhydride E1/2: -1.34 » WE:  dropping Hg
» RE: SCE
» AE:  Pt
chromeno[2,3-b] 140.2 C8H12O2 solvent:  ACN » CV
pyridin-5-one E0RED: - 1.46 » WE:  glassy carbon
» RE: Ag/AgCl
» AE:  Pt
2,3-dihydro- 136.2 C8H8O2 solvent:  ACN » CV
benzofuran-5-ol E1/2: 0.66 » WE:  glassy carbon 
» RE: SCE
» AE:  Pt-coil
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FURAN
2-methyl furan 82.1 C5H6O solvent:  ACN » P
Eox: 1.18 » WE:  Pt
» AE:   Pt  
» RE: Ag/AgCl
2,4-dimethyl furan 96.1 C6H8O solvent:  ACN » P
Eox: 0.90 >> for details see above
2,5-dimethyl furan 96.1 C6H8O solvent:  ACN » P
Eox: 0.95 >> for details see above
benzofuran 118.1 C8H6O solvent:  ACN » P
Ep: 1.82 » WE:  Pt
» AE:   Au
» RE: SCE
4,6-dimethyl-dibenzothiophene 212.3 C14H12S solvent:  ACN » not described
Eox : 
2,3,4,5-tetramethyl-thiophene 140.2 C8H12S solvent:  ACN » CV
Eox : 0.89 ISTD: Ferrocene
» WE:  Pt-disk
irreversible reaction » AE:   Pt-wire
» RE: Ag/AgCl
2-methyl thiophene 98.2 C5H6S solvent:  ACN » CV
E° > 1.8 ISTD: Ferrocene
» WE:  glassy carbon
» AE:   Pt-wire
» RE: Ag/AgCl
PIPERIDINE
1-methyl piperidine 99.2 C6H13N solvent:  ACN » CV
Eox1/2: 1.18  » WE:   Pt
» RE: SCE
» AE:  Pt
1-benzyl-piperidine 175.3 C12H17N » not described » not described
2,2,6-trimethyl-piperidine 127.2 C8H17N solvent: H2O » CV
Eox1/2: - 0.1 » WE:   Au
» RE: SCE
» AE:  Pt
piperidine 85.2 C5H11N solvent: H2O » Potentiometrie
E1/2 :0.422 V » WE:  Pt-black electrode
» RE: SCE
1-ethyl-piperidine 113.2 C7H15N solvent: H2O » CV
Eox1/2: 1.1  » WE:  Pt
» RE: SCE
» AE:  Pt
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1-hydroxy-piperidine 101.2 C5H11NO solvent: ACN » CV
E1/2: -1.26 ISTD: Ferrocene
» WE:  Pt
» RE: Ag/AgCl
» AE:  Pt
1-chloro-piperidine 119.6 C5H10ClN solvent: PB » CV
ISTD: Ferrocene
E1/2: 0.2 » WE:  Pt/glassy carbon
irreversible » RE: Ag/AgCl
reduction » AE:  Pt
1-methylsulfanylpiperidine 131.2 C6H13NS solvent: ACN » CV
E1/2: 0.81 ISTD: Ferrocene
» WE:  Au
» RE: SCE
» AE:  Pt
2,2,6,6-tetramethyl- 141.3 C9H19N solvent: H2O » CV
piperidine E1/2: - 0.05 ISTD: Ferrocene
» WE:  Au
» RE: SCE
» AE:  Pt
2-ethyl-1,2,3,4-tetrahydro- 161.3 C11H5N solvent: - » CV
isoquinoline E1/2: 1.2 » WE:  Pt
» RE: SCE
» AE:  Pt
2-methyl-4-piperidino- 190.3 C12H8N2 solvent: - » P
aniline E1/2: -0.315  » WE:  Pt
» RE: SCE
pH: 11 » AE:  Pt
1-piperidine-1-yl-azepane 182.3 C11H22N2 solvent: CH2Cl2 » CV
Eop: 0.20 » WE:  Pt
» RE: SCE
» AE:  Pt
1-(2,2,2-trifluoro 167.2 C7H12F3N solvent: ACN » CV
-ethyl)-piperidine Eop: 0.83 » WE:  Pt
» RE: SCE
» AE:  Pt
pyrimidone 138 C7H10N2O solvent: : DMF » CV
E1/2
red: - 2.09 ISTD: Ferrocene
» WE:  Hg-Stand
» AE:   Pt-wire
» RE: SCE
4,6-dimethyl-1-phenyl- 200.24 C12H12N2O solvent: : DMF » CV
1H-pyrimidine-2-one E1/2
red: - 1.94 ISTD: Ferrocene
» WE:  Hg-Stand
» AE:   Pt-wire
» RE: SCE
CYCLOPENTANONE
cyclo pentanone 84.12 C5H8O solvent: : aequ. » P
solution no further information 
E1/2
red: - 1.94 on the electrode material
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FURANONE
3-methyl-2,5-furandione 112.08 C5H4O3 solvent: MeOH/Benzene» P
E1/2: - 0.72 » WE:  Hg-Stand
» AE:   -
» RE: SCE
cyclohepta[b]furan-2-one 146.15 C9H6O2 solvent: ACN » CV
Eox: 1.13 » WE:  Pt
» AE:   Pt-wire
» RE: Ag/AgCl
3,4-dimethyl-2,5-furandione 126.11 C6H6O2 solvent: DMF/Bu4NPF» CV
Ep: -1.99 » WE:  Hg coated Pt-disk
» AE:   Pt-wire
» RE: Ag/AgCl
isobenzofuran-1,3-dione 148.12 C8H4O3 solvent: MeOH/Benzene» P
E1/2: -1.12 » WE:  Hg-Stand
» AE:   -
» RE: SCE
4-iodo-phthalic 274.01 C8H3IO3 solvent: buffer » P
acid anhydride E1/2: -1.34 » WE:  Hg-Stand
» AE:   -
» RE: SCE
LACTONE
benzofuran-2,3-dione 148.12 C8H4O3 solvent: DMSO » P
coumarandione Ered1/2: -0.65 » WE:  Hg-Stand
» AE:   -
» RE: SCE
PIPERAZINE
piperazine 86.1 C4H10N2 solvent: - » CV
E1/2 (1): -1.96/68 » WE:  dropping Hg
E1/2 (2): -2.32/62 » RE: SCE
» AE:  Pt-wire
piperazine-2,5-dione 114.1 C4H6N2O2 solvent: H2O no further information 
 Ek
0: 0.4 on the method at all
pH: 7.0
1,2,3,4-tetrahydro-quinoxaline 134.2 C8H10N2 solvent: buffer » P
no further information 
E1/2 : 0.05 V on the electrode material
4-piperazino-aniline 177.3 C10H15N3 solvent: aqu.sol » P
E1/2: -0.304 » WE:   Pt
photographic dye » RE H-electrode
pH: 11 » AE: -
5,10-dimethyl-5,10-dihydro- 210.3 C14H14N2 solvent: ACN » CV
phenazine E1/2: 0.14 » WE:   Pt
» RE: SCE
» AE:  Pt-wire
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5,10-dimethyl-5,10dihydrophenazine212.3 C14H16N2 solvent: ACN » V
Ep: -0.06 » WE:   Pt
» RE: Ag/AgCl
rev. potential » AE: Pt-wire
1,4-bis(4-methylpiperazino)benzene274.4 C16H26N4 solvent: ACN » V
Ep: 0.246 » WE:   Pt
» RE Normal H-electrode
» AE: Pt-wire
IMIDAZOLE
imidazole 68.08 C3H4N2 solvent: ACN » V
E1/2: 1.45 » WE:   Pt
» RE: Ag/AgCl
» AE: Pt-wire
2-imidazol-4-ethylamine 111.15 C5H9N3 solvent: PB » CV
E1/2: 0.05 » WE:  modified graphite
» AE:   Pt-wire
» RE: Ag/AgCl
PURINE
purine 120.11 C5H4N4 CHECK again
6-methylpurine 134.14 C6H6N4 solvent: DMF » P
E1/2: -2.06 » WE:   Pt
» RE: SCE
» AE:-
1,7-dimethyl-xanthine 180.17 C7H8N4O2 solvent: DMF » CV
E1/2:  1.22 » WE:   glassy carbon
» RE: SCE
» AE:Pt
adenine 135.13 C5H5N5 solvent: DMSO » P
E1/2: -2.41 » WE:   Pt
» RE: SCE
» AE:-
guanine 151.13 C5H5N5O solvent: DMSO » CV
E1/2: -2.76 » WE:   glassy carbon
» RE Luggin
» AE:Pt-sheet
BENZIMIDAZOLE
benzimidazole 118.1 C7H6N2 solvent: ACN » V
E1/2: 1.31 » WE:   Pt
irreversible » RE: Ag/AgCl
half-wave potential » AE: Pt
1,2-dimethyl-1H-benzoimidazole 146.2 C9H10N2 solvent: ACN » CV
Ep/2 
1A: 1.38 ISTD: Ferrocene
» WE:  glassy carbon
» AE:   Pt-wire
» RE: SCE
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2-methyl-1H-imidazole 132.2 C8H8N2 solvent: ACN » CV
Ep/2 
1A: 1.38 ISTD: Ferrocene
» WE:  glassy carbon
» AE:   Pt-wire
» RE: SCE
2-propyl-1H-benzimidazole 160.2 C10H12N solvent: ACN » V
E1/2: 1.83 V » WE:   Pt
irreversible » RE: Ag/AgCl
half-wave potential » AE: Pt
2-phenyl-1H-benzoimidazole 194.2 C13H10N2 solvent: ACN » CV
Ep: 1 V » AE:   Pt-wire
» RE: Ag/AgCl
» WE:  Pt
TRIAZOLE
1,3-dichloro-1H-[1,2,4]triazole 137.96 C2HCl2N2 solvent: ACN » V
E1/2: -0.1 V » WE:   Pt
» RE: Ag/AgCl
» AE: Pt
TETRAZOLE
tetrazole 70.05 CH4N4 check again
5-phenyl-tetrazole 146.15 C7H6N4
THIAZOLE
thiazole 82.1 C3H3NS solvent: ACN » P
E1/2: 1.980 V » WE:   Pt
» RE: Ag/AgCl
» AE: Pt
2-chloro-thiazole 119.6 C3H2ClNS » P
» WE:   
» RE: SCE
» AE: -
2-halogen-thiazole 164.0 C3H2BrNS solvent: aqu.sol. » P
E1/2 (I): 0.24 V » WE:   
E1/2 (Br): 0.59 V » RE: SCE
E1/2 (Cl): 0.91 V » AE: -
at pH: 1
E1/2 (I): 0.70 V
E1/2 (Br): 1.47 V
at pH: 8-10
5-phenyl-thiazole 161.2 C9H7NS solvent: ACN » P
E1/2: 1.41 V » WE:   Pt
» RE: Ag/AgCl
» AE: Pt
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5,6-dimethyl-benzothiazol- 178.3 C9H10N2S solvent: MeOH/H2O» P
2-ylamine E1/2: -1.24 V » WE:  Pt
irreversible » RE: SCE
reaction » AE:  Pt
THIADIAZOLE
2,5-diphenyl-Thiadiazole 238.31 C14H10N2S
INDOLE-DERIVATIVES
3-benzyl-1-methyl- 297.4 C22H19N solvent: ACN » P
2-phenylindole Eox1/2: 0.51 V » WE:  graphit/rotating Pt
» RE: Ag/AgCl
» AE: -
indolinone 218.3 C12H14N2O2 solvent: H2O » Pulse radiolysis
1-methyl-tryptophan Ered: 1.14 V
methylparabensäure 128.1 C4H4N2O3 solvent:40 % EtOH » P
methyl-Imidazolidintrione E1/2 : -0.74V » WE:  dropping Hg
» RE: SCE
» AE: -
BARBITURIC ACID /-DERIVATIVES
1-5-dimethyl-barbituric acid 156.1 C6H6N2O3 solvent: acetic acid » CV
and MeOH » WE:  pyrolytic graphite 
Eox1/2: 1.1V » RE: SCE
» AE: -
1,3-dimethyl-barbituric acid 156.1 C6H6N2O3 solvent: acetic acid » CV
and MeOH » WE:  pyrolytic graphite 
Eox1/2: 1.58 V » RE: SCE
» AE: -
alloxan 142.1 C4H2N2O4 solvent: Eimer and » P
pyrimidine-2,4,5,6-tetraone Amend Buffer » WE:  
E1/2 (1) : -0.115 V » RE: SCE
E1/2 (2) . -0.965 V » AE: -
E1/2 (3):  - 1.52 V
5-(benzothiazol hydrazono)-1,3-dimethyl-pyrimidine,2,4,6-trione317.3 C13H11N5O3S solvent: DMF » P
E1/2: -0.72 V » WE:  dropping Hg
» RE: SCE
» AE: -
BARBITAL
barbital 184.2 C8H12N2O3 solvent: Borate Buffer» P
5,5-diethyl-pyrimidine-2,4,6-trione E1/2: -0.036 V » WE:  
» RE: SCE
» AE: -
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MORPHOLINE
morpholine 87.1 C4H9NO CHECK AGAIN! 
4-ethyl-morpholine 115.2 C6H13NO solvent: EtOH » redox titration
E1/2 : 0.19 V
4-chloro-morpholine 121.6 C4H8ClNO solvent: 
CHECK LITERATURE AGAIN!! 
4-aminomorpholine 102.1 C4H10N2O solvent: EtOH » P
E1/2 : 0.8V no further information 
on the method at all
4-butyl-morpholine 143.2 C8H17NO solvent: EtOH » redox titration
E1/2 : 0.203 V
4-(2-methyl-propenyl)-morpholine141.2 C8H15NO solvent: ACN » P
E1/2 : 0.19 V » WE:   glassy carbon
» RE: Ag/AgCl
» AE: Pt
4-thiophen-2-yl-morpholine 169.2 C8H11NOS solvent: ACN » no information about 
Eox : 0.55 V the method
4,7-dimethyl-3,4-dihydro- 163.2 C10H13NO solvent: ACN » P
2H-benzo[1,4]oxazine E1/2: 0.60 V » WE:   no info available
» RE: SCE
» AE:  no info available
4-(4-piperidin-1-yl-phenyl)- 246.4 C15H22N2O
morpholine
XANTHINES
theobromin 180.2 C7H8N4O2 solvent: H2O » CV
PB ISTD: Ferrocene
» WE:  glassy carbon
Ep. 1.3V » AE:   Pt-wire
(low pH-value) » RE: SCE
7-methylxanthine 166.1 C6H6N4O2 solvent: water with» CV
phosphate buffer ISTD: Ferrocene
» WE:  glassy carbon
Ep. 0.925 V » AE:   Pt-wire
» RE: SCE
theophyllin 180.2 C7H8N4O2 solvent: aq.phosphate» CV
buffer » WE:  pyrolytic graphite
Eox: 1.0 V » RE: SCE
» AE: Pt  gauze
caffeine 194.2 C8H10N4O2 solvent: aq.phosphate» CV
buffer » WE:  pyrolytic graphite
Eox: 1.45 V » RE: SCE
Ered: 0.76 V » AE: Pt  gauze
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FURAN
2-methyl furan 82.1 C5H6O solvent:  ACN » P
Eox: 1.18 » WE:  Pt
» AE:   Pt  
» RE: Ag/AgCl
2,4-dimethyl furan 96.1 C6H8O solvent:  ACN » P
Eox: 0.90 >> for details see above
2,5-dimethyl furan 96.1 C6H8O solvent:  ACN » P
Eox: 0.95 >> for details see above
benzofuran 118.1 C8H6O solvent:  ACN » P
Ep: 1.82 » WE:  Pt
» AE:   Au
» RE: SCE
4,6-dimethyl-dibenzothiophene 212.3 C14H12S solvent:  ACN » not described
Eox : 
2,3,4,5-tetramethyl-thiophene 140.2 C8H12S solvent:  ACN » CV
Eox : 0.89 ISTD: Ferrocene
» WE:  Pt-disk
irreversible reaction » AE:   Pt-wire
» RE: Ag/AgCl
2-methyl thiophene 98.2 C5H6S solvent:  ACN » CV
E° > 1.8 ISTD: Ferrocene
» WE:  glassy carbon
» AE:   Pt-wire
» RE: Ag/AgCl
PIPERIDINE
1-methyl piperidine 99.2 C6H13N solvent:  ACN » CV
Eox1/2: 1.18  » WE:   Pt
» RE: SCE
» AE:  Pt
1-benzyl-piperidine 175.3 C12H17N » not described » not described
2,2,6-trimethyl-piperidine 127.2 C8H17N solvent: H2O » CV
Eox1/2: - 0.1 » WE:   Au
» RE: SCE
» AE:  Pt
piperidine 85.2 C5H11N solvent: H2O » Potentiometrie
E1/2 :0.422 V » WE:  Pt-black electrode
» RE: SCE
1-ethyl-piperidine 113.2 C7H15N solvent: H2O » CV
Eox1/2: 1.1  » WE:  Pt
» RE: SCE
» AE:  Pt
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8-chlorotheophylline 214.6 C7H7ClN4O2 solvent: ACN » CV
E1/2 ox:  1.82 V » WE:  - 
irreversible oxidation » RE: SCE
process » AE: -
PYRAZOLIDINE
pyrazolidine 176.17 C9H8N2O2
1,2-diphenyl-pyrazolidine 252.27 C15H12N2O2
DIOXOLANE
1,3-dioxolane 74.08 C3H6O2 solvent: ACN » CV
Eox1/2: -0.9 » WE:  glassy carbon
» RE: Ag/AgCl
» AE: Pt-coil
2-methyl-dioxolane 88.11 C4H8O2 solvent: ACN » CV
Eox1/2: -1.15 » WE:  glassy carbon
» RE: Ag/AgCl
» AE: Pt-coil
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Table C: Colour Compound List 
 
 
 
 
Chemical Name MW MF Structure Solvent Eox/Ered [V]
systematic name and trivial name
P: polarography
CV: cyclic voltammetry
ACN: acetonitrile
AZO COMPOUNDS
amaranth (acid red)  535.49 C20 H11 N2 O10 S3 solvent : unknown » P
2,7-naphthalenedisulfonic acid E'0: - 0.250 
two electron potential
QUINONES
lawsone 174.16 C10H6O3 solvent : unknown » P
1,4 naphthalenedione E1/2:  - 0.460   
2-hydroxy-1,4-naphthoquinone
solvent : unknown » P
E1/2:  - 0.330  
p -chloranil 254.88 C6Cl4O2 solvent: ACN method:
E1/2:  - 0.330   not described
solvent: ACN
E1/2:  0.350  
solvent: DMF » CV
Erp:   - 0.880 
solvent: MeOH method: 
E1/2: 0.780 to  0.880  potentiometric 
titration
growing redox potentials
with increasing acidification
solvent: CH2Cl2 » CV
E1/2: 0.240 
solvent: benzene method: not 
E1/2: 0.312   described
chloranilic acid 208.99 C6H2Cl2O4 solvent: aqu.sol method: not 
2,5-dichloro-3,6-dihydroxy-[1,4]  + 0.1N HCl described
benzoquinone E'0: 0.420 
o-chloranil 254.88 C6Cl4O2 solvent: benzene method: not 
tetrachloro-[1,2]benzoquinone E' 0:  0.833 described
solvent: aqu.sol 
E' 0:  0.794 
anthraquinone- 368.33 C14H8O8S2 solvent: aqu.sol method: not 
1,5-disulfonate E'0: 0.239 described
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anthraquinone- 368.33 C14H8O8S2 solvent: aqu.sol method: not 
2,6-disulfonate E'0 : 0.228 described
solvents: 1% Ethanol » P
E1/2 : -0. 440 to -0.600  
solvent: DMSO » CV
∆Ep: 0.130 
alizarin 240.21 C14H8O4 solvent: - method: not 
1,2-dihydroxy-9,10- E' 0:  0.494 described
anthraquinone solvent: - method: not 
E1/2:  0.610 to 0.890 described
anthraquinone- 252.23 C15H8O4 solvent: - method: not 
2-carboxylate E'0:  0.208 described
9,10-dioxo-9,10-dihydro-
anthracene-2-carboxylic acid
lapachol 242.3 C15H8O3 solvent: - method:
[1,4]naphtoquinone E' 0 : 0.272 titration
potentiometric
plumbagin 188.18 C11H8O3 solvent: MeOH method: not 
2-methyl-5-hydroxy- E' 0: 0.383 described
1,4-napthoquinone
menadione 172.18 C11H8O2 solvent: - » P
2-methyl-1,4-naphthoquinone E1/2:  - 0.225  
solvent: - » CV
E'pc1:  -277 
solvent: MeOH
E1/2: 0.017  to 0.481 
juglone 174.16 C10H6O3 solvent: DMSO » CV
5-hydroxy-1,4-napthoquinone △Ep: 0.220  (peak1)
△Ep: 0.490  (peak2)
E' 0:  0.450 
1,4-naphthoquinone 158.16 C10H6O2 solvent: ACN method: not 
E' 0:  0.459 described
solvent: 0.1 M TBAP » P
 +ACN
E1/2: -0.685  
1,2-naphthoquinone 158.16 C10H6O2 solvent: aqu.sol method: not 
E'0:  0.579 described
4-amino-1,2-naphthoquinone 173.11 C10H7NO2 solvent: aqu. EtOH » P
E' 0 :  0.440 
1,2-naphthquinone- 237.21 C10H5O5 solvent: aqu. sol method: 
4-sulfonate E' 0:  0.425 potentiometric
 titration
1,4-benzoquinone 108.1 C6H4O2 solvent: ACN » CV
p -benzoquinone ∆E :  0.910 
solvent: DMF » P
E1/2:   - 0.390 
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FLUORESCENT MOLECULES
fluorescein 332.31 C20H12O5 solvent: - method: 
3',6'-dihydroxy-spiro[phthalan- E'0 :  -0.572 titration
1,9'-xanthen]-3-one
rhodamin 442.56 C28H30N2O3 solvent: - method: 
E'0 :  -0.542  titration
E1/2:  -0.852 
tetracyanoquinodimethane 204.19 C12H4N4 solvent: - method: not 
Erp: 0.170 described
solvent: - method: not 
E'0 :  0.460 described
POLYENE
b-b-carotene 536.88 C40H56 solvent: - » CV
trans-b-carotene Eo1: 0.540
all- trans-crocetin 536.88 C40H56 solvent: DMF/DMSO/H2O» CV
8,8'-diapo- q,q -carotenedioic acid E'0: 0.550  to 0.870 
xanthone 196.21 C13H8O2 solvent:  DMF » P
xanthen-9-one E1/2 (1): -1.15 
E1/2 (2): -1.55
E1/2 (3): -2.1
solvent: - » CV
E1/2: -0.910 
solvent: DMF » P
E1/2: -1.6
thioxanthone 212.27 C13H8OS solvent: - » CV
thioxanthen-9-one E 1/2 : -1.73 
solvent: - » CV
E 1/2 : -1.62 
POLYMETHINS
malachitgreen 329.46 C23H25N2 Cl
leucomalachitgreen 329.46 C23H26N2
FLAVONOIDES
quercetin 302.24 C15H10O7 solvent: buffer » P
E1/2 : -1.62 V
rhamnetin 316.27 C16H12O7 informtation about the
(3,3',4',5-tetrahydroxy- half-wave potential is 
7-methoxyflavon) only available in Russian!
flavonol 238.24 C15H10O3 informtation about the
half-wave potential is 
only available in Russian!
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vitamin B2 376.37 C17H20N4O6 solvent: - method: not 
riboflavin E1/2:  -208  described
CHALKON
chalkon 208.26 C15H12O solvent: buffer » P
1,3-diphenyl-acetophenon E1/2 (1): -0.620  
E1/2 (2): -1.006  
at pH 1.81
E1/2 (1): -1.190  
E1/2 (2): -1.340  
E1/2 (3):: -1.690 
at pH 11.98
INDIGOID COMPOUNDS
indigo 262.27 C16H10N2O2 solvent: DMF » CV
1H,1H'-[2,2']biindolylidene-2,2'-dione E1/2 (1): -0.780 
E1/2 (2): -1.260  
indigo carmine 420.37 C16H8N2O8S2
(2-) solvent: - » CV
3,3'-dioxo-1,3,1'3'-tetrahydro 22.99 *2Na
(1+)
E'0 : -0.220 
[2,2']biindolylidene,5,5'-
disulfonic acid
MISCELLANEOUS
DDQ 227.01 C8Cl2N2O2 solvent: - » CV
2,3-dichloro-5,6-dicyano-1,4-benzoquinone E1/2 (1): 0.550
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Table D: List 
 
 
Chemical Name MF MW Structure Epot [V] Conditions
ARYLPROPIONIC-DERIVATIVES
furbiprofen 244.3 C15H13FO2 solvent: EtOH » P
E1/2: -1.97 vs SCE » WE: dropping mercury 
Froben E1/2: -2.40 vs FC » RE: SCE
solvent: DMSO » AE: Pt-wire
E1/2: -2.42 vs SCE
E1/2: -2.82 vs FC
ibuprofen 206.3 C13H18O2 solvent: EtOH » P
E1/2: -2.03 vs SCE for further information: 
Brufen E1/2: -2.46 vs FC see above
solvent: DMSO
E1/2: -2.66 vs SCE
E1/2: -3.06 vs FC
naproxen 230.3 C14H14O3 solvent: EtOH » P
E1/2: -1.95 vs SCE for further information: 
Aleeve E1/2: -2.38 vs FC see above
solvent: DMSO
E1/2: -2.39 V vs SCE
E1/2: -2.79 V vs FC
ARYLACETIC-DERIVATIVES
indomethacine 357.8 C19H16ClNO4 solvent: BR » differential pulse voltammetry 
(pH: 7.2)
(Indocid ®) Ep1: -0.55 » WE: droppinn mercury electr.
Ep2: -1.44 » RE: Ag/AgCl
Ep3: -1.68 » AE: Pt-wire
PYRAZOLIDINES
kebuzone 322.4 C19H18N2O3 solvent: DMSO » P
1st cathotic step: » WE:dropping mercury
E1/2: -1.36 » RE: Ag/AgCl
2nd cathotic step » AE: Pt-wire
E1/2: -1.91 
phenylbutazone 308.4 C19H20N2O2 solvent: DMSO » direct current polarography
1st cathotic step: » WE:dropping mercury
Ambene® (D) E1/2: -1.37.0 » RE: Ag/AgCl
Butadion® (CH) 2nd cathotic step » AE: Pt-wire
E1/2: -1.94 
Oxyphenbutazone 324.4 C19H20N2O3 solvent: DMSO » direct current polarography
1st cathotic step: » WE:dropping mercury
main metabolit of E1/2: -1.38 » RE: Ag/AgCl
phenbutazon 2nd cathotic step » AE: Pt-wire
E1/2: -2.0
SALICYLIC ACID-DERIVATIVES
acetylsalicylic acid 180.2 C9H8O4 solvent: ACN » P
E1/2 (1) :   -1.64                      » WE: dropping mercury 
Aspirin » RE: silver wire
» AE: platinum wire 
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CATECHOLAMINES
epinephrine 183.2 C9H13NO3 solvent: buffer » normal pulse  polarography
E1/2 :   0.380                   » WE: carbon
EpiPen » RE: SCE (in Vitro ),Ag/AgCl (in Vivo )
» AE: Pt-wire
L-Dopa 197.2 C9H11NO4 solvent: buffer » normal pulse  polarography
E1/2 :   0.450                   » WE: carbon
Madopar » RE: SCE (in Vitro ),Ag/AgCl (in Vivo )
» AE: Pt-wire
isoprenaline 211.3 C11H17NO3 solvent: buffer » V
E1/2 :   0.370                   » WE: Au
» RE: Ag/AgCl wire
» AE: Pt-wire
R-adrenaline 183.2 C9H13NO3 solvent: buffer » CV
E1/2 :   0.370                   » WE: glassy carbon
» RE: Ag/AgCl wire
» AE: Pt-wire
dopamin HCL 158.2 C8H11NO2 solvent: aq. HCl » CV
Eox:0.68 » WE:  dropping mercury
Ered: -0.33 » AE:  mercury
» RE:  SCE
BRONCHODILATATOR
theophyllin 180.2 C7H8N4O2 solvent: buffer » CV
Eox: 1.0 » WE: pyrolytic graphite
» RE: SCE
» AE: Pt  gauze
STIMULATING AGENT
caffeine 194.2 C8H10N4O2 solvent: buffer » CV
Eox: 1.45 » WE: pyrolytic graphite
Ered: 0.76 » RE: SCE
» AE: Pt  gauze
8-chlorotheophylline 214.6 C7H7ClN4O2 solvent: ACN » CV
E1/2 ox:  1.82 » WE: - 
irreversible » RE: SCE
oxidation » AE: -
IMINOSTILBEN-DERIVATIVES
carbamazepin 236.3 C15H12N2O solvent: ACN » CV
» WE: glassy carbon
Tegretol Ep: -2.27 » RE: Ag/AgCl wire
» AE: Pt-wire
8-AMINO-QUINOLINES
primaquine 259.4 C15H21N3O Check literature!
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chloroquine 319.9 C18H26ClN3 solvent: - method: -
1st cathotic step:
Nivaquin E1/2: -0.97
2
nd
 cathotic step
E1/2: -1.20 
proguanil 253.7 C11H16ClN5 solvent: - » P
E1/2 :   1.22 V           » WE: -
Paludrine (Mono) » RE:  -
Malarone (Combi) » AE:  -
ALDEHYDEHYDROGENASE-INHIBITOR
disulfiram 296.5 C10H0N2S4 solvent: EtOH » P
E1/2 : - 0.4 » WE: -
Antabus vs SCE » RE:  -
» AE:  -
VITAMINES
thiamine 265.4 C12H17N4OS solvent: - » P
» WE: -
Benerva » RE:  -
» AE:  -
pyridoxine 169.2 C8H11NO3 solvent: - » CV
E1/2: -1.52 V
solvent: - » differential pulse  voltammetry
Ep: 0.29 V » WE: glassy carbon
» RE: Ag/AgCl
» AE:  Pt-wire
PHENOTHIAZINE-DERIVATIVES
pecazine 310.5 C19H22N2S solvent: buffer » P
E1/2 : 0.503 » WE: rotating gold wire
solvent: EtOH » AE: -
E1/2 : 0.600 » RE: mercury-mercurous
sulfate electrode
prochlorperazine 373.9 C20H24ClN3S solvent: buffer » P
E1/2 : 0.547 » WE: rotating gold wire
solvent: EtOH » AE: -
E1/2 : 0.620  » RE: mercury-mercurous
sulfate electrode
thioridazine 370.6 C21H26N2S2 solvent: buffer » Photoionization
Eox : 0.58
Melleril
chlorpromazine 318.9 C17H19ClN2S solvent: buffer » Photoionization
E1/2 : 0.6
Chlorazine
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promazine 284.4 C17H20N2S solvent: buffer » Photoionization
Eox :  0.56 
solvent: buffer » P 
E1/2 : 0.473 » H-Cell with mercury-mercurous
solvent: EtOH sulfate reference electrode
E1/2 : 0.545 » oxidations were carried out at 
a rotating gold wire electrode.
trifluorperazine 407.5 C21H24F3N3S solvent: - » CV
Eox: 0.66 » WE:  adjustable platinum
disc embedded in a glass seal
» RE: SCE
perphenazine 404.0 C21H26ClN3OS solvent: buffer » P
E1/2 : 0.619 
Trilafon solvent: EtOH
E1/2 : 0.639
perazine 339.5 C20H25N3S solvent: - no information about the method
Eox : 0.72 the electrodes and the solvent
fluphenazine 437.5 C22H26F3N3OS solvent: buffer » P
E1/2 : 0.583 » WE: rotating gold wire
Dapotum solvent: EtOH electrode
E1/2 : 0.684 » RE: mercury-mercurous
sulfate electrode
acetophenazine 411.6 C23H29N3O2S
methopromazine 314.4 C18H22N2OS solvent: EtOH » photogalvanical method
E0 : 0.71 no information about the method
the electrodes and the solvent
methotrimeprazine 328.5 C19H24N2OS Check literature!
thioproperazine 446.6 C22H30N4O2S2 Check literature!
CLOZAPINE-ANALOGUES
clotiapine 343.9 C18H18ClN3S solvent: buffer » CV 
Ep: - 0.920 » WE: carbon paste
Entumin » AE: carbon paste
» RE:  Ag/AgCl in 3 M KCl
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clozapine 326.8 C18H19ClN4 solvent: buffer » CV 
Ep:  -0.375 » WE: carbon paste
Leponex » AE: carbon paste
» RE:  Ag/AgCl in 3 M KCl
perlapine 291.4 C19H21N3 solvent: -
E1/2 : - 1.57 » P
irreversibel » WE: dropping mercury 
half way » AE: Pt-foil
 potential » RE: saturated Hg2Cl2
TRICYCLIC ANTIDEPRESSANT
mianserin 264.4 C18H20N2 solvent: MeOH » V
Eox: 0.76 » WE: glassy carbon
Tolvon » AE: Pt
» RE: Ag/AgCl (sat)
mirtazapine solvent: MeOH » V
Eox:0.76 » WE: glassy carbon
» AE: Pt
Remeron » RE: Ag/AgCl (sat)
protryptillin 263.4 C19H21N solvent: EtOH » CV 
Eox: 1.85 » WE: glassy carbon
» AE: Pt
» RE: Ag/AgCl (sat)
NA-REUPTAKE INHIBITOR
venlafaxine 277.4 C17H27NO2 solvent: BR » square wave voltammetry
E: -1.0 » WE: dropping Mercury
Efexor best pH-range: » AE: glassy carbon
8.0-9.0 » RE: Ag/AgCl (sat)
Note! a broad range of pH-values have been measured
SEROTIN-REUPTAKE INHIBITOR
paroxetine 329.4 C19H20FNO3 solvent: BR » CV 
Ep: 1.15 » WE:glassy carbon
Deroxat » AE: Pt
» RE: Ag/AgCl
BENZODIAZEPINES
diazepam 284.7 C16H13ClN2O solvent:- » P
E1/2: 1.50 » WE: dropping Mercury
Valium » AE: Pt-wire electrode
» RE: SCE
flurazepam 387.9 C21H23ClFN3O solvent:- » P
E1/2: +1.05 » WE: Pt-sheet
Dalmadorm » AE: rotating platinum disk
» RE: SCE
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prazepam 324.8 C19H17ClN2O solvent:- » P
E1/2: -0.6 » WE: dropping Mercury
Demetrin » AE: glassy carbon
» RE: Ag/AgCl (sat)
Note! Prazepam is hardly soluble in Britton-Robinson Buffer,
therefore 10% of DMF was added to increase solubility
cinolazepam 357.8 C18H13ClFN3O2 solvent:- » coulorimetry
E1/2 (1): -0.58 » WE: -
Gerodorm E1/2 (1): -0.84 » AE: -
» RE: Ag/AgCl
half-wave potential changes if the pH-value is increased::> see article
triazolam 343.2 C17H12Cl2N4 solvent: EtOH » V 
E1/2: -1.38 » WE: Pt
Halcion » AE: Pt
» RE: SCE
tofisopam 382.5 C22H26N2O4 solvent:- » P
E1/2: -1.04
Grandaxin
Brotizolam 393.7 C15H10BrClN4S
Lendormin
HYPNOTICS
Chloralhydrate 165.4 C2H3Cl3O2 solvent: buffer » P
E1/2: -1.06 » WE:  dropping mercury
Chloraldurat E1/2: -1.66 » AE:  mercury
» RE:  SCE
HYPNOTICA
Barbital 184.2 C8H12N2O3 solvent: buffer » P
E1/2 : -0.03                     » WE: dropping mercury 
Veronal (D) pH:9.3 » AE: platinum wire 
» RE: silver wire
ANTIEPILEPTICS/HYPNOTICA
Phenobarbital 232.2 C12H12N2O3 solvent: ACN » P
E1/2 (1) :   -2.07                     » WE: dropping mercury 
Luminal » AE: platinum wire 
» RE: silver wire
COUMARINES
6-methyl coumarines 160.2 C10H8O2 solvent:  MeOH » P
E1/2: 1.63 no further information on 
the electrode material
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5-methoxypsoralen 216.2 C12H8O4 solvent:  buffer » CV
Eox: 1.63 » WE: -
irreversible » AE: -
oxidation » RE:  SCE
7-methyl-coumarin 160.2 C10H8O2 solvent:  buffer » CV
Eox: 2.17 » for further information:
irreversible oxidationsee above
psoralen 186.2 C11H6O3 solvent:  buffer » CV
Eox: 1.89 » for further information:
see above
7.8-dihydroxy- 178.1 C9H6O4 solvent:  - » P
coumarin E1/2: -1.8 » WE: -
pH-dependency » AE: -
» RE:  SCE
4-methyl-coumarin 160.2 C10H8O2 solvent:  - » P
E1/2: -1.64 » for further information:
Note! No information concerning solvents or electrode material see above
3-methyl-coumarin 160.2 C10H8O2 solvent:  - » P
E1/2: -1.68 » for further information:
see above
7-hydroxycoumarin 162.1 C9H6O3 solvent:  - » P
(Umbelliferone) E1/2: -1.67 » for further information:
see above
6-hydroxycoumarin 162.1 C9H6O3 solvent:  - » P
E1/2: -1.56 » for further information:
see above
3,4-dimethylcoumarin 174.2 C11H10O2 solvent:  - » P
E1/2: -1.73 » for further information:
see above
3,4,7-trimethyl- 188.2 C12H12O2 solvent:  - » P
coumarin E1/2: -1.81 » for further information:
see above
7-hydroxy-4-methyl- 176.2 C10H8O3 solvent:  - » P
coumarin E1/2: -1.82 » for further information:
see above
8-methoxy coumarin 176.2 C10H8O3 solvent:  - » P
E1/2: -1.56 » for further information:
see above
coumarin 146.2 C9H6O2 solvent:  - » P
E1/2: -1.53 » for further information:
see above
7-aminocoumarin 161.2 C9H7NO2 solvent:  EtOH » P
E1/2: -1.052 » WE:  dropping mercury
» AE:  mercury
» RE:  SCE
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ANTIPARASITAl DRUG
praziquantel 312.4 C19H24N2O2 article in Russian
Biltricide (D)
benzylbenzoate 212.3 C14H12O2 solvent:  ACN » P
E1/2 :   2.16           » WE: -
ANTISCABIOSUM (D) » AE:  -
» RE: SCE
ALKALOIDS
ergometrine 325.4 C19H23N3O2 article missing,has to be rechecked
maleate
FUNGICIDES
bithionol 356.1 C12H6Cl4O2S will be left out cause of ist toxicity
TUBERCULOSTATICS
isoniazid 137.1 C6H7N3O solvent:  Buffer » P
E1/2: -1.33 » WE:  dropping mercury
Rimifon » AE:  mercury
» RE:  SCE
iproniazid 179.2 C9H13N3O solvent:  Buffer » P
pH: 2.4 » WE:  dropping mercury
E1/2: -0.624 » AE:  mercury
pH: 8.8 » RE:  Ag/AgCl (sat)
E1/2: -1.236
PYRAZINAMIDES
pyrazine-2-carboxylic 213.24 C12H11N3O solvent: DMF » CV
acid benzylamide Ep: -2.13 » WE:   carbon
» AE:  -
» RE:  SCE
pyrazindamide 123.1 C5H5N3O solvent: DMF » CV
Ep: -2.11 » WE:   carbon
Rifater (Combi) » AE:  -
» RE:  SCE
protionamide 180.3 C9H12N2S solvent: - » P
E1/2: -0.9 » WE: -
» AE:  -
» RE: SCE
ANTIMYCOBACTERIAL
p-aminosalicylic acid 153.1 C7H7NO3 no exact information
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ANTIBIOTICS
pyrimethamine 248.3 C12H12N2O2S solvent: DMF » P
E1/2 (1): -2.04  » WE: dropping mercury 
E1/2 (2) :-2.50 V » AE:  -
Dapsone ® » RE: Ag/AgCl
solvent: ACN » P
E1/2 (1): -2.11  » WE: dropping mercury 
E1/2 (2) :-2.32 » AE:  -
Note! Potential is decreasing when adding the amount of water » RE: Ag/AgCl
4-(4-nitro- 278.3 C12H12N2O4S solvent: DMSO » P
benzenesulfonyl E1/2 (1): -2.48 no information about the electrodes
anilin
vs the normal hydrogen
electrode
SULFONAMIDES/ ANTIINFECTIVA
sulfadiazine 250.3 C12H12N4O2S solvent: ACN » P
E1/2 (1) :   -1.31                      
sulfadiazin-Heyl (D) E1/2 (2) :   -1.58  » WE: dropping mercury 
E1/2 (3) :   -1.56  » AE: platinum wire 
E1/2 (3) :   -1.95 » RE: silver wire
sulfametazine 278.3 C12H14N4O2S solvent: ACN » P
also (sulfadiamine) E1/2 (1) :   -1.45                   » WE: dropping mercury 
» RE: silver wire
» AE: platinum wire 
sulfadimidine 465.6 C21H19N7O2S2 solvent: ACN » P
E1/2 (1) :   -0.56                  » WE: dropping mercury 
» AE: platinum wire 
» RE: silver wire
sulfacetamide 214.2 C8H10N2O3S solvent: ACN » P
E1/2 (1) :   -2.07                     » WE: dropping mercury 
Blephamid (D) » AE: platinum wire 
» RE: silver wire
CEPHALOSPORINE-ANTIBIOTICS
ampicillin 349.4 C16H19N3O4S
Ampicillin-STADA (D)
cefaloglcycin 405.4 C18H19N3O6S solvent: ACN » P
» WE:  dropping mercury
E1/2:-1.60 » AE:  mercury
» RE:  SCE
cefalotin 396.4 C16H16N2O6S2 solvent: ACN » P
» WE:  dropping mercury
E1/2:-1.53 » AE:  mercury
» RE:  SCE
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cefalexin 347.4 C16H17N3O4S solvent: ACN » P
» WE:  dropping mercury
E1/2:-1.70 » AE:  mercury
» RE:  SCE
TETRACYCLINES
tetracycline 444.4 C22H24N2O8 solvent: DMF » P
» WE:  dropping mercury
no Potential » AE:  mercury
mentioned » RE:  SCE
trimethoprim 290.3 C14H18N4O3 solvent: ACN » P
E1/2:  1.5 » WE: rotating Pt-disk 
(Bactrim® Roche) » AE: rotating gold disk
» RE: SCE
GYRASE-INHIBITORS
enoxacin 320.3 C15H17FN4O3 solvent: - » P
E1/2 (1) :   -1.43    V                » WE:dropping mercury
Gyramid (D) E1/2 (2) :   -1.60    V» AE: Pt-wire
» RE: SCE
solvent: - » CV
Ep (1) :   1.00                » WE: graphic electrode
no further information on the other electrodes
norfloxacine 319.3 C16H18FN3O3 solvent: - » CV
Noroxin ® at pH:5.51 no information on electrodes and 
E1/2: -1.29 solvents
at pH:6.51
E1/2: -1.37
solvent: - » P
E1/2 (1) :   -1.48               for further details: see above
E1/2 (2) :   -1.69  
pefloxacine 333.4 C17H20FN3O3 solvent: - » P
E1/2 (1) :   -1.53             
Peflacin (D) E1/2 (2) :   -1.71 for further details: see above
Ep (1) : 0.95                
ciprofloxacine 331.4 C17H18FN3O3 at pH:6.51 » CV
Ciproxin® E1/2: -1.21 [V] no information on electrodes and 
electrochemical potential is dependent on the at pH:10.00 solvents
pH-value E1/2: -1.74 [V]
ofloxacine 361.4 C18H20FN3O4 solvent: - » P
Tarivid ® E1/2 (1) :   -1.46              for further details: see above
E1/2 (2) :   -1.67
levofloxacine 361.4 C18H20FN3O4 solvent: - » P
Tavanic® for further details: see above
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ANTACIDA
pantoprazole 383.4 C16H15F2N3O4S solvent: BR » CV
» WE: carbon paste
Ep: 1.175  » AE: Pt wire
Pantozol Ep: 1.080 » RE:  Ag/AgCl/3M KCl 
irreversible oxidation bec.
ANTIALLERGICAL /MASTCELL STABILISATING DRUGS
nedocromil 375.4 C19H21NO7 solvent: - » P
sodium E1/2: -1.01 » WE: -
» AE:
Tilarin » RE:  Ag/AgCl in 3 M KCl
ANTIHISTAMINICA
cetirizine 388.9 C21H25ClN2O3 solvent: CH2Cl2 » CV
E1/2: ~-0.185 no further details on the electrodes
(Zyrtec®)
VITAMIN K DERIVATIVE
phytomenadione 450.7 C31H46O2 solvent: DMF » CV
» WE: platinum
Mephyton (US) Ep: -1.206 V » AE: platinum
» RE:  Ag/AgC
ZYTOSTATICA
methotrexate 454.4 C20H22N8O5 Check Literature!
Methotrexate Lederle bsp.
ANTIBIOTIC
mitomycin 334.3 C15H18N4O5 » P
Mitomycin-C Kyowa
ALKYLATING AGENT
dacarbazine 182.2 C6H10N6O solvent: BR » P
Dacin E1/2.-1.07 » WE:dropping mercury
pH: 7.2 » AE: Pt
» RE: SCE
ANTINEOPLASTICAL DRUGS
flouracil 130.1 C4H3FN2O2 solvent: buffer » CV
Efudix » WE: pyrolytic graphite plate
» AE: cyclindrical Pt-gauze
» RE: Ag/AgCl
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1-(1'-oxocyclopentan- 212.2 C9H9FN2O3 solvent: DMF » CV
2'yl)-5-fluorouracil Ered: -0.48 V » WE:  Pt
» AE:  Pt-wire
» RE:  Ag/AgCl (sat)
irreversible cathodicreduction peaks
ANTIHYPERTONIC/DIURETIC DRUGS
triamterene 253.3 C12H11N7 solvent: - » P
Ep (1): -0.9 
DYAZIDE Ep (2): 0.86
(Combination-Drug) Ep (3): 1.3 
hydralazine 160.2 C8H8N4 article written in polish !!
no further information available
DIURETICS
methylchlothiazide 360.2 C9H11Cl2N3O4S2 solvent: ACN » P
E1/2  :-1.58 » WE: dropping mercury 
» AE: platinum wire 
» RE: silver wire
β -RECEPTOR-INHIBITOR
metoprolol 267.4 C15H25NO3 solvent: buffer » CV
E1/2: 0.137 » WE: dropping mercury 
Beloc » AE: platinum wire 
» RE: silver wire
timolol maleate 316.4 C13H24N4O3S solvent: - » CV
E1/2: 0.154 > for more details see above
Timoptic
Propranolol solvent: - » CV
Inderal E1/2: 0.082 > for more details see above
ACE-INHIBITOR
ramipril 416.5 C23H32N2O5 solvent: DMF » P
E1/2: -1.230 » WE: dropping mercury 
Triatec at pH: 7.0 » AE: platinum wire 
» RE: Ag/AgCl
quinapril 438.5 C25H30N2O5 solvent: DMF » CV
Ep
red: - 1.21 » WE: dropping mercury electrode
» AE: Pt-wire
» RE: SCE
"AGAINST EREKTILE DYSFUNCTION"
yohimbine 354.5 C21H26N2O3 solvent: MeOH » coulometry
E1/2: 0.838 » WE: -
» AE: -
» RE: SCE
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VASODILATATOR
papaverine 339.4 C20H21NO4 solvent: - » CV
E1/2: -0.085 > for more details see above
papaveraldine 353.4 C20H19NO5 Check again literature
CHOLINESTERASE-INHIBITOR
neostigmine 223.3 C12H19N2O2 solvent: - » CV
E1/2: - 0.027 » WE: glassy carbon
» AE: Pt
» RE: Ag/AgCl (sat)
MISCELANNEOUS
nicotinic acid 123.1 C6H5NO2 solvent: - » P
pH: 2.4 » WE:  dropping mercury
E1/2: -1.05 » AE:  mercury
pH: 8.8 » RE:  Ag/AgCl (sat)
E1/2: -1.62
nicotine 162.2 C10H14N2 solvent:buffer » P
E1/2: -1.62 » WE:  dropping mercury
» AE:  mercury
» RE:  Ag/AgCl (sat)
acetylcysteine 163.2 C5H9NO3S solvent: buffer » P
E1/2 (1): -0.41 » WE:  dropping mercury
Fluimucil E1/2 (2): -0.595 » AE:  Pt
» RE:  SCE
cisapride 465.95 C23H29ClFN3O4 solvent:  buffer no information on the method
Eox  : 1.05 
lacidipine 455.55 C26H33NO6 solvent:  buffer »  differential pulse voltammetry
Ep: 0.81 » WE:   glassy carbon
» AE:   Pt-wire
» RE:   Ag/AgCl
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Table E: Data of Fig. 17, Chapter 4 
 
Compound ** Predicted microsomal Measured* microsomal 
 rat clearance [µl/min]  rat clearance [µl/min]
8-me-coumarin 298.10 225.54
prochlorperazine 791.14 973.00
verapamil 820.03 650.00
desipramine 687.23 777.67
I13_2nd 587.38 450.63
ciprofloxacine -98.58 4.80
5-methoxy-psoralen 457.89 1033.67
venlafaxine 1105.12 643.67
loratadine 467.17 434.91
E9_2nd 867.84 766.86
G11_2nd 489.69 590.00
K9_2nd 1051.60 701.00
I11_2nd 382.96 577.00
A11_2nd 645.10 622.00
O13_2nd 288.40 416.00
E5_2nd 1180.15 1878.00
G9_2nd 881.79 739.89
O7_2nd 925.06 857.31
O9_2nd 480.10 646.58
K11_2nd 406.44 566.22
A13_2nd 352.63 513.00
M5_2nd 1321.17 1258.00
I17_2nd 92.98 318.00
A9_2nd 945.83 810.63
I7_2nd 1183.89 941.00
M17_2nd 794.50 301.00
E13_2nd 293.85 471.00
I9_2nd 1017.79 718.62
G5_2nd 1339.36 1637.00
C9_2nd 1152.95 797.00
K13_2nd 1056.41 442.25
A7_2nd 1099.60 1085.19
E11_2nd 914.41 598.24
K19_2nd 721.51 267.75
G15_2nd 263.97 375.82
M7_2nd 1142.01 883.27
E7_2nd 1247.96 1020.39
M11_2nd 920.66 552.31
C11_2nd 453.58 611.78
I15_2nd 761.11 364.20
E17_2nd 647.39 336.16
O11_2nd 383.35 525.89
O15_2nd 231.39 351.62
M15_2nd 360.95 356.73
C13_2nd 479.07 289.40
C7_2nd 729.82 1049.06
C17_2nd 405.35 338.49
* microsomal rat clearance were estimated by the colleagues from the department of DMPK
** compound names containing numbers are codes for internal compounds  
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Table F: Data of Fig. 3 and 4, Chapter 4 
 
Compound** CL_mic_rat * Eox vs FOC % CPDdis
[mL/min/mg protein] [V]
E5_2nd 1878.00   -0.32 ± 0.001 31.13 ± 12.43
G5_2nd 1637.00   -0.29± 0.113 27.71 ± 25.74
M5_2nd 1258.00   -0.32 ± 0.001 20.78 ± 16.54
A7_2nd 1085.19  -0.16 ± 0.06
C7_2nd 1049.06  -0.27 ± 0.17 9.94 ± 14.95
E7_2nd 1020.39  -0.30 ± 0.17 15.4 ± 8.33
I7_2nd 941.00  -0.30 ± 0.14  5.14 ± 12.41
M7_2nd 883.27   -0.31 ± 0.19 20.99 ± 16.56
O7_2nd 857.31  -0.27± 0.22 19.83 ± 13.81
A9_2nd 810.63  -0.28 ± 0.11  2.29 ± 14.20
C9_2nd 797.00  -0.19 ± 0.10 19.42 ± 19.04
E9_2nd 766.86  -0.20 ± 0.11
G9_2nd 739.89  -0.23 ± 0.16 0.56 ± 11.36
I9_2nd 718.62  -0.15 ± 0.00 2.59 ± 35.60
K9_2nd 701.00  -0.26 ± 0.07 30.63 ± 14.53
M9_2nd 669.23  -0.15 ± 0.00 13.7 ± 11.81
O9_2nd 646.58  -0.07 ± 0.11 2.39 ± 2.27
A11_2nd 622.00  0.19 ± 0.22 7.73 ± 7.00
C11_2nd 611.78  -0.05 ± 0.01  9.26 ± 14.83
E11_2nd 598.24  -0.08 ± 0.00 39.86 ± 25.18
G11_2nd 590.00   0.22 ± 0.19 17.25 ± 24.20
I11_2nd 577.00  -0.27 ± 0.11 3.52 ± 3.09
K11_2nd 566.22  -0.12 ± 0.15 4.42 ± 3.08
M11_2nd 552.31  -0.20 ±  0.0 6.38 ± 4.39
O11_2nd 525.89     0.22 ± 0.15 9.67 ± 29.54
A13_2nd 513.00   0.16 ± 0.16 11.69 ± 11.78
C13_2nd 491.97  -0.01 ± 0.19 6.09 ± 8.78
E13_2nd 471.00   -0.29 ±  0.28 12.07 ± 8.40
I13_2nd 450.63    0.06 ±  0.38 3.02 ± 1.03
K13_2nd 442.25   0.07 ±  0.04 3.91 ± 5.32
O13_2nd 416.00    0.23 ±  0.11 1.81 ± 3.21
G15_2nd 375.82   0.19 ±  0.19 1.89 ± 2.50
I15_2nd 364.20   0.03 ±  0.00 1.39 ± 2.76
M15_2nd 356.73   -0.12 ±  0.055   9.51 ± 28.03
O15_2nd 351.62   0.17 ±  0.002 13.97 ± 8.10
A17_2nd 341.89 16.11 ± 19.76
C17_2nd 338.49   0.15 ±  0.032 11.12 ± 14.84
E17_2nd 336.16   -0.24 ±  0.206 5.01 ± 4.43
I17_2nd 318.00 0.25 ±  0.05 34.98 ± 46.47
K17_2nd 310.37 20.16 ± 37.82
M17_2nd 301.00  -0.10 ±  0.03 24.23 ± 39.00
A21_2nd 255.63 2.76 ± 2.33
desipramine 777.67   -0.22 ± 0.012 10.91 ± 0.1
verapamil 650.00    -0.24 ± 0.011 7.97 ± 0.15
loratadine 434.91   0.002 ± 0.001 3.26 ± 0.11
8-Me-coumarin 225.54  -0.26 ± 0.003 1.12 ± 2.37
5-Me-psoralen 1033.67  -0.23 ± 0.002 0.20 ± 1.1
paroxetine 2.15 ± 0.064  0.05 ± 0.064 18.70 ± 0.1
sertraline 97.75 ± 0.012 6.67 ± 0
nitrendipine 66.13  -0.15 ± 0.104 6.59 ± 3.3
prochlorperazine 973.00  -0.15 ± 0.002 2.74 ± 3.23
ciprofloxacine 4.80   -0.15 ± 0.006 22.60 ± 3.3
venlafaxine 643.67  -0.08 ± 0.009 6.94 ± 0.1
* microsomal rat clearance were estimated by the colleagues from the department of DMPK
** compound names containing numbers are codes for internal compounds
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Table G: Cyclic Voltammograms of compounds used in Fig. 9, Chapter 4  
* Voltammograms are raw data 
 
 
Eox [V] average Eox [V]
ferrocene 0.242
0.245 0.241 ± 0.004
0.237  
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scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
Verapamil in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 Verapamil
-0.0013
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
-5000
0
5000
10000
15000
20000
 
 
l/n
A
E/V/Ag/AgCl
 Ferrocene
Example for Ferrocene, used as internal standard
0.242
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-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-6000
-4000
-2000
0
2000
4000
6000
8000
10000
12000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
Loratadine in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 Loratadine
0.243
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
0
20000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
8-methyl-Coumarin in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 8MeCou
-0.021
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
0
20000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
Prochlorperazine in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 Prochlorperazine
0.096
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
-5000
0
5000
10000
15000
20000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
10 scans
Paroxetin in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 Paroxetine
0.290
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
A7_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl +10% DMSO
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
I/n
A
E/V/Ag/AgCl
 A7_2nd
0.082
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
0
20000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
5 scans
Ciprofloxacin in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 Cipro
0.092
 
Appendix: Cyclo Voltammograms 
 
  172 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
-5000
0
5000
10000
15000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
Venlafaxine in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 Venlafaxine
0.157
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
0
10000
20000
30000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
Nitrendipine in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 Nitrendipine
0.087
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
80000
A13_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
scanrange: -0.3  to 1.0 V
scanrate: 0.640 V/s
I/n
A
E/V/Ag/AgCl
 A13_2nd
0.404
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
O7_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
 O7_2nd
-0.027
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
M7_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
 M7_2nd
-0.067
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
G5_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
 G5_2nd
-0.046
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-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
-5000
0
5000
10000
15000
20000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
O15_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 O15_2nd
0.414
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
M5_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
I/n
A
E/V/Ag/AgCl
 M5_2nd
-0.076
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
-5000
0
5000
10000
15000
20000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
A17_2nd in 0.05mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
l/n
A
E/V/Ag/AgCl
 A17_2nd_1
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
C9_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
 C9_2nd
0.055
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-30000
-20000
-10000
0
10000
20000
30000
40000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
E9_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
 E9_2nd
0.045
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
E/V/Ag/AgCl
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
E7_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
 E7_2nd
-0.056
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-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
80000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
A11_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 A11_2nd
0.431
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
0
20000
40000
60000
80000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
M15_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 M15_2nd
0.119
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
A9_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
I/n
A
E/V/Ag/AgCl
 A9_2nd
-0.036
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
I9_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
 I9_2nd
0.09
 
0,0 0,4 0,8
-60000
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
M9_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 M9_2nd
0.096
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
K9_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
 K9_2nd
-0.023
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0,0 0,4 0,8
-20000
0
20000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
O9_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 O9_2nd_1
0.169
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
0
20000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
I15_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 I15_2nd
0.268
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
0
20000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
E11_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 E11_2nd
0.161
0,0 0,4 0,8
-20000
0
20000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
C11_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 C11_2nd
 0.188
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
0
20000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
I11_2nd  in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 I11_2nd
0.365
-0.027
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
G11_2nd in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 G11_2nd
0.025
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-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
E5_2nd in 0.05mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
-0.074
0.092
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
0
10000
20000
30000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
K11_2nd in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 K11
0.120
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
0
20000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
M11_2nd in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
l/n
A
E/V/Ag/AgCl
 M11
0.043
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
80000
O11_2nd in 0.05mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
I/n
A
E/V/Ag/AgCl
 O11_2nd
0.456
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
E13_2nd in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 E13_2nd
-0.05
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
C13_2nd in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 C13_2nd 0.234
 
Appendix: Cyclo Voltammograms 
 
  177 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
80000
100000
K13_2nd in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
I/n
A
E/V/Ag/AgCl
 K13_2nd
0.311
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
80000
100000
120000
I13_2nd in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
I/n
A
E/V/Ag/AgCl
 I13_2nd
0.301
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-120000
-80000
-40000
0
40000
80000
120000
160000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
G15_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 G15_2nd
0.435
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
0
10000 scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
C17_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 C17_2nd_1
0.387
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
80000
100000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
O13_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 O13_2nd_2
0.472
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
G9_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
 G9_2nd
0.013
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-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
-5000
0
5000
10000
15000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
I17_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 I17_2nd
0.492
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
-5000
0
5000
10000
15000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
E17_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 E17_2nd
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
0
10000
20000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
M17_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 M17_2nd
0.139
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-10000
0
10000
20000
30000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
A21_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 A21_2nd
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-60000
-40000
-20000
0
20000
40000
60000
80000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
C7_2nd in 0.05 mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
I/n
A
E/V/Ag/AgCl
 C7_2nd
-0.027
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
80000
K17_2nd in 0.05mM Phosphatebuffer, 0.0001 mmol KCl and 10% DMSO
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
l/n
A
E/V/Ag/AgCl
 K17_2nd
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-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-40000
-20000
0
20000
40000
60000
scanrange: -0.3 to 1.0
scanrate: 0.640 V/s
I7_2nd in 0.05 mM Phosphatebuffer, 0.0001 mM KCl and 10 % DMSO
I/n
A
E/V/Ag/AgCl
 I7_2nd
-0.056
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
-10000
0
10000
20000
30000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
5-Methoxy Psoralen in 0.05 mM Phosphatebuffer, 0.0001mM KCl + DMSO 10%
I/n
A
E/V/Ag/AgCl
 5-Me-Pso
0.007
 
-0,2 0,0 0,2 0,4 0,6 0,8 1,0
-20000
-10000
0
10000
20000
30000
40000
scanrange: -0.3 to 1.0 V
scanrate: 0.640 V/s
l/n
A
E/V/Ag/AgCl
 Sertraline
Sertraline in 0.05 mM Phosphatebuffer, 0.0001 mM KCl+ 10% DMSO
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